

# SUBJECT INDEX

## A

- Ab initio* MO methods, 21
- Ab initio* molecular dynamics (AIMD) studies
- 1,6-anhydrodioxolenium from and, 98
  - for finding ring-inversion barrier, 110–114, 111f, 112f, 112t
- Acceptor-bound approach, to solid-phase synthesis, 220, 222, 224
- p*-Acetamidophenylthio glycosides, active-latent strategy for, 186
- 3-Acetoxy-2,2-dimethylpropanoate
- protecting group, acyl-transfer side reaction and, 129–130
- Acetylated selenoglycoside, activation of, 255–256
- Achmatowicz rearrangement, for  $\alpha$ -mannans synthesis, 260–261
- Activator, for selective activation, 178–179
- Active-latent strategy, for oligosaccharide synthesis, 185–188
- Acyl-transfer side reaction
- in 3-acetoxy-2,2-dimethylpropanoate protecting group, 129–130
  - in 2,6-dimethoxybenzoyl, 129
  - in galactopyranosyl oxacarbenium ions, 123, 126–128
  - proton transfer and, 131–132
- Additives, oxacarbenium ions and, 99
- ADF. *See* Amsterdam density functional
- Aerobacter aerogenes*, 5
- AFM. *See* Atomic force microscopy
- AIM. *See* Atoms in molecules study
- AIMD. *See* *Ab initio* molecular dynamics studies
- Alditol oligosaccharides, of
- T. cruzi* mucins, HPAEC-PAD analysis of, 334
  - Allinger's MM1 force field, 24
  - Allinger's MM2/MMP2 program, 29–30
- Allyl glycosides, in stereocontrolled synthesis of  $\alpha$ -mannans, 263–264
- Allylic couplings, 68
- ALTONA, 25
- Altona equation, 24, 40, 61
- Amsterdam density functional (ADF), for galactopyranoside study, 89
- 1,6-Anhydrodioxolenium, stability of, 97–98
- Antiprotozoal therapy, targets of, 315, 320, 345–350, 348f–351f
- Armed–disarmed approach
- inverse, 200–201
  - for oligosaccharide synthesis, 197–201
- Armed–disarmed effect, in galactopyranosyl oxacarbenium ions, 120
- Aspinall, Gerald, 2–9
- Atomic force microscopy (AFM), for ring-inversion barrier, 112–113
- Atoms in molecules (AIM) study, for galactopyranosyl oxacarbenium, 85
- Automated synthesis, of oligosaccharides, 224–226

## B

- Bacillus anthracis* tetrasaccharide, synthesis of, 281, 284–285
- Barfield transmission effect, 28–30
- Barton/Cookson generalization, 5–6
- Benzenesulfinyl piperidine-triflic anhydride system, for selective activation, 179–181
- Benzoic acid derivatives, TcTS inhibition with, 348, 349f
- S*-Benzoxazolyl (SBox) glycosides
- disarming by, 202–203
  - in orthogonal strategy, 192

- S-Benzoxazolyl (SBox) glycosides (*cont.*)  
 for selective activation, 180–182  
 as super-armed glycosyl donors, 207  
 temporary deactivation concept, 195
- 2-*O*-Benzoyl-tri-*O*-benzoyl-protected  
 glycosyl donor, investigation of, 207
- Benzyl ethers, for glycosylation reactions,  
 116
- Biallylic couplings, 68
- Biantennary heptasaccharide,  
 convergent block synthesis  
 of, 172–173
- Bidirectional approaches  
 to oligosaccharide synthesis, 211–213  
 in solid-phase synthesis, 220
- Biological effects, of TcTS, 350–352
- Biological functions, of *T. cruzi* mucins, 335
- Biological properties, of *T. cruzi* GIPLs,  
 318–319
- Blood-group B antigen, synthesis of, 232–233
- Bohlmann effect, in galactopyranosyl  
 oxacarbenium ions, 119
- Bromine  
 for selective activation, 179–181  
 for two-step activation, 182–184
- C**
- CAGPLUS, 25
- Campylobacter jejuni*, 7
- Campylobacter spp.*, 7
- Candida albicans*, 287
- Canonical vector representation  
 development of, 110  
 of galactopyranosyl oxacarbenium  
 ions, 95, 96t, 97  
 pseudorotation in, 111, 111f
- Carbohydrate structures, in *T. cruzi* mucins,  
 327–335, 329f
- Carbon–carbon couplings, 51–59  
 $^3J_{\text{CCCC}}$ , 55–59  
 $^3J_{\text{CCOC}}$ , 52–55, 56f
- Carbon–tin couplings,  $^3J_{\text{CCCSn}}$ , 64
- Catalytic mechanism, of TcTS, 336–340,  
 337f–338f
- CBS calculation. *See* Complete basis set  
 calculation
- Cell surface glycoconjugates, of  
*T. cruzi*, 313–354  
 glycoinositolphospholipids, 313–321,  
 314f–316f, 322f  
 mucins, 321–335, 322f, 326f, 326t, 329f  
 other glycoproteins, 352–354, 353f–354f  
 trans-sialidase, 336–352,  
 337f–338f, 348f–351f
- Cellulomonas fimi*, enzyme from, 234
- Ceramides, of *T. cruzi*, 314–315, 317,  
 319–320
- Chagas' disease, 312
- CHARMM force field, 38–39, 50
- CHARMM molecular modeling, 52
- Chemical synthesis  
 of glycosyl amino acids of  
*T. cruzi* mucins, 333–334  
 of oligosaccharides in *T. cruzi* mucins,  
 328–333  
 of *T. cruzi* GIPL, 321–325, 322f
- Chemoenzymatic, of glycosyl amino  
 acids of *T. cruzi* mucins, 333–334
- Chemoselective strategies  
 for oligosaccharide synthesis, 196–207  
 armed–disarmed approach, 197–201  
 disarming by remote substituents,  
 202–203  
 disarming by torsional effects, 203–206  
 inverse armed–disarmed approach,  
 200–201  
 reactivity–based programmable  
 strategy, 201–202  
 super-armed glycosyl donors, 206–207  
 in one-pot glycosylation strategies, 215  
 for stereocontrolled synthesis of  
 $\alpha$ -mannans, 269, 271
- CHYMESA, 59
- CIP. *See* Contact ion pair
- Complete basis set (CBS) calculation, for  
 glycopyranoside study, 89, 145
- Contact ion pair (CIP)  
 methodology development for, 146

- oxacarbenium ion  
 equilibrium with, 99  
 facial selectivity and, 100–101  
 ionization and, 137
- Convergent block synthesis, 169–177  
 advantages of, 173  
 of alternating  $\beta$ -(1 $\rightarrow$ 3)- $\beta$ -(1 $\rightarrow$ 4)-mannan, 295–297  
 of biantennary heptasaccharide, 172–173  
 of high mannose-type oligosaccharide, 173–175  
 of Lewis X structure, 175–176  
 linear v., 171  
 of  $\alpha$ -mannans, 258  
 of  $\beta$ -mannans, 292–293  
 in one-pot glycosylation strategies, 216  
 of pneumococcal oligosaccharide serotype 14, 176–177  
 polymer-supported synthesis with, 220–222  
 in solid-phase synthesis, 220  
 of *Spergularia ramosa* pentasaccharide, 171–172  
 variation A, 169–171  
 variation B, 175
- COSY-45 method, 51
- Coupling constants  
 angular dependence of, 18–19, 21  
 online calculators for, 70–72  
 over five bonds, 68–69, 69f  
 over four bonds, 64–68  
 summary for, 72–73  
 vicinal, 21–59  
 carbon–carbon, 51–59  
 fluorine, 60–63  
 proton–carbon, 36–45  
 proton–nitrogen, 45–47  
 proton–phosphorus, 47–51, 48f  
 proton–proton, 21–36
- Coupling reactions, development of, 167
- Covalent inhibitors, TcTS inhibition with, 348–349, 350f
- Cremer–Pople representation, canonical vector representation v., 110
- Crescenzi, Vittorio, 12–16
- CS MOPAC PRO, 67
- Cyanoethylidene orthoester, in stereocontrolled synthesis of  $\alpha$ -mannans, 267–269
- Cyanoorthoacetate, in stereocontrolled synthesis of  $\alpha$ -mannans, 267–269
- Cyclohexane phosphonate derivatives, TcTS inhibition with, 346
- Cyclohexanes,  $^3J_{\text{HCCCH}}$  values in, 25
- ## D
- DEMON-KS program, 40
- DEMON-NMR procedure, 40
- Density functional theory (DFT) methods for galactopyranosyl oxacarbenium ions, 88  
 rotation and, 119  
 $^3J_{\text{CCCC}}$ , 59  
 $^3J_{\text{CCOC}}$ , 55, 56f  
 $^3J_{\text{FCCF}}$ , 63  
 $^4J_{\text{HCCCH}}$ , 65–66, 66f  
 $^4J_{\text{HC=CCH}}$ , 68  
 $^3J_{\text{HCNC}}$ , 32–33  
 $^3J_{\text{HCOC}}$ , 39–40  
 $^3J_{\text{HCOH}}$ , 33–35, 35f  
 $^3J_{\text{HOCC}}$ , 43, 44f
- DFT. *See* Density functional theory methods
- Dihedral angle  
 couplings over four bonds, 64–68  
 $^3J_{\text{CCCC}}$ , 57–59  
 $^3J_{\text{CCOC}}$ , 52–54  
 $^3J_{\text{FCCF}}$ , 62–63  
 $^3J_{\text{HCCC}}$ , 41  
 $^5J_{\text{HCCCCH}}$ , 68–69  
 $^4J_{\text{HCCCH}}$ , 65, 66f  
 $^3J_{\text{HCCH}}$ , 22–26, 30  
 $^3J_{\text{HCCN}}$ , 46, 46f–47f  
 $^3J_{\text{HCNF}}$  and  $^4J_{\text{HCCNF}}$ , 62  
 $^3J_{\text{HCNH}}$ , 33  
 $^3J_{\text{HCOC}}$ , 37, 39, 39f  
 $^3J_{\text{HCOP}}$ , 48, 50  
 $^3J_{\text{HCSC}}$ , 42  
 $^3J_{\text{HOCC}}$ , 43, 44f

- Dihedral angle (*cont.*)  
 Karplus equation and, 30–31  
 NMR coupling constants and, 18–21
- 2,6-Dimethoxybenzoyl (DMOB), synthesis and testing of, 129
- Dimethyldioxirane (DMDO), for two-step activation, 184–185
- 2,4-Dinitrophenyl glycosides, torsional disarming of, 205–206
- 2,3-Di-*O*-( $\beta$ -D-galactopyranosyl)-D-galactose, sialylation of, 341
- Disarming by remote substituents, for oligosaccharide synthesis, 202–203
- Disarming by torsional effects, for oligosaccharide synthesis, 203–206
- 2,6-Di-*tert*-butyl-4-methylpyridine (DTMP), for glycosylation reactions, 140–141
- DMDO. *See* Dimethyldioxirane
- DMOB. *See* 2,6-Dimethoxybenzoyl
- Donor substrates, for TcTS reaction, 342–347
- Donor-bound approach, to solid-phase synthesis, 220, 222–223
- Double stereo-differentiation, in galactopyranosyl oxacarbenium ions, 120–121
- DTMP. *See* 2,6-Di-*tert*-butyl-4-methylpyridine

## E

- EHT-MO calculations, for  ${}^3J_{\text{HCCH}}$ , 25
- $\alpha$ -(1 $\rightarrow$ 4)-Eicomannan, stereocontrolled synthesis of, 272–273
- Electronegativity orientation  
 ${}^3J_{\text{CCOC}}$ , 54  
 ${}^3J_{\text{HCCF}}$ , 60  
 ${}^3J_{\text{HCCH}}$ , 23–24, 23f–24f  
 in Karplus equation, 30–31
- Endoplasmic reticulum membrane-associated oligosaccharide, convergent block synthesis of, 173–175
- Enzymatic approach, to oligosaccharide synthesis, 228–234  
 with glycosidases, 233–234  
 with glycosyltransferases, 230–233
- 2-Ethoxytetrahydropyran, studies of, 89
- S-Ethyl glycosides  
 in orthogonal strategy, 190–193  
 for selective activation, 179–182  
 for two-step activation, 182–184
- Extended W couplings, 68–69, 69f

## F

- Facial selectivity, of galactopyranosyl oxacarbenium ions, 98–109, 141  
 CIPs and SSIPs and, 100–101  
 ionization and, 137, 138f  
 leaving groups, 104  
 methanol complexes, 101–102  
 protecting-group strategies, 103–104  
 proton transfer in, 102, 103f  
 reactivity order and, 99–100  
 reversibility, 109
- Fischer approach, selective activation v., 177
- Five bond coupling constants  
 ${}^5J_{\text{HCCCH}}$ , 68–69, 69f  
 ${}^5J_{\text{HCC=CCH}}$ , 69
- Fluorine  
 in orthogonal strategy, 189–191  
 for two-step activation, 182–184
- Fluorine couplings, 60–63  
 ${}^3J_{\text{CCCF}}$  and  ${}^3J_{\text{COCF}}$ , 62  
 ${}^3J_{\text{FCCF}}$ , 62–63  
 ${}^3J_{\text{HCCF}}$ , 60–61  
 ${}^3J_{\text{HCNF}}$  and  ${}^4J_{\text{HCCNF}}$ , 61–62
- Fluorous tag-supported synthesis, of oligosaccharides, 226–229
- Force field  
 Allinger's MM1, 24  
 CHARMM, 38–39, 50  
 MM2–85, 31  
 for molecular mechanic calculations, 87
- Four bond coupling constants  
 ${}^4J_{\text{HCCH}}$ , 64–68, 66f  
 ${}^4J_{\text{HC=CCH}}$ , 68
- FPT-INDO calculations, 38, 42
- Free energy, in geometry optimization, 110

Frequency calculations, for galactopyranosyl oxacarbenium ions, 91–92, 93t, 94, 94f, 95f

Fucosyl GM1 oligosaccharide, synthesis of, 209–210

## G

1G7 antigen, GPI in, 317–318

$\beta$ -Gal-(1→3)-Gal-R derivatives, trans-sialylation of, 343–344

Galactofuranose, 354

Galactopyranosyl oxacarbenium ions

background for, 84–89

galactose derivative selection, 85, 87

reactivity of, 84–86

study methods for, 87–89

facially selective complexes, 98–109, 141

CIPs and SSIPs and, 100–101

leaving groups, 99, 104

linear transit, 105, 106–107f,

107–108f, 109

methanol complexes, 101–102

protecting-group strategies, 103–104

proton transfer in, 102, 103f, 141

reactivity order and, 99–100

reversibility, 109

ionization in, 136–140, 142

facial selectivity and, 137, 138f

stereoselectivity and, 137–138, 139f, 142

thermal vibrational excitation, 140–141

ring conformations of, 89–98, 141

geometric parameters of, 95–97, 96t

geometry optimization, 91–95,

93t, 94f, 95f

starting geometry for, 89–91,

91f, 92, 94

rotation role in, 118–130, 119f

acyl-transfer side reaction, 123, 126–128

hyperconjugative interactions,

118–119, 119f, 120f

neighboring-group participation,

122–123, 122f, 124f, 125–126t, 141

protecting groups, 119–121

substituents, 121

side-chain orientation and

conformation, 109–118

protecting group interactions, 118

reactivity, 109–110

ring-inversion barrier, 110–114,

111f, 112f, 112t

steric buttressing, 116–117

through-bond activation, 115, 115f

through-space interaction efficiency,

114

Galactose-binding site, of TcTS, 338–339

inhibition of, 349–350, 351f

$\beta$ -D-Galp(1→4)[ $\beta$ -D-Galp(1→6)]GlcNAc, synthesis of, 329–331

$\beta$ -D-Galp(1→4)GlcNAc, synthesis of, 329–330

Galili pentasaccharide, bidirectional strategy for synthesis of, 212–213

Galp, of *T. cruzi* GPIs, 328

$\beta$ -D-Galp(1→3)- $\beta$ -D-Galp-(1→6)-[ $\beta$ -D-Galp-(1→4)]-D-GlcNAc, synthesis of, 331–332

$\beta$ -D-Galp(1→2)[ $\beta$ -D-Galp(1→3)]- $\beta$ -D-Galp(1→6)[ $\beta$ -D-Galp(1→4)]-D-GlcNAc, sialylation of, 341

$\beta$ -D-Galp(1→3)[ $\beta$ -D-Galp(1→2)]- $\beta$ -D-Galp(1→6)[ $\beta$ -D-Galp(1→4)]-D-GlcNAc, synthesis of, 331–333

$\alpha$ -D-Galp-(1→6)- $\beta$ -D-Galp-OMe, sialylation of, 342

$\beta$ -D-Galp-(1→6)- $\beta$ -D-Galp-OMe, sialylation of, 343

$\beta$ -Galp-(1→4)-GlcNAc- $\alpha$ -L-threonine (LacNAc- $\alpha$ -threonine), synthesis of, 333

GAUSSIAN94 program

for  $^3J_{CCOC}$ , 53

for  $^3J_{HCCF}$ , 61

GAUSSIAN98 program

for  $^3J_{HCOC}$ , 40

for  $^4J_{HCCC}$ , 67

GAUSSIAN03 program

for  $^3J_{CCOC}$ , 55

for  $^3J_{HOCC}$ , 43–45

- Genetic variability, of *T. cruzi* mucins, 322–327, 326f, 326t
- Geometrical factors,  $^3J_{CCOC}$ , 54–55
- Geometry optimization  
free energy in, 110  
for galactopyranosyl oxacarbenium ions, 91–95, 93t, 94f, 95f
- GIPL. *See* Glycoinositolphospholipids
- Globo-H hexasaccharide, automated synthesis of, 225–226
- Glycobiology, of *T. cruzi*, 311–355  
concluding remarks, 354–355  
glycoinositolphospholipids, 313–321, 314f–316f, 322f  
introduction, 312  
life cycle of the parasite, 312–313, 313f  
mucins, 321–335, 322f, 326f, 326t, 329f  
other glycoproteins, 352–354, 353f–354f  
trans-sialidase, 336–352, 337f–338f, 348f–351f
- Glycofuranosyl groups, oxacarbenium ions and, 84
- Glycoinositolphospholipids (GIPL), of *T. cruzi*, 313–321  
biological and immunological properties of, 318–319  
biosynthesis of, 319–321  
chemical synthesis of, 321–325, 322f  
as GPI anchors in *T. cruzi* glycoproteins, 315–318, 316f
- Glycophosphatidylinositol (GPI)  
in minor *T. cruzi* glycoproteins, 317–318  
of *T. cruzi* anchors  
lipid remodeling of, 319–320  
structure of, 314, 314f  
in *T. cruzi* glycoproteins, 315–318, 316f  
transfer of, 320–321  
of tGPI mucins, 335  
in trans-sialidases, 317
- Glycopyranosyl groups, oxacarbenium ions and, 84
- Glycopyranosyl oxacarbenium ions, importance of, 83–84
- Glycosidases, oligosaccharide synthesis with, 233–234
- Glycosidic bonds  
breakage of, 84  
formation of, 84  
 $\alpha$ -mannans stereocontrolled synthesis with, 255–256, 260–261  
stereocontrol of, 165
- Glycosphingolipid, armed–disarmed approach for synthesis of, 199
- Glycosyl amino acids, of *T. cruzi* mucins, chemical and chemoenzymatic synthesis of, 333–334
- Glycosyl chlorides, in stereocontrolled synthesis of  $\alpha$ -mannans, 262–263
- Glycosyl donors, super-armed, for oligosaccharide synthesis, 206–207
- Glycosyl processing enzymes (GPEs). *See also* Galactopyranosyl oxacarbenium ions  
applications of, 83–84  
glycosylation by, 130  
KIE studies for TSs of, 113–114  
reactivity of, 121  
study of, 85, 87
- Glycosylation reactions. *See also* One-pot glycosylation strategies  
1,6-anhydrodioxolenium from, 97–98  
calculations for  
based on existing methodologies, 145  
requiring methodology development, 145–146  
charge neutralization in, 137  
coupling reactions, 167  
DTMP for, 140–141  
enzymatic approach to, 228–230  
experimental studies of, 146–147  
oxacarbenium ions and, 98  
principles of, 165–167  
proton transfer in, 105, 106–107f, 109, 130–136  
energetic magnitude of, 135–136  
neighboring-group participation, 131–132, 133–134f, 135

rates of, 131  
 timing of, 130–131  
 reactivity order in, 99–100  
   manipulation of, 136  
 stereoselectivity of, 103–104, 103f  
   control of, 165  
   factors influencing, 166–167  
   manipulation of, 136  
   steric buttressing, 116–117  
 summary of, 140–144  
 transition states of, 141  
 Glycosyltransferase mechanisms,  
   modeling of, 130–131  
 Glycosyltransferases, oligosaccharide  
   synthesis with, 230–233  
 Glycosynthase, oligosaccharide  
   synthesis with, 234–235  
 GM3 trisaccharide, synthesis of, 231–232  
   gp 85, 336  
 GP72, 352–354, 354f  
 GPEs. *See* Glycosyl processing enzymes  
 GPI. *See* Glycophosphatidylinositol  
 GPI malarial toxin, automated synthesis of,  
   225  
 GS-4071, 346

## H

Haasnoot equation, 24, 31, 40, 61  
 Hartree–Fock (HF) methods, for  
   galactopyranosyl oxacarbenium ions, 88  
 Hassel–Ottar effect, galactopyranosyl  
   oxacarbenium ions and, 93, 95, 95f, 117  
 H-bonds. *See* Hydrogen bonds  
 Helferich-type glycosylation,  
    $\alpha$ -mannans synthesis with, 262–263  
*Helicobacter pylori*, 7–8  
*Helicobacter spp.*, 7  
 Heparin-like oligosaccharides, selective  
   activation synthesis of, 179–180  
 Heptasaccharyl *myo*-inositol, of *T. cruzi*,  
   synthesis of, 321, 322f, 323–325  
 HF. *See* Hartree–Fock methods  
 High mannose-type oligosaccharide,  
   convergent block synthesis of, 173–175

Homotetramer, synthesis of, 228  
 H-type II pentasaccharide, traditional linear  
   synthesis of, 169–170  
 Huggins electronegativity scale, 27, 51, 60  
 Hydrogen bonds (H-bonds)  
   in galactopyranosyl oxacarbenium  
     ions, 85  
   facial selectivity, 102, 103f  
   methodology development for, 145  
   selectivities of, 116–117  
   proton transfer rates and, 131, 135–136  
   study of, 85, 87  
 Hydrolysis, of galactopyranosides v.  
   glucopyranosides, 84–86  
 Hydroxyl reactivity, in oligosaccharide  
   synthesis, 208–210  
 Hyperconjugative interactions, in  
   galactopyranosyl oxacarbenium ions,  
   118–119, 119f, 120f

## I

IDCP. *See* Iodonium (di- $\gamma$ -collidine)  
   perchlorate  
 Immunological properties, of *T. cruzi* GIPLs,  
   318–319  
*In situ* preactivation  
   for oligosaccharide synthesis, 182–185  
   in one-pot glycosylation strategies, 218  
 1D INADEQUATE, 58  
 2D INEPT experiment, 37  
 Inhibitors, of TcTS, 345–350, 348f–351f  
 Inositolphosphoceramide (IPC),  
   of *T. cruzi*, in lipid remodeling,  
   319–320  
 Inositolphospholipid (IPL), of GPI  
   anchors, 316–317  
 Intermolecular processes, with  
   oxacarbenium ions, 99  
 Intramolecular processes, with  
   oxacarbenium ions, 99  
 Intrinsic reaction coordinate (IRC)  
   calculation,  
   for galactopyranosyl oxacarbenium  
   ions, 92

Inverse armed–disarmed  
 approach, 200–201

Iodonium (di- $\gamma$ -collidine) perchlorate  
 (IDCP), for armed–disarmed  
 approach, 198–199

Ionic liquid-supported oligosaccharide  
 synthesis, 228, 279

Ionization, in galactopyranosyl  
 oxacarbenium ions, 136–140, 142  
 facial selectivity and, 137, 138f  
 leaving groups, 99, 104, 145  
 stereoselectivity and, 137–138, 139f  
 thermal vibrational excitation, 140–141

IPC. *See* Inositolphosphoceramide

IPC synthase, 320

IPL. *See* Inositolphospholipid

IRC. *See* Intrinsic reaction coordinate  
 calculation

## J

$^3J_{CCCC}$ , 55–59

$^3J_{CCCF}$ , 62

$^3J_{CCCSn}$ , 64

$^3J_{CCOC}$ , 52–55, 56f

$^3J_{COCF}$ , 62

$^3J_{FCCF}$ , 62–63

$^3J_{HCCC}$ , 41–42

$^5J_{HCCCCH}$ , 68–69

$^5J_{HCC=CCH}$ , 69

$^4J_{HCCCCH}$ , 64–68, 66f

$^4J_{HC=CCH}$ , 68

$^3J_{HCCF}$ , 60–61

$^3J_{HCCCH}$ , 21–32

$^3J_{HCCN}$ , 45–47, 46f–47f

$^4J_{HCCNF}$ , 61–62

$^3J_{HCNF}$ , 61–62

$^3J_{HCNH}$ , 32–33

$^3J_{HCOC}$ , 37–41, 39f

$^3J_{HCOH}$ , 33–36

$^3J_{HCOP}$ , 47–51, 48f

$^3J_{HCSC}$ , 42–43

$^3J_{HCSIH}$ , 36

J-HMBC NMR, 39

$^3J_{HOCC}$ , 43–45, 44f

## K

Karplus equation  
 couplings over five bonds, 68–69, 69f  
 couplings over four bonds, 64–68, 66f  
 introduction to, 18–19  
 molecular modeling impact, 20–21  
 NMR spectroscopy improvements, 19–20  
 online calculators for coupling  
 constants and torsions, 70–72  
 summary for, 72–73  
 vicinal coupling constants, 21–59  
 carbon–carbon couplings, 51–59  
 fluorine couplings, 60–63  
 proton–carbon couplings, 36–45  
 proton–nitrogen couplings, 45–47  
 proton–phosphorus couplings, 47–51,  
 48f  
 proton–proton couplings, 21–36

KIE. *See* Kinetic isotope effect studies

Kinetic isotope effect (KIE) studies, for GPE  
 transition states, 113–114

Koenigs–Knorr approach, selective  
 activation v., 177

## L

LacNAc- $\alpha$ -threonine.  
*See*  $\beta$ -Galp-(1 $\rightarrow$ 4)-GlcNAc- $\alpha$ -L-  
 threonine

Lactitol, 349–350, 352

Lactose derivatives  
 TcTS inhibition with, 349–350, 351f  
 trans-sialylation of, 343–344

Leaving groups  
 active–latent strategy for, 185–188  
 armed–disarmed approach for, 198–201  
 bidirectional approaches with, 211–213  
 chemoselective strategies for, 196–197  
 galactopyranosyl oxacarbenium ions and,  
 99  
 ionization, 104, 145  
 orthogonal and semi-orthogonal strategies  
 for, 188–193  
 selective activation of, 177–188  
 heparin-like oligosaccharides, 179–180



- with three leaving groups, 179–181
  - three-step sequential, 180–182
  - steric hindrance deactivation, 193–194
  - temporary deactivation concept, 193–196
  - two-step activation and *in situ* preactivation of, 182–185
  - Leloir pathway, for oligosaccharide synthesis with glycosyltransferases, 230–233
  - Lewis X structure
    - convergent block synthesis of, 175–176
    - solid-phase synthesis of, 220–222
  - Life cycle, of *T. cruzi*, 312–313, 313f
  - Linear oligosaccharide synthesis, 167–169
    - convergent block v., 171
    - of H-type II pentasaccharide, 169–170
    - of pneumococcal oligosaccharide serotype 6A, 167–169
  - Linear transit (LT), for galactopyranosyl oxocarbenium ions, 105, 106–107f, 107–108f, 109
  - $\beta$ -(1→3)-Linked glucan, 5
  - Lipid remodeling, of GPI, 319–320
  - Lipopeptidophosphoglycan (LPPG), of *T. cruzi*, 314–315
    - oligosaccharide structures found in, 315, 315f
  - LPPG. *See* Lipopeptidophosphoglycan
- M**
- $\alpha$ -(1→2)-Mannan, synthesis of, 278–281
  - $\alpha$ -(1→4)-L-Mannan, synthesis of, 261
  - $\alpha$ -(1→6)-Mannan, synthesis of, 279
  - $\beta$ -(1→2)-Mannan, synthesis of, 286–289
  - $\beta$ -(1→3)-Mannan,  $\beta$ -(1→4)-mannan alternating with
    - block synthesis, 295–297
    - direct synthesis, 294–296
  - $\beta$ -(1→4)-Mannan
    - $\beta$ -(1→3)-mannan alternating with
      - block synthesis, 295–297
      - direct synthesis, 294–296
    - synthesis of, 293–294
  - Mannans, stereocontrolled synthesis of
    - introduction to, 251–252, 286
    - $\alpha$ -mannans
      - in absence of neighboring-group participation, 252–261
      - neighboring group-directed, 262–281
    - $\beta$ -mannans
      - by direct methods, 291–299
      - by indirect methods, 286–291
  - $\alpha$ -Mannans, stereocontrolled synthesis of
    - in absence of neighboring-group participation, 252–261
    - block synthesis, 258
    - in frozen solvent conditions, 254–255
    - glycosidic bond formation for, 255–256, 260–261
    - Helferich-type glycosylation, 262–263
    - $\alpha$ -(1→4)-L-Mannan, 261
    - 3-*O*-methyl-(1→4)- $\alpha$ -D-mannan, 258–259
      - one-pot strategy for, 252–254
    - $\alpha$ -(1→3)-Pentamannan, 259–260
      - trichloroacetimidate approach to, 257
    - neighboring group-directed, 262–281
      - with allyl glycosides, 263–264
      - chemoselective cleavage, 269, 271
      - cyanoethylidene orthoester approach to, 267–269
    - $\alpha$ -(1→4)-eicomannan, 272–273
      - with glycosyl chlorides, 262–263
    - $\alpha$ -(1→2)-mannan, 278–281
    - $\alpha$ -(1→6)-mannan, 279
      - mannosyl iodide for, 270–272
    - MPEG glycosides for, 276–278
    - O-2-protecting group in, 272–273
    - $\alpha$ -(1→3)-pentamannan, 264–265
      - pentenyl glycoside approach to, 264–267
      - pentenyl orthoester approach to, 266, 268, 270
      - polymer-supported, 279–280
      - thioglycoside activation for, 275–276
      - trichloroacetimidate method for, 268–269, 271
      - trichloroacetimidate with thioglycoside donors, 274–275

- $\beta$ -Mannans, stereocontrolled synthesis of  
 by direct methods, 291–299  
   alternating  $\beta$ -(1→3)- $\beta$ -(1→4)-mannan,  
     294–296  
   block synthesis, 295–297  
 block-synthesis, 292–293  
 $\beta$ -(1→4)-mannan, 293–294  
 $\beta$ -(1→3)-mannohexaose, 297–299  
 $\beta$ -(1→2)-mannooctaose, 291–292  
 $\beta$ -(1→4)-mannotetraose, 294–295  
 $\beta$ -(1→3)-mannotriose, 296–298  
 by indirect methods, 286–291  
 $\beta$ -(1→2)-mannan synthesis, 286–289  
 $\beta$ -(1→2)-mannooctaose synthesis,  
   289–291  
 $\beta$ -(1→2)-mannotetraose synthesis,  
   288–290  
 $\beta$ -(1→4)-mannotriose synthesis,  
   286–287
- $\beta$ -(1→2)-Mannohexaose, synthesis of,  
 286–288
- $\beta$ -(1→3)-Mannohexaose, synthesis of,  
 297–299
- $\beta$ -(1→4)-Mannohexaose, synthesis of,  
 293–294
- $\beta$ -(1→2)-Mannooctaose, synthesis of  
 direct methods, 291–292  
 indirect methods, 289–291
- Mannosyl donors, 252, 252f
- Mannosyl iodide, for stereocontrolled  
 synthesis of  $\alpha$ -mannans, 270–272
- $\beta$ -(1→2)-Mannotetraose, synthesis of,  
 288–290
- $\beta$ -(1→4)-Mannotetraose, synthesis of,  
 294–295
- $\beta$ -(1→3)-Mannotriose, synthesis  
 of, 296–298
- $\beta$ -(1→4)-Mannotriose, synthesis of, 286–287
- MCSCF *ab initio* calculations, 31–32, 63
- MD/MM methods, 21
- MestRe-J, 71
- Methanol complexes, facial selectivity of  
 galactopyranosyl oxacarbenium  
 ions, 101–102
- 2-Methoxytetrahydropyran, studies of, 89
- Methyl glycosides, torsional  
 disarming of, 205–206
- 3-*O*-Methyl-(1→4)- $\alpha$ -D-mannan,  
 synthesis of, 258–259
- 2'-*O*-(4-Methylumbelliferyl)- $\alpha$ Neu5Ac  
 (MUNeu5Ac) derivatives  
 as donors for TcTS reaction, 342–344  
 trans-sialylation with, 345
- Methylumbelliferyl  $\alpha$ -sialosides,  
 as donor for TcTS reaction, 342
- Microreactor synthesis,  
 of oligosaccharides, 228–229
- MM. *See* Molecular mechanics
- MM2–85 force field, 31
- MO calculations, for  $^3J_{\text{CCCC}}$ , 55–56
- Molecular mechanics (MM),  
 oxacarbenium ions and, 87
- Molecular modeling  
 CHARMM, 52  
 impact of, 20–21
- Monomethylpolyethylene (MPEG)  
 glycoside, for  $\alpha$ -mannans  
 stereocontrolled synthesis, 276–278
- MPEG glycoside. *See*  
 Monomethylpolyethylene glycoside
- Mucin oligosaccharides, as acceptors  
 of sialic acid, 339–341
- Mucin-associated surface proteins (MASP), 327
- Mucins, of *T. cruzi*, 321–335, 322f,  
 326f, 326t, 329f  
 biological functions of, 335  
 carbohydrate structures in, 327–335, 329f  
 genetic variability of, 322–327, 326f, 326t  
 GPI in, 316–317
- MUNeu5Ac derivatives. *See* 2'-*O*-(4-  
 Methylumbelliferyl)- $\alpha$ Neu5Ac  
 derivatives
- Murray's reagent. *See* Dimethyldioxirane
- Mycobacterium smegmatis*, 258
- Mycobacterium spp.*, 7

## N

- Neighboring-group participation  
 in galactopyranosyl oxacarbenium ions,  
 122–123, 122f, 124f, 125–126t, 141

- methodology development for, 145
  - proton transfer and, 131–132, 133–134f, 135
  - in stereocontrolled synthesis of  $\alpha$ -mannans, 262–281
    - with allyl glycosides, 263–264
    - chemoselective cleavage, 269, 271
    - cyclohexylidene orthoester approach to, 267–269
    - $\alpha$ -(1 $\rightarrow$ 4)-eicomannan, 272–273
      - with glycosyl chlorides, 262–263
    - $\alpha$ -(1 $\rightarrow$ 2)-mannan, 278–281
    - $\alpha$ -(1 $\rightarrow$ 6)-mannan, 279
    - mannosyl iodide for, 270–272
    - MPEG glycosides for, 276–278
    - O-2-protecting group in, 272–273
    - $\alpha$ -(1 $\rightarrow$ 3)-pentamannan, 264–265
    - pentenyl glycoside approach to, 264–267
    - pentenyl orthoester approach to, 266, 268, 270
    - polymer-supported, 279–280
    - thioglycoside activation for, 275–276
    - trichloroacetimidate
      - method for, 268–269, 271
      - trichloroacetimidate with thioglycoside donors, 274–275
  - in stereocontrolled synthesis of  $\alpha$ -rhamnans, 282t–284t
- NETNES, 315, 352, 353f
- GPI in, 318
- Neu5Ac2en, 345
- Neutral species, oxacarbenium ion equilibrium with, 99
- N*-Glycolylneuraminic acid, TcTS transfer of, 345, 347
- p*-Nitrophenylthio glycosides, active-latent strategy for, 186
- NMR coupling constants, angular dependence of, 18–19, 21
- NMR spectroscopy, improvements of, 19–20
- Non-Leloir pathway, for oligosaccharide synthesis with glycosyltransferases, 232–233
- Nonnatural donors, for TcTS reaction, 342–343
- Nucleophiles, in glycosylation reactions, 99
  - methodology development for, 146
- ## O
- Oligosaccharide synthesis
  - automated synthesis, 224–226
  - chemical glycosylation principles, 165–167
  - chemoselective strategies for, 196–207
    - armed–disarmed approach, 197–201
      - disarming by remote substituents, 202–203
      - disarming by torsional effects, 203–206
    - inverse armed–disarmed approach, 200–201
  - reactivity-based programmable strategy, 201–202
  - super-armed glycosyl donors, 206–207
- cis-cis* patterned, 199–200
- convergent block, 169–177
  - advantages of, 173
  - of biantennary heptasaccharide, 172–173
  - of high mannose-type oligosaccharide, 173–175
  - of Lewis X structure, 175–176
  - of pneumococcal oligosaccharide serotype 14, 176–177
  - of *Spergularia ramosa* pentasaccharide, 171–172
  - variation A, 169–171
  - variation B, 175
- enzymatic approach to, 228–234
  - with glycosidases, 233–234
  - with glycosyltransferases, 230–233
- fluorous tag-supported synthesis, 226–229
- introduction to, 162–165, 164f
  - challenges of, 163
  - new methods for, 163–165
- ionic liquid-supported, 228
- linear, 167–169
  - of H-type II pentasaccharide, 169–170

- Oligosaccharide synthesis (*cont.*)
- of pneumococcal oligosaccharide serotype 6A, 167–169
  - microreactor synthesis, 228–229
  - one-pot glycosylation strategies, 214–219
    - development of, 121
    - by *in situ* preactivation, 218
    - major concepts of, 214–216
    - by programmable strategy, 216–218
    - regioselective synthesis, 208–209
    - by selective activation, 216–217
  - outlook for, 234–235
  - polymer-supported synthesis, 219–222
  - rapid and high-throughput
    - technologies for, 213–228
    - fluorous tag-supported and microreactor synthesis, 226–229
  - one-pot glycosylation strategies, 214–219
    - polymer-supported, solid-phase, and automated synthesis, 219–226
  - regioselectivity-based strategies for, 208–213
    - bidirectional approaches, 211–213
    - hydroxyl reactivity, 208–210
    - triphenylmethyl reactivity, 210–211
  - selective strategies for, 177–196
    - active–latent strategy, 185–188
    - orthogonal and semi-orthogonal strategies, 188–193
    - selective activation, 177–182
    - steric hindrance deactivation, 193–194
    - temporary deactivation concept, 193–196
    - two-step activation and *in situ* preactivation, 182–185
  - solid-phase synthesis, 219–224
    - acceptor-bound approach, 220, 222, 224
    - donor-bound approach, 220, 222–223
    - types of, 220
    - trans-trans* patterned, 200
- Oligosaccharides
- of *T. cruzi*, sialylation of, 339–347
  - of *T. cruzi* LPPG, 315, 315f
  - of *T. cruzi* mucins
    - chemical synthesis of, 328–333
    - HPAEC-PAD analysis of, 334
    - interstrain variation of, 328, 329f
- O-linked oligosaccharides,
- of *T. cruzi* mucins
    - chemical synthesis of, 328–333
    - interstrain variation of, 328, 329f
- One-pot glycosylation strategies, 214–219
- development of, 121
  - by *in situ* preactivation, 218
  - major concepts of, 214–216
  - $\alpha$ -mannan synthesis with, 252–254
  - by programmable strategy, 216–218
  - reactivity-based programmable strategy for, 201–202
  - regioselective synthesis, 208–209
  - by selective activation, 216–217
  - super-armed glycosyl donors for, 206–207
- Orthoesters, neutral, galactopyranosyl oxacarbenium ions, 123, 126–128
- Orthogonal strategies
- for oligosaccharide synthesis, 188–193
  - in solid-phase synthesis, 220
- Oxacarbenium ions
- glycosidic bonds and, 84
  - nucleophile reactions with, 99
- P**
- Pasteurella multocida*, enzyme from, 231–232
- PC MODEL, 67
- PCILO quantum chemical method, 42–43
- Pentafluorobenzoyl ester, disarming by, 202–203
- $\alpha$ -(1→3)-Pentamannan, synthesis of, 259–260
- Pentenyl glycoside, in stereocontrolled synthesis of  $\alpha$ -mannans, 264–267
- O-Pentenyl glycosides
- active–latent strategy for, 186
  - armed–disarmed approach for, 198–199
  - in orthogonal strategy, 192
  - selective activation, 180–182

- two-step activation for, 184–185
- Pentenyl orthoester, in stereocontrolled synthesis of  $\alpha$ -mannans, 266, 268, 270
- S*-Phenyl glycosides  
in orthogonal strategy, 189–191  
for two-step activation, 182–184
- Phenylselenenyl, for selective activation, 179–181
- Phosponic acid derivatives, TcTS inhibition with, 346, 348f
- Phytoalexin-elicitor active oligosaccharide, steric hindrance deactivation synthesis of, 193–194
- PI-88. *See*  $\alpha$ -(1→3)-Pentamannan
- PIROUETTE, 67
- Pneumococcal oligosaccharide group B type III, inverse regioselectivity synthesis of, 210–211
- Pneumococcal oligosaccharide serotype 6A, traditional linear synthesis of, 167–169
- Pneumococcal oligosaccharide serotype 14 convergent block synthesis of, 176–177  
temporary deactivation concept  
synthesis of, 195–196
- p*-Nitrophenyl  $\alpha$ -sialosides, as donor for TcTS reaction, 342
- 2'-*O*-(*p*-Nitrophenyl)- $\alpha$ Neu5Ac (*p*NPNeu5Ac) derivatives  
as donors for TcTS reaction, 342–344  
trans-sialylation with, 344–346
- p*NPNeu5Ac derivatives.  
*See* 2'-*O*-(*p*-nitrophenyl)- $\alpha$ Neu5Ac derivatives
- Polymer-supported synthesis  
convergent building-block strategy with, 220–222  
of  $\alpha$ -mannans, 279–280  
of oligosaccharides, 219–222
- Polyols, reactivity-based regioselective glycosylation of, 208–210
- Pople–Santry LCAO–MO method, 23
- Potential energy surface (PES)  
of galactopyranosyl oxocarbenium ions, 96f, 97  
hydronium ions on, 130
- Programmable strategy  
for oligosaccharide synthesis, 201–202  
in one-pot glycosylation strategies, 216–218
- Promoter, for armed–disarmed approach, 197–198
- Propargyl ethers, for glycosylation reactions, 116
- Protecting groups  
for galactopyranosyl oxocarbenium ions, 87–88  
facial selectivity, 103–104  
interaction of, 118  
methodology development for, 145  
reactivity and, 119–120  
rotation and, 119  
in glycosylation reactions, 165–166  
product purity and, 129
- Proton transfer  
in galactopyranosyl oxocarbenium ions, 141  
facial selectivity, 102, 103f  
methodology development for, 145  
neutral orthoesters, 123, 126–128  
in glycosylation reactions, 105, 106–107f, 109, 130–136  
acyl-transfer and, 131–132  
energetic magnitude of, 135–136  
methodology development for, 145  
neighboring-group participation, 131–132, 133–134f, 135  
rates of, 131  
timing of, 130–131
- Proton–carbon couplings, 36–45  
 $^3J_{\text{HCCC}}$ , 41–42  
 $^3J_{\text{HCOC}}$ , 37–41, 39f  
 $^3J_{\text{HCSC}}$ , 42–43  
 $^3J_{\text{HOCC}}$ , 43–45, 44f
- Proton–nitrogen couplings,  $^3J_{\text{HCCN}}$ , 45–47, 46f–47f
- Proton–phosphorus couplings,  $^3J_{\text{HCOP}}$ , 47–51, 48f

Proton-proton couplings, 21–36

$^3J_{\text{HCCH}}$ , 21–32

$^3J_{\text{HCNH}}$ , 32–33

$^3J_{\text{HCOH}}$ , 33–36

$^3J_{\text{HCSIH}}$ , 36

$^4J_{\text{HCCCH}}$ , 64–68, 66f

$^4J_{\text{HC=CCH}}$ , 68

$^5J_{\text{HCCCCH}}$ , 68–69, 69f

$^5J_{\text{HCC=CCH}}$ , 69

Pseudorotation, in canonical

vector representation, 111, 111f

PSEUROT program, 29, 41, 60

Pyranose rings

$^3J_{\text{HCCH}}$  values in, 26

$^3J_{\text{HCOH}}$  values in, 34–35, 35f

Pyridine derivatives, TcTS inhibition

with, 348, 348f

## Q

QM. *See* Quantum mechanical studies

QM-MM. *See* Quantum mechanical-molecular mechanics studies

Quantum mechanical (QM) studies

deficiencies of, 89

of oxacarbenium ions, 84, 87–89

Quantum mechanical-molecular mechanics

(QM-MM) studies, of oxacarbenium

ions, 87

experimental agreement, 117

for structure study, 89–90

## R

Reactivity-based programmable strategy, for  
oligosaccharide synthesis, 201–202

Regioselectivity-based strategies, for  
oligosaccharide synthesis, 208–213

bidirectional approaches, 211–213

hydroxyl reactivity, 208–210

triphenylmethyl reactivity, 210–211

Remote substituents disarming, for

oligosaccharide synthesis, 202–203

Rhamnans, stereocontrolled synthesis of

introduction to, 251–252, 286

$\alpha$ -rhamnans, 281–285, 282t–284t

$\beta$ -rhamnans

by direct methods, 299–301

by indirect methods, 291

$\alpha$ -Rhamnans, stereocontrolled synthesis of,  
281–285

in absence of neighboring-group

participation, 282t

neighboring group-directed, 282t–284t

$\beta$ -Rhamnans, stereocontrolled synthesis of

by direct methods, 299–301

$\beta$ -rhamnotetraose, 300–301

$\beta$ -(1→4)- $\beta$ -(1→2)-rhamnotriose,

299–300

by indirect methods, 291

$\beta$ -rhamnotetraose, synthesis of, 300–301

$\beta$ -(1→4)- $\beta$ -(1→2)-Rhamnotriose, synthesis  
of, 299–300

Ring conformation, of galactopyranosyl

oxacarbenium ions, 89–98, 141

geometric parameters of, 95–97, 96t

geometry optimization, 91–95, 93t, 94f, 95f

leaving groups, 104

protecting groups and, 104

starting geometry for, 89–91, 91f, 92, 94

Ring-inversion barrier

atomic force microscopy for, 112–113

in galactopyranosyl oxacarbenium ions,

110–114, 111f, 112f, 112t

3D ROESY-HSQC technique, 52

Rotation, role in galactopyranosyl

oxacarbenium ions, 118–130, 119f

acyl-transfer side reaction, 123, 126–128

hyperconjugative interactions,

118–119, 119f, 120f

neighboring-group participation,

122–123, 122f, 124f, 125–126t

protecting groups, 119–121

substituents, 121

## S

*Saccharomyces cerevisiae*, 257

SAPA. *See* Shed acute-phase antigen

SBox. *See* S-Benzoxazolyl

SCPT-INDO calculations, 58

- Selective activation  
for oligosaccharide synthesis, 177–182  
  heparin-like oligosaccharides, 179–180  
  with three leaving groups, 179–181  
  three step sequential, 180–182  
in one-pot glycosylation strategies,  
  215–217  
orthogonal strategies v., 189  
in solid-phase synthesis, 220
- Selective strategies, for oligosaccharide  
synthesis, 177–196  
active-latent strategy, 185–188  
orthogonal and semi-orthogonal strategies,  
  188–193  
selective activation, 177–182  
steric hindrance deactivation, 193–194  
temporary deactivation concept, 193–196  
two-step activation and *in situ*  
  preactivation, 182–185
- Selenoglycosides, two-step  
activation for, 184–185
- Semi-orthogonal strategies,  
for oligosaccharide synthesis, 188–193
- Shed acute-phase antigen (SAPA), 336
- Sialic acid  
mucin oligosaccharides as acceptors  
of, 339–341  
TcTS transfer of, 336, 337f
- Sialic acid-binding site  
compounds studied as inhibitors of,  
  345–349, 348f–350f  
of TcTS, 338–339
- Sialyl donor, for TcTS reaction,  
modifications of, 343–347
- Sialylation, of *T. cruzi* oligosaccharides,  
  339–347
- $\alpha$ -(2→3)-Sialyllactose, as donor  
for sialylation of *T. cruzi*  
oligosaccharides, 341
- Sialyltransferase, oligosaccharide  
synthesis with, 231–232
- Side-chain orientation and conformation, in  
galactopyranosyl oxacarbenium  
ions, 109–118
- reactivity, 109–110  
  ring-inversion barrier, 110–114,  
    111f, 112f, 112t  
  steric buttressing, 116–117  
  through-bond activation, 115, 115f  
  through-space interaction efficiency, 114
- Solid-phase synthesis  
acceptor-bound approach, 220, 222, 224  
donor-bound approach, 220, 222–223  
of  $\alpha$ -mannans, 279–280  
types of, 220
- Solvation energy, for CBS  
  calculation, 89
- Solvents  
 $\alpha$ -mannan stereocontrolled  
  synthesis in frozen, 254–255  
oxacarbenium ions and, 99
- Solvent-separated ion pair (SSIP)  
methodology development for, 146  
oxacarbenium ion  
  equilibrium with, 99  
  facial selectivity and, 100–101  
  ionization and, 137
- SOPPA *ab initio* calculations, 63
- Spergularia ramosa* pentasaccharide,  
  convergent block synthesis of, 171–172
- SSIP. *See* Solvent-separated ion pair
- Ssp4, GPI in, 318
- STaz. *See* S-ThiazolinyI
- Stereocontrolled synthesis of mannans and  
rhamnans, 251–301  
introduction to, 251–252, 286  
 $\alpha$ -mannans  
  in absence of neighboring-group  
    participation, 252–261  
  neighboring group-directed, 262–281  
   $\alpha$ -rhamnans, 281–285, 282t–284t
- Stereoselectivity, of glycosylation reactions,  
  103–104, 103f  
  manipulation of, 136  
  steric buttressing, 116–117
- Stereospecificity, of galactopyranosyl  
  oxacarbenium ions, 103–105, 109, 142  
  ionization and, 137–138, 139f

- Stereospecificity, of galactopyranosyl oxacarbenium ions (*cont.*)  
 pressure dependence of, 121
- Steric buttressing, in glycosylation reactions, 116–117
- Steric hindrance deactivation,  
 for oligosaccharide synthesis, 193–194
- Sucrose, electron density of, 85
- Super-armed glycosyl donors, for  
 oligosaccharide synthesis, 206–207
- T**
- Tc85 glycoprotein, 336–337
- TcMUC family. *See Trypanosoma cruzi*  
 mucin gene family
- TcSMUG family. *See Trypanosoma cruzi*  
 small mucin gene family
- TcTS. *See Trypanosoma cruzi* trans-sialidases
- Temporary deactivation concept, for  
 oligosaccharide synthesis, 193–196
- 2,3,4,6-Tetra-*O*-methyl- $\beta$ -D-glycopyranosides,  
 87. *See also* Galactopyranosyl  
 oxacarbenium
- tGPI mucins, carbohydrate  
 structures in, 335
- Thermal vibrational excitation,  
 ionization of galactopyranosyl  
 oxacarbenium  
 ions by, 140–141
- S-ThiazolinyI (STaz)  
 in orthogonal strategy, 190–192  
 for selective activation, 182  
 temporary deactivation  
 concept, 193–195
- Thioglycosides  
 for  $\alpha$ -mannans stereocontrolled synthesis  
 activation for, 275–276  
 in trichloroacetimidate approach,  
 274–275  
*in situ* preactivation for, 185
- Through-space stabilizing electronic effect, in  
 galactopyranosyl oxacarbenium, 85  
 efficiency of, 114  
 energetics of, 103–104
- Thr-Thr-[LacNAcThr]-Thr-Thr-Gly,  
 synthesis of, 333–334
- Torsional angles  
 of oligonucleotides, 48–49, 48f  
 online calculators for, 70–72
- Torsional effects disarming, for  
 oligosaccharide synthesis, 203–206
- Transition states (TS), of glycosylation  
 reactions, 141
- Trialkylsilyl ethers, for glycosylation  
 reactions, 116
- Trichloroacetimidate approach,  
 to  $\alpha$ -mannans stereocontrolled  
 synthesis, 257,  
 259–260, 268–269, 271  
 with thioglycoside donors, 274–275
- Trifluoroacetimidate approach,  
 to  $\alpha$ -mannans stereocontrolled  
 synthesis, 259–260
- Triphenylmethyl reactivity, in  
 oligosaccharide synthesis, 210–211
- Tritylated thioglycosides, for bidirectional  
 strategy of synthesis, 213–214
- Trypanosoma cruzi*, 311–355  
 cell surface glycoconjugates of, 313–354  
 glycoinositolphospholipids, 313–321,  
 314f–316f, 322f  
 mucins, 321–335, 322f, 326f,  
 326t, 329f  
 other glycoproteins, 352–354, 353f–354f  
 trans-sialidase, 336–352, 337f–338f,  
 348f–351f  
 concluding remarks, 354–355  
 introduction to glycobiology of, 312  
 life cycle of, 312–313, 313f
- Trypanosoma cruzi* mucin gene (TcMUC)  
 family, 324, 326f, 326t, 327
- Trypanosoma cruzi* small mucin gene  
 (TcSMUG) family, 322–324, 326f, 326t
- Trypanosoma cruzi* trans-sialidases (TcTS),  
 52, 336–352, 337f–338f, 348f–351f  
 biological effects of, 350–352  
 GPI in, 317  
 inhibition of, 345–350, 348f–351f



- in selective sialylation of
  - oligosaccharides, 339–347
- structure and catalytic
  - mechanism, 336–340, 337f–338f
- Trypomastigote small surface antigen (TSSA), of *T. cruzi*, 324, 327
- TSSA. *See* Trypomastigote small surface antigen
- Two-step activation
  - active–latent strategy v., 186
  - for oligosaccharide synthesis, 182–185
  - in solid-phase synthesis, 220

## V

- VB calculations, 21
  - for  $^3J_{\text{HCCH}}$ , 21–22
  - for  $^3J_{\text{CCCC}}$ , 55–57
  - for  $^4J_{\text{HCCCH}}$ , 65
- Vicinal coupling constants, 21–59
  - carbon–carbon couplings, 51–59
    - $^3J_{\text{CCCC}}$ , 55–59
    - $^3J_{\text{CCOC}}$ , 52–55, 56f
  - carbon–tin couplings,  $^3J_{\text{CCCSn}}$ , 64
  - fluorine couplings, 60–63
    - $^3J_{\text{CCCF}}$  and  $^3J_{\text{COCF}}$ , 62
    - $^3J_{\text{FCCF}}$ , 62–63
    - $^3J_{\text{HCCF}}$ , 60–61
    - $^3J_{\text{HCNF}}$  and  $^4J_{\text{HCCNF}}$ , 61–62
  - proton–carbon couplings, 36–45
    - $^3J_{\text{HCCC}}$ , 41–42

- $^3J_{\text{HCOC}}$ , 37–41, 39f
- $^3J_{\text{HCSC}}$ , 42–43
- $^3J_{\text{HOCC}}$ , 43–45, 44f
- proton–nitrogen couplings,
  - $^3J_{\text{HCCN}}$ , 45–47
- proton–phosphorus couplings,
  - $^3J_{\text{HCOP}}$ , 47–51, 48f
- proton–proton couplings, 21–36
  - $^3J_{\text{HCCH}}$ , 21–32
  - $^3J_{\text{HCNH}}$ , 32–33
  - $^3J_{\text{HCOH}}$ , 33–36
  - $^3J_{\text{HCSIH}}$ , 36

## W

- W couplings, 64–68, 66f
  - extended, 68–69, 69f

## X

- Xylanase, oligosaccharide synthesis with, 234–235
- Xylans, synthesis of, 234–235
- 2-*O*- $\beta$ -D-Xylopyranosyl-D-xylose, 6
- 2-*O*- $\beta$ -D-Xylopyranosyl-L-arabinose, 6

## Z

- Zanamivir, 345
- Zero point energy (ZPE), for CBS calculation, 89
- ZPE. *See* Zero point energy

## AUTHOR INDEX

Page numbers in roman type indicate that the listed author is cited on that page; page numbers in *italic* denote the page where the literature citation is given.

### A

- Abbadi, A., 69, 95  
 Abe, N., 350, 392  
 Adachi, M., 45, 91  
 Adair, N. K., 39, 88  
 Adibekian, A., 173, 360  
 Adinolfi, M., 41–42, 59–60, 89–90, 93  
 Adriaenssens, E., 313, 387  
 Adryan, P., 33, 85  
 Aerts, J. M., 312, 386  
 Agarwal, A., 47, 68, 91, 94  
 Agashe, H. B., 340, 391  
 Aghajari, N., 120–122, 137  
 Agnihotri, G., 49, 51, 91–92  
 Ahluwalia, J., 118, 136  
 Ahn, M., 239–240, 290, 373, 382  
 Ahn, Y., 235, 372  
 Aiba, S.-I., 224, 330–331, 371, 390  
 Aich, U., 37–38, 88  
 Ait El Maate, F., 307–308, 383  
 Akahane, T., 321, 388  
 Akahani, S., 140, 159  
 Akiyama, Y., 173, 360  
 Aksenova, A. A., 209, 211, 368  
 al Daher, S., 11, 19  
 Albericio, F., 310, 384  
 Albersheim, P., 190, 364  
 Alberti, G., 30–31, 83  
 Albertin, L., 173, 360  
 Alberto, F., 114, 134  
 Alhaique, F., 109, 131  
 Aliès, F., 69, 95  
 Alix, A., 78, 98  
 Almeida Paz, F. A., 243, 374  
 Almeida, T., 36, 39, 75, 87, 97  
 Al-Mughaid, H., 181, 362  
 Alroy, J., 12, 19  
 Al-Shamalia, M., 33, 85  
 Alves, R. B., 67, 94  
 Amado, J., 75, 97  
 Amijs, C. H. M., 265, 378  
 An, Y.-Z., 245, 375  
 Anczewski, W., 253, 377  
 Anderson, J. L., 245, 375  
 André, S., 142, 146, 149–150, 152–153,  
     155–156, 158, 161, 163, 170, 180, 197,  
     208, 294–295, 326, 358, 362, 365, 367,  
     382, 389  
 Andrews, N., 143, 157, 162  
 Andrieux, C., 125, 138  
 Angyalosi, G., 313, 387  
 Annabi, B., 188, 363  
 Annunziata, R., 271–274, 379  
 Anton, J. A., 214–215, 369  
 Antonakis, K., 75, 97  
 Antoni, P., 289, 381  
 Aoi, K., 325, 328, 388, 390  
 Aoi, N., 110, 133  
 Aoki, J., 349, 392  
 Apostolopoulos, V., 312, 387  
 Appeldoorn, C. C. M., 329–330, 390  
 Arce, E., 341–342, 392  
 Armstrong, G. D., 142, 161, 172, 219,  
     222–223, 370  
 Arosio, D., 203–204, 222, 291–292, 310, 351,  
     367, 382  
 Arrieta, J. G., 114–116, 134  
 Arya, P., 185, 363  
 Asaka, Y., 61, 93  
 Asakura, J. I., 61, 93

- Ashton, P. R., 247, 289, 336–339, 347–348, 375, 381, 391
- Astronomo, R. D., 303–305, 383
- Astruc, D., 352, 392
- Auriault, C., 313, 387
- Auriol, D., 106, 130
- Autumn, K., 169, 357
- Avignon, G., 71, 96
- Awasthi, C., 79, 98
- Azizian, S., 71, 95
- B**
- Baburek, E., 33, 85
- Baciu, I. E., 115, 135
- Bae, A.-H., 78, 98
- Baek, M.-G., 296, 310–311, 328–329, 382, 385, 390
- Baigude, H., 310, 315–316, 385, 387
- Baker, G. R., 249, 286, 303, 376, 380, 383
- Baker, H., 286, 325, 380
- Baker, J. R. Jr., 310, 327, 384, 389
- Balanarsaiah, E., 68, 94
- Balasubramanian, K. K., 44, 90
- Balasubramaniam, P., 340, 391
- Balazs, E. A., 8, 13, 18–19
- Baldini, L., 203–204, 222, 292, 310, 351, 367
- Baldwin, J. W., 253, 377
- Ballardini, R., 210, 369
- Ballut, S., 216, 369
- Balogh, J., 40–41, 89
- Balogh, M., 33, 85
- Baly, A., 173, 359
- Balzarini, J., 242, 374
- Bandaru, N. M., 330–331, 390
- Banerjee, A. K., 34, 86
- Banerjee, U. C., 223, 370
- Banks, H. D., 201, 366
- Banks, M. R., 244, 374
- Bansal, R. K., 34, 86
- Baratt, G. M., 312, 386
- Baravelli, V., 77, 97
- Barett-Bergshoeff, M. M., 312, 386
- Barker, G. R., 4, 17
- Barnes, M. L., 185, 363
- Barnes, N., 312, 386
- Baron, A. J., 293, 382
- Barone, G., 41–42, 59–60, 89, 93
- Barrett-Bergshoeff, M., 313, 387
- Barrientos, A. G., 173, 359–360
- Baskaran, S., 34, 86
- Basso, A., 103, 128
- Basu, A., 328, 389
- Baum, L. G., 140, 144, 157–158, 159–160, 163
- Baum, R. P., 273–274, 379
- Baussanne, I., 227, 371
- Bayley, H., 172, 359
- Behera, R. K., 249, 376
- Behringer, C., 118, 136
- Beine, R., 103, 115, 118–119, 127, 136
- Bein, T., 30–31, 83
- Bejblová, M., 32, 84
- Belgacem, M. N., 69, 95
- Bellefleur, M.-A., 217, 369
- Ben, A., 40, 89
- Benaglia, M., 271–274, 379
- Bencomo, V. V., 142, 161
- Benesi, A. J., 338–339, 391
- Benhamioud, K., 184–186, 363
- Benito, J. M., 218, 224, 227, 370–371
- Benoist, E., 227, 371
- Berglund, J., 189, 363
- Bernad, A., 341, 392
- Bernardi, A., 203–205, 222, 291–292, 310, 351, 367, 382
- Bertozzi, C. R., 142–143, 161–162, 170, 253–255, 257, 259, 357, 377
- Bethell, D., 32, 84
- Bezouška, K., 205, 287, 367, 381
- Bhaduri, A. N., 312, 385
- Bhaskar, P. M., 33, 56, 58, 61, 84, 92–93
- Bhella, R. S., 312, 385
- Bhowmik, P., 258, 377
- Bianco, A., 63, 94, 252, 376
- Biedendieck, R., 115–116, 119, 135
- Biessen, E. A. L., 310, 313, 385, 387

- Bignon, C., 114, 134  
 Bijsterbosch, M. K., 312–313, 386–387  
 Billign, T., 45, 91  
 Binder, T. P., 103, 128  
 Bingel, C., 246, 375  
 Birch, R. G., 120, 137  
 Blais, J.-C., 209–210, 212–213, 367, 369  
 Blixt, O., 257, 259, 330, 377, 390  
 Bloch, K. J., 7, 17  
 Boas, U., 287, 380  
 Böck, C., 294–295, 382  
 Boehm, F. J., 146, 163  
 Boehm, G., 126, 138  
 Böker, M., 106, 130  
 Bols, M., 38, 88  
 Bonnett, R., 210, 369  
 Bonting, K., 114, 125, 133  
 Boons, G.-J., 34, 37, 87  
 Borges, C., 81, 99  
 Bornscheuer, U., 122, 137  
 Borrachero, P., 82, 99  
 Borrock, M. J., 314, 387  
 Boseb, A. K., 44, 90  
 Bosi, S., 242, 374  
 Botella, A., 32, 84  
 Böttcher, C., 248–249, 376  
 Bouchu, A., 42, 90  
 Bouckaert, J., 140, 159, 185, 189, 363–364  
 Boudon, C., 248, 375  
 Bracher, P. J., 310, 384  
 Bradley, R. K., 260, 378  
 Brady, K. T., 39, 88  
 Branderhorst, H. M., 292–293, 382  
 Branland, P., 209, 367  
 Breck, D. W., 30–31, 83  
 Bresalier, R. S., 142–143, 156, 161  
 Brewer, C. F., 103, 128, 140–150, 152–156,  
 158, 160–161, 163, 170, 173, 177,  
 358, 365  
 Briand, J.-P., 252, 376  
 Brocca, P., 173, 359  
 Brochette, S., 42, 90  
 Brocke, C., 319–320, 388  
 Brodie, S. J., 310, 314, 385  
 Brouwer, A. J., 307–308, 383  
 Brown, C. L., 247, 289, 336–339, 347–348,  
 375, 381, 391  
 Brown, K. L., 42, 90  
 Bruce, T., 181, 362  
 Brufani, M., 63, 94  
 Bu, H., 258, 377  
 Buchholz, K., 102, 105, 107–108, 110–111,  
 115–116, 122–123, 127, 129–133,  
 135–136  
 Buchholz, T. J., 314, 387  
 Buckley, L. J., 253, 377  
 Buczy, R., 117, 136  
 Budka, J., 205, 367  
 Bugge, B., 11–12, 19  
 Buhleier, E., 286, 336, 380  
 Bull, D. S., 40, 89  
 Bultel, L., 78, 98  
 Bundle, D. R., 40, 89, 142, 161, 172, 219,  
 222–223, 358, 370  
 Burchell, J., 143, 162  
 Burchert, M., 140, 160  
 Burke, S. D., 233, 372  
 Bursna, S., 32, 84  
 Burton, D. R., 303–305, 319, 383, 388  
 Butter, S. A., 32, 84  
 Buttersack, C., 69, 95  
 Byrd, J. C., 142–143, 156, 161
- C**
- Cadogan, J. I. G., 244, 374  
 Cai, F., 34, 86  
 Cai, Y., 203, 366  
 Cairo, C. W., 146, 163  
 Calinaud, P., 57, 92  
 Calvete, J. J., 149, 163  
 Camblor, M. A., 35–36, 87  
 Cameron, N. R., 173, 359–360  
 Caminade, A.-M., 356, 393  
 Camponovo, J., 352, 392  
 Camps, X., 247, 375  
 Cañada, J., 173, 359  
 Canda, T., 75, 97  
 Cantù, L., 173, 359

- Cantz, M., 140, 160  
 Cao, J., 244, 374  
 Cao, L., 261–263, 378  
 Cao, X., 67, 94  
 Cao, Z., 327, 388  
 Cappelle, S., 109, 131  
 Cardullo, F., 247, 375  
 Carlson, D., 143, 162  
 Caro, H. N., 224, 371  
 Carrettoni, L., 205, 366  
 Carrez, D., 213, 369  
 Carvalho de Souza, A., 173, 360  
 Casadevall, A., 159, 164  
 Casnati, A., 201, 203–204, 208, 222, 292,  
     310, 351, 365–367  
 Cataldo, J. R., 312, 386  
 Catalone, B. J., 339, 391  
 Cavada, B. S., 142–143, 145–149, 154–155,  
     161, 163  
 Cavaleiro, J. A. S., 209, 217, 243, 367, 369,  
     374  
 Čejka, J., 32, 84  
 Černý, M., 79, 98  
 Cerning, J., 114, 133  
 Chabre, Y. M., 171, 177, 198–199, 358, 361,  
     365  
 Chaen, H., 126, 138  
 Chai, W., 171, 358  
 Chakraborti, A. K., 33, 47, 85, 91  
 Chakraborty, P., 312, 386  
 Chaleix, V., 209, 213–214, 368  
 Chambert, R., 114–115, 133–135  
 Champavier, Y., 209, 213–214, 368  
 Chan, W. P., 169, 357  
 Chandra, T., 42, 90  
 Chang, C.-C., 314, 318, 387–388  
 Chang, D.-K., 314, 318, 387–388  
 Chapat, J.-F., 35, 87  
 Chassaing, S., 78, 98  
 Chastain, M., 102, 127, 230, 372  
 Chatal, J. C., 227, 371  
 Cheetham, P. S. J., 121, 124, 137  
 Chen, C.-C., 173, 190, 360, 364  
 Chen, C.-H. B., 245, 375  
 Chen, C.-L., 173, 360  
 Chen, G.-F., 173, 360  
 Chen, H., 105, 128, 217, 369  
 Chen, J.-Y., 30–31, 33–34, 83, 86, 260, 377  
 Chen, N. Y., 32, 84  
 Chen, X., 209–211, 253–255, 257, 259,  
     368–369, 377  
 Cheng, H. M., 82, 99  
 Cheng, S.-F., 51, 92, 314, 387  
 Cheng, Y., 287, 381  
 Cheshev, P. E., 330, 390  
 Cheung, P., 140, 160  
 Chevolut, Y., 240, 373  
 Chheda, J. N., 69, 74, 94  
 Chiappe, C., 201, 366  
 Chierici, E., 203, 366  
 Chinarev, A. A., 330, 390  
 Chmurski, K., 224, 371  
 Cho, K., 251, 376  
 Cho, S.-J., 173, 360  
 Choi, S. K., 168, 170, 357–358  
 Chou, K.-C., 169, 357  
 Choudhary, M. S., 8, 18  
 Choudhury, D., 189, 363  
 Chowdhury, N., 67, 94  
 Christensen, J. B., 287, 380  
 Chu, C., 32, 84  
 Chu, S., 180, 361  
 Chung, S. K., 352, 392  
 Cipolla, L., 354, 393  
 Cisciolkla, T., 212, 369  
 Clausen, H., 143, 162  
 Cleare, W., 159, 164  
 Climenti, M. J., 33, 85  
 Cloninger, M. J., 287, 327–328, 334, 336,  
     381, 389, 391  
 Cloutet, E., 352, 392  
 Codrington, J. F., 12, 19  
 Coe, D. M., 34, 86  
 Coego, A., 115, 135  
 Cohen-Anisfeld, S. T., 230, 372  
 Cohn, R. W., 260, 377  
 Colbert, D. T., 260, 377  
 Coleman, A. W., 201, 365

- Collet, B., 49, 91  
 Collins, P. M., 74, 96  
 Colonna, B., 210, 369  
 Connell, S. D., 293, 382  
 Connor, L. J., 143, 157, 162  
 Consoli, G. M. L., 203, 206–207, 366–367  
 Constable, E. C., 270–271, 379  
 Contino-Pépin, C., 198–199, 365  
 Cook-Blumberg, L., 209, 368  
 Cools, L., 189, 363  
 Corazon Trono, M., 193, 195, 364  
 Corma, A., 30–31, 33, 35–36, 69, 74, 84–85, 87, 94  
 Corma, J., 32, 84  
 Correa, J., 308–309, 384  
 Corti, M., 173, 359  
 Coste-Sarguet, A., 224, 370  
 Côté, G. L., 108–110, 122, 130, 132, 137–138  
 Cotillon, M., 69, 95  
 Cotten, M., 312, 386  
 Coudane, J., 312, 386  
 Couri, M. R. C., 67, 94  
 Coviello, T., 109, 131  
 Cozzi, F., 271–274, 379  
 Crehan, G., 32, 84  
 Crespo, L., 310, 384  
 Crittenden, R., 115, 135  
 Croisy, A., 213, 369  
 Crønstedt, A. F., 30, 84  
 Crout, D. H. G., 103, 128  
 Cruz, W. O., 34, 86  
 Cummings, R., 140, 159, 170, 357  
 Cunsolo, F., 203, 366  
 Curl, R. F., 241, 374  
 Czjzek, M., 114, 134  
 Czlapiński, J. L., 255, 377
- D**
- Da Ros, T., 242, 374  
 Da Silva, E., 201, 365  
 Dahmann, G., 172, 358  
 Dai, H., 252, 260, 376, 378  
 Dam, T. K., 140–143, 145–150, 152–156, 158, 160–161, 163, 170, 195, 358, 365  
 Daniel, P. F., 12, 19  
 Daniels, M. A., 144, 162  
 Danishefsky, S. J., 38, 88, 230, 372  
 Danon, D., 146, 163  
 Darbre, T., 317, 387–378  
 Das, B., 67, 94  
 Das, P. K., 312, 386  
 Das, S. K., 142, 146, 161, 193–195, 364–365  
 Dasgupta, S., 33, 52–53, 70, 85, 92, 95  
 D'Auria, M., 75, 97  
 Davies, G. J., 114, 116, 128, 134  
 Davis, B. G., 173, 359  
 Davis, M. M., 159, 163  
 De Almeida, M. V., 67, 94  
 de Brabander-van den Berg, E. M. M., 336, 391  
 De Genst, E., 189, 363  
 De Greve, H., 190, 364  
 de la Fuente, J. M., 173, 359–360  
 de la Torre, M. D. L., 243, 374  
 de la Torre Ramirez, J. M., 243, 374  
 de Lederkremer, R. M., 38, 43, 88, 90  
 De Maeyer, M., 114, 135  
 de Mol, N. J., 290–291, 382  
 De Montalk, G. P., 121, 137  
 De Paz, J. L., 171, 358  
 De Ranter, C. J., 114, 134  
 de Vries, R., 293, 382  
 De Wolf, M. J. S., 204, 367  
 Dedola, S., 173, 361  
 Dedonder, R., 114–115, 133  
 Defaye, J., 224, 227, 370–371  
 DeGasperi, R., 11, 19  
 Deguise, I., 344–346, 392  
 Dekker, M., 123, 137–138  
 Del Favero, E., 173, 359  
 Delgado, R., 341, 392  
 DeLuca, A. W., 143, 162  
 Demetriou, M., 140, 144, 160, 162  
 Demuth, B., 107–108, 130  
 Demuth, K., 108, 111–112, 131, 133  
 Denkwalter, R. G., 310, 384  
 Dennis, J. W., 140, 144, 160, 162  
 Derevitskaja, V. A., 230, 372

- Derouane-Abd Hamid, S. B., 32, 84  
 Derouane, E. G., 32, 84  
 Dersch, P., 119, 136  
 Descotes, G., 42, 90  
 Deshpande, D., 312, 386  
 Desjardins, L., 213, 369  
 Dessen, A., 146, 152–153, 163  
 Dewald, J., 286, 325, 380  
 Di Gulielmo, G. M., 140, 160  
 Diáñez, M. J., 82, 99  
 Diaz, V., 341, 392  
 Diebold, S. S., 312, 386  
 Diederich, F., 243, 247–248, 374–375  
 Dijkhuizen, L., 108–116, 125, 127,  
     130–133, 135–136, 138  
 Dijkstra, B. W., 109, 112, 131, 133  
 Dillon, C. J., 32, 84  
 Disney, M. D., 171, 358  
 Dittmeyer, R., 124, 137  
 Djedaini-Pilard, F., 224, 370  
 Djouzi, Z., 125, 138  
 Dobrindt, U., 329–330, 390  
 Dodziuk, H., 253, 377  
 Doelle, H. W., 115, 135  
 Doelle, M. B., 115, 135  
 Dohi, H., 256–257, 377  
 Dolgonos, G., 253, 377  
 Dols, M., 106, 130  
 Dominique, R., 193–195, 364  
 Domurado, M., 312, 386  
 Dondoni, A., 76, 97, 196, 201, 203, 243,  
     365–366, 374  
 Dondorff, M. M., 108–109, 130  
 Donker, W., 312, 386  
 Doores, K. J., 173, 359  
 Dörner, S., 228, 371  
 Doz, F., 209–210, 212–213, 367, 369  
 Drain, C. M., 209–211, 368–369  
 Drewry, D. H., 34, 86  
 Drickamer, K., 140–141, 159, 161, 310, 385  
 Drijfhout, J. W., 312, 387  
 Drijfhout, R., 318, 388  
 Du, Y., 45, 51, 91–92  
 Duarte, R., 209, 368  
 Duarte, T., 81, 99  
 Dubber, M., 178, 182, 218, 323, 362, 370, 388  
 Dube, D. H., 143, 162  
 Ducret, A., 103, 128  
 Ducros, V. M., 105, 128  
 Dudič, M., 205, 367  
 Dudkin, V. Y., 102, 127, 230, 372  
 Duhamet, J., 69, 71–72, 95–96  
 Dumesic, J. A., 69, 74, 95  
 Dumy, P., 228, 372  
 Duncan, R., 287, 380  
 Dunkerton, L. V., 39, 88  
 Dupradeau, F.-Y., 219–220, 370  
 Durand, R., 69, 71–72, 95–96  
 Duthaler, R. O., 282–284, 380  
 Dutta, T., 340, 391  
 Dwek, R. A., 170, 319, 357, 388  
 Dwyer, F. G., 32, 84  
 Dwyer, G. G., 32, 84  
 Dziadek, S., 319–320, 388
- E**
- Ebert, K. H., 106, 111, 129  
 Ebitani, K., 33, 85  
 Echegoyen, L., 247, 375  
 Eckhardt, A. E., 143, 162  
 Eckhardt, T. H., 110, 132  
 Edwards, J. R., 103, 128  
 Eeuwema, W., 109–110, 112, 131–133  
 Eggleston, G., 110, 122, 132, 137–138  
 Egron, M.-J., 75, 97  
 Eguchi, A., 240, 373  
 Eguchi, S., 243, 374  
 Ehlers, S., 177–178, 182, 361–362  
 Ehrhardt, C., 282–284, 380  
 Ejchart, A., 253, 377  
 Ekelhof, B., 124, 137  
 Eklund, P. C., 260, 377  
 Eklund, S. H., 106, 108, 129  
 el Maate, F. A., 307, 329–330, 383, 390  
 el-Hiti, G. A., 32–33, 84–85  
 Elkin, T., 260, 378  
 Elsner, K., 302, 383  
 Ende, W. V., 114, 134–135

- Enes, R. F., 243, 374  
 Eneyskaya, E. V., 114–115, 134  
 Engel, J., 159, 164  
 Erhardt, M., 252, 376  
 Esfand, R., 286, 310, 334, 380, 384  
 Esko, J., 140, 159, 170, 357  
 Esser, M. T., 102, 127  
 Estrada, M. D., 82, 99  
 Estroff, L. A., 310, 384  
 Esumi, Y., 349–352, 392  
 Euske, J. M., 39, 88  
 Evangelista, E. A., 67, 94  
 Evans, J. E., 11, 19  
 Evans, N. A., 12, 19  
 Eversole, W. G., 30–31, 83  
 Eylar, E. H., 10, 18  
 Ezekowitz, R. A. B., 312, 386
- F**
- Fabbri, D., 77, 97  
 Faber, E. J., 110–111, 132  
 Fabre, E., 110, 132  
 Faijes, M., 105, 129  
 Fajula, F., 74, 96  
 Falentin, C., 78, 98  
 Fan, E., 228, 230, 238–240, 290, 372–373, 382  
 Farinha, A. S. F., 243, 374  
 Faugas, P., 71, 96  
 Faustino, M. A. F., 209, 368  
 Fay, M., 141, 161  
 Fazio, F., 171, 358  
 Fearing, R., 169, 357  
 Feher, F. J., 240, 373  
 Feizi, T., 171, 358  
 Feldman, A. K., 183, 363  
 Feng, M., 102, 127  
 Ferkol, T., 312, 386  
 Fernandes, A. C., 57, 93  
 Fernández, A., 173, 359  
 Fernandez-Megia, E., 308–309, 384  
 Fernández-Santana, V., 173, 359  
 Ferreira, B., 34, 86  
 Ferreira, M. J., 36, 39, 75, 81, 87, 97, 99  
 Ferretti, J. J., 111, 132  
 Ferrier, R. J., 39, 74, 88, 96  
 Field, R. A., 49, 61, 63, 91, 93–94, 173, 360–361  
 Figdor, C. G., 159, 163  
 Figueiredo, J. A., 57, 75, 93, 97  
 Figueiredo, M., 75, 97  
 Figures, W. R., 103, 128  
 Finiels, A., 35, 87  
 Finn, M. G., 77, 98, 258, 342, 344, 377  
 Finne, J., 180, 182, 362  
 Finnefrock, A. C., 230, 372  
 Fišerová, A., 205, 367  
 Fischer, E., 34, 87  
 Fitremann, J., 69, 95  
 Flager, M. J., 296–297, 382  
 Fletcher, H. G. Jr., 4, 16  
 Florent, J.-C., 42, 90  
 Flowers, H. M., 5–6, 8, 17–18  
 Fokin, V. V., 78, 98, 183, 363  
 Fokt, I., 39, 88  
 Folkin, V. V., 258, 342, 344, 377  
 Fontanella, M., 203–204, 222, 292, 310, 351, 367  
 Fontanille, P., 74, 96  
 Font, J., 78, 97  
 Foote, C. S., 245, 375  
 Forchielli, E., 5, 17  
 Forni, L., 33, 85  
 Fortier, S., 188, 363  
 Foster, D. A., 210–211, 369  
 Franck, B., 210, 368  
 Franck, R. W., 209, 368  
 Fraser, I. P., 312, 386  
 Fraser-Reid, B. O., 34, 37, 39, 45, 56–58, 74, 87–88, 91–93, 96  
 Fréchet, J. M. J., 183, 285, 288–289, 302, 323, 363, 380–381, 383, 388  
 Freeze, H., 140, 159, 170, 357  
 Fricke, T., 236, 238, 373  
 Friedman, B., 312, 386  
 Frison, N., 310, 385  
 Frutz, M.-A., 69, 95  
 Fuji, S., 122–123, 137



- Fujisawa, T., 78, 98, 256, 377  
 Fujita, N., 210, 368  
 Fujiwara, S., 34, 86  
 Fujiwara, T., 111, 132  
 Fukasawa, M., 312, 387  
 Fukuda, M., 142, 156, 161  
 Fukuda, S., 126, 138  
 Fukui, N., 245–246, 375  
 Full, R. J., 169, 357  
 Fuller-Schaefer, C., 296–297, 382  
 Fülling, G., 210, 368  
 Fulton, D. A., 201, 224, 365, 370  
 Furneaux, R. H., 310, 314, 385  
 Furuike, T., 224, 371  
 Futerman, C. L., 106, 111, 129  
 Fütterer, K., 114–115, 134
- G**
- Gabius, H.-J., 140, 142, 146, 149–150,  
 152–153, 155–156, 158, 160–161, 163,  
 170, 173, 180, 197, 208, 212, 294–295,  
 326, 358–359, 362, 365, 367, 369, 382,  
 389  
 Gac, S., 312, 386  
 Gadelle, A., 224, 370  
 Gajhede, M., 121, 137  
 Galante, E., 206–207, 367  
 Galecki, A. T., 327, 389  
 Galipeau, J., 188, 363  
 Gamage, S. D., 296–297, 382  
 Gambaryan, A. S., 330, 390  
 Gamblin, D. P., 173, 359  
 Gandini, A., 69, 95  
 Gandolfi, M. T., 210, 369  
 Ganong, W. F., 169, 357  
 Gansser, C., 5, 17  
 Gan, Z., 195, 310, 365, 384  
 Ganzle, M. G., 115, 135  
 Gao, C., 264, 378  
 Gao, Y., 240, 373  
 García, H., 30–31, 33, 84–85  
 Garcia Castro, R., 341, 392  
 García Fernández, J. M., 219–220, 224, 227,  
 370–371  
 García-López, J. J., 224, 371  
 Garcia-Rubio, I., 279–281, 379  
 Gardossi, L., 103, 128  
 Garg, H. G., 10, 18  
 Garg, M., 340, 391  
 Garofalo, C., 190, 364  
 Garwood, W. E., 32, 84  
 Gaspard, S., 208–209, 367  
 Gaspard, B., 41, 89  
 Gatard, S., 352, 392  
 Gaucher, S. P., 178–179, 361  
 Gautier, E. C. L., 33, 86  
 Ge, Y., 203, 366  
 Gelas, J., 57, 92  
 Genghof, D. S., 103, 128  
 Geng, X., 230, 372  
 Geraci, C., 203, 206–207, 366–367  
 Gerasimenko, O. V., 143, 157, 162  
 Gerken, T. A., 142–143, 145–149, 154–155,  
 161–162  
 Germain, A., 74, 96  
 Gervay-Hague, J., 173, 360  
 Gesson, J.-P., 40, 89  
 Gestin, J. F., 227, 371  
 Gestwicki, J. E., 142, 146, 161, 163  
 Giacalone, F., 242, 374  
 Gianneschi, N. C., 265, 378  
 Giannis, A., 194, 364  
 Gibson, M. I., 173, 359  
 Giguère, D., 193, 217, 364, 369  
 Gil, R. P. F., 67, 94  
 Gilbert, H. J., 105, 128  
 Gilbert, M., 292–293, 382  
 Gilpin, M. L., 111, 132  
 Gilson, J.-P., 30–31, 33, 83  
 Giménez-Martínez, J. J., 224, 371  
 Gingras, M., 198, 200, 365  
 Giordano, A., 105, 118, 129  
 Giovannini, P. P., 76, 97  
 Giralt, E., 310, 384  
 Giron-Gonzalez, M. D., 219–220, 370  
 Gisselbrecht, J.-P., 248, 375  
 Gitsov, I., 289, 381  
 Goddard, W. A., 286, 380

- Goekjian, P. G., 198, 200, 365  
 Goldberg, R., 116, 118, 136  
 Golubev, A. M., 114–115, 134  
 Gómez, A. M., 56–57, 92–93  
 Gómez-García, M., 227, 371  
 Gómez-Guillén, M., 82, 99  
 Gómez-Sánchez, A., 82, 99  
 Gonçalves, V. L. C., 56, 92  
 Gong, F.-C., 209, 368  
 Gonzales, J. M., 74, 96  
 Gonzy-Treboul, G., 114, 134  
 Görls, H., 273–274, 379  
 Gosney, I., 244, 374  
 Gotlieb, K. F., 69, 95  
 Goto, H., 126, 138  
 Gottschaldt, M., 273–274, 379  
 Götze, S., 115–119, 133–134  
 Gouin, S. G., 78, 98, 189, 219–220, 363, 370  
 Goussault, Y., 11, 18  
 Graf, L., 191, 364  
 Graham, A. E., 33, 86  
 Graham, R., 143, 162  
 Gramlich, V., 248, 375  
 Grandjean, C., 310, 313, 385, 387  
 Granet, R., 209, 213–214, 367–368  
 Grangeiro, T. B., 149, 163  
 Granovsky, M., 140, 160  
 Gras-Masse, H., 310, 313, 385, 387  
 Greatex, B. W., 310, 314, 385  
 Green, L. G., 78, 98, 183, 363  
 Greenwell, T. K., 318, 388  
 Gregory, J. D., 13, 19  
 Griegel, S., 212, 369  
 Grierson, D. S., 209–210, 212–213, 367, 369  
 Griffith, B. R., 45, 91  
 Grigorian, A., 144, 162  
 Grimm, K. M., 102, 127  
 Gronenborn, A. M., 328, 389  
 Gross, M., 248, 375  
 Gross, P. H., 8, 18  
 Grosso Ciponte, A., 205, 367  
 Gryniewicz, G., 39, 88  
 Gu, L., 253, 260–263, 377–378  
 Guan, H., 180, 362  
 Guerquin-Kern, J.-L., 208–209, 213, 367–369  
 Guibert, A., 114, 123, 134  
 Guimond, S., 159, 164  
 Guisnet, M., 30–31, 33, 36, 39, 83, 87  
 Gulhane, R., 47, 91  
 Guo, C.-C., 209, 368  
 Guo, C.-T., 351–352, 392  
 Gupta, D., 146, 152–153, 163  
 Gupta, V. K., 286, 303, 380, 383
- ## H
- Haag, R., 287, 380  
 Haataja, S., 180, 182, 362  
 Habicher, T., 247–248, 375  
 Hacker, J., 329–330, 389  
 Hacking, A. J., 116, 136  
 Hada, N., 228, 372  
 Hadad, C., 352, 356, 392–393  
 Haddon, R. C., 258, 260, 377  
 Haeckel, R., 79, 98  
 Hafner, H., 260, 378  
 Hahn, C. S., 68, 94  
 Haines, A. H., 58, 93  
 Hakomori, S. I., 7, 17, 143, 162  
 Halcomb, R. L., 38, 88  
 Halford, M. D., 8, 18  
 Halkes, K. M., 173, 360  
 Hall, M., 286, 325, 380  
 Hamada, S., 111, 132  
 Hamelryck, T., 140, 159  
 Hamilton, C. J., 103, 128  
 Hamilton, D. M., 106, 129  
 Hamon, M. A., 258, 260, 377  
 Hamouda, T., 327, 389  
 Hanack, M., 217, 370  
 Hana, S., 315–316, 387  
 Hancock, S. M., 105, 118, 128  
 Hanessian, S., 34, 37, 57, 87, 92, 180–181, 362  
 Hang, H. C., 142–143, 161  
 Hanisch, F.-G., 143, 162  
 Hansen, H. C., 180, 182, 362  
 Haraguchi, S., 78, 98  
 Hardy, E., 173, 359

- Hargreaves, J. S. J., 32, 84  
 Harrison, D., 110, 132  
 Hart, G., 140, 159, 170, 357  
 Hasebe, R., 68, 94  
 Hasegawa, T., 78, 98, 256, 267–269, 377, 379  
 Haser, R., 120–122, 137  
 Hashida, M., 312, 387  
 Hatanaka, M., 312, 386  
 Hatano, K., 350–352, 392  
 Hatch, D. M., 296–298, 382–383  
 Hattori, K., 315–316, 387  
 Hawker, C. J., 183, 258, 289, 342, 344, 363, 377, 381  
 Hayashi, K., 260, 378  
 Hayashi, T., 210, 369  
 Hayes, E. D., 293, 382  
 Hayes, M. M., 310, 384  
 Hayes, W., 178–179, 362  
 He, H., 32, 84  
 He, L.-N., 34, 86  
 He, M., 45, 91  
 Heath, J. R., 241, 253, 374, 377  
 Hecht, H. J., 115–116, 133  
 Hechter, O., 4, 16–17  
 Heegaard, P. M. H., 287, 380  
 Hehre, E. J., 103, 106, 128–129  
 Heidecke, C. D., 301, 383  
 Heincke, K., 107, 130  
 Helfferich, B., 37, 87  
 Hellmuth, H., 109–113, 131, 133  
 Henriksen, A., 121, 137  
 Henrissat, B., 108, 114, 131, 134  
 Hernáiz, M. J., 173, 360  
 Hernalsteens, J.-P., 190, 364  
 Hernandez, L., 114–116, 134–135  
 Hernández-Mateo, F., 173, 177, 193, 195, 219–220, 224, 361, 364–365, 370–371  
 Herrera, L., 173, 359  
 Herscovici, J., 75, 97  
 Herscovics, A., 11, 18  
 Herzner, H., 173, 359  
 Heynngnezz, L., 173, 359  
 Hilgraf, R., 183, 363  
 Hilkens, J., 143, 157, 162  
 Hilliard, J., 312, 386  
 Hillringhaus, L., 112–113, 133  
 Hill, R. L., 143, 162  
 Himo, F., 183, 363  
 Hino, K., 126, 138, 349–351, 392  
 Hino, T., 244, 374  
 Hirabayashi, J., 143, 157, 162  
 Hirano, T., 245–246, 375  
 Hirsch, A., 247–249, 375–376  
 Hisaeda, Y., 210, 369  
 Hobbel, S., 112–113, 133  
 Hodgson, P. K. G., 244, 374  
 Hodnett, B. K., 33, 85  
 Hofer, B., 109–110, 112, , 131, 133  
 Hogquist, K. A., 144, 162  
 Hojo, H., 321, 388  
 Hol, W. G. J., 220, 228, 230, 238–240, 290, 370, 372–373, 381–382  
 Hölderich, W. F., 30–31, 83  
 Hollingsworth, M. A., 143, 162  
 Holmbom, B., 69, 74, 94  
 Homann, A., 115–116, 119, 135  
 Hook, S. M., 310, 314, 385  
 Horvath, C., 204, 367  
 Hoshino, M., 245–246, 375  
 Hoshino, O., 8, 18  
 Hoshino, T., 111, 132  
 Hossain, L. H., 277–279, 379  
 Hotchkiss, J. A. T., 125, 138  
 Hou, Z., 238–240, 373  
 Hourdin, G., 74, 96  
 Howorka, S., 172, 359  
 Hrin, R., 102, 127  
 Hsieh, S. T., 169, 357  
 Hsu, T.-L., 303–305, 383  
 Huang, Y.-M., 209, 213–214, 368  
 Hu, H., 260, 377  
 Hu, N., 257, 259, 377  
 Hu, X., 201, 366  
 Hua, Y., 51, 92  
 Hudec, J., 30–31, 84  
 Hudson, C. S., 4, 16

Huel, C., 209, 368  
 Huffman, C. B., 260, 378  
 Hui, L., 210–211, 369  
 Hulíková, K., 205, 367  
 Hult, A., 289, 340, 381, 391  
 Hultgren, S., 190, 364  
 Hung, C.-S., 189, 363  
 Hung, S.-C., 79, 98  
 Hunt, J. N., 258, 342, 344, 377  
 Huo, Q., 30–31, 33, 83

## I

Iadonisi, A., 41–42, 59–60, 89–90, 93  
 Ibers, J. A., 214–215, 369  
 Iborra, S., 35–36, 69, 74, 87, 94  
 Ichikawa, Y., 141, 161  
 Igai, K., 350, 392  
 Ihre, H., 289, 381  
 Ikeda, K., 44, 90  
 Iloukhani, H., 71, 95  
 Im, J. U., 354, 393  
 Imberty, A., 171, 217, 240, 358, 369, 373  
 Inazu, T., 60, 93  
 Ince, S. J., 181, 362  
 Inohara, H., 140, 159  
 Inoue, S., 126, 138  
 Iqbal, Z., 217, 370  
 Irimura, T., 12, 19  
 Isac-García, J., 177, 224, 361, 371  
 Ishida, Y., 244, 374  
 Ishii, S., 245–246, 375  
 Ishizuka, T., 44, 90  
 Ismael, I., 75, 97  
 Isnail, R. A., 33, 85  
 Isobe, H., 250–251, 376  
 Isobe, M., 44, 91  
 Itkis, M. E., 258, 260, 377  
 Ito, H., 244, 374  
 Ito, T., 245–246, 375  
 Ito, Y., 41, 89  
 Itoh, K., 325, 388  
 Iverson, T., 260, 378  
 Iyer, S. S., 296–298, 382–383  
 Izquierdo, M., 173, 359

Izumi, Y., 68, 94  
 Izzo, L., 287, 380

## J

Jacobsen, R. P., 4, 16–17  
 Jacquot, R., 32, 84  
 Jaeger, K.-E., 317, 387  
 Jahn, D., 115–116, 119, 135  
 Jahn, M., 105, 128–129  
 Jain, N. K., 340, 391  
 James, L. F., 11, 19  
 Jameson, S. C., 144, 162  
 Jang, W. J., 354, 393  
 Janotka, I., 30–31, 84  
 Jarosz, S., 38–39, 69, 88, 95  
 Jayaraman, M., 302, 383  
 Jayaraman, N., 247, 289, 330–331, 347–348,  
 375, 381, 390, 392  
 Je, J., 253, 377  
 Jeanloz, D. A., 9, 18  
 Jeanloz, R. W., 3–14, 16–19  
 Ježek, J., 310, 384–385  
 Jelinek, J., 126, 138  
 Jensen, A. W., 242, 374  
 Jensen, K. J., 34, 38, 87  
 Jentoft, N., 143, 162  
 Jeon, H. B., 37, 87  
 Jespersen, H. M., 109, 131  
 Jessop, T. C., 252, 376  
 Jiang, X., 260, 378  
 Jiménez-Barbero, J., 170, 358  
 Jochum, A., 240, 373  
 Joerdening, H. J., 107, 130  
 Joffre, J., 35, 87  
 Johansson, E. M. V., 317, 387–388  
 Johansson, M., 340, 391  
 Johnson, K. M., 314, 387  
 Jonckheer, A., 114, 135  
 Jonker, D., 110, 132  
 Joosten, J. A. F., 307–308, 329–330, 383, 390  
 Jordao, C. I. C., 243, 374  
 Jördening, H. J., 105–106, 108, 111–112, 115,  
 118, 129–131, 133, 135  
 Jordens, J. J., 318, 388

- Jordens, R., 312, 387  
 Jordi, E., 114, 134  
 Joseph, R., 260, 378  
 Joucla, G., 110, 132  
 Joyce, J. G., 102, 127, 230, 372  
 Jung, S. M., 106, 111, 129  
 Justino, J., 75, 97  
 Jyojima, T., 43, 90
- K**
- Kabra, M., 340, 391  
 Kahne, D., 172, 359  
 Kajihara, Y., 80, 99  
 Kakehi, K., 240, 373  
 Kaldapa, C., 209, 367  
 Kale, R. R., 296–298, 382–383  
 Kallos, G., 286, 325, 380  
 Kalovidouris, S. A., 210, 330, 369, 390  
 Kaltgrad, E., 258, 342, 344, 377  
 Kaltner, H., 142, 146, 149–150, 152–153,  
 155–156, 158, 161, 163, 208, 294–295,  
 367, 382  
 Kamena, F., 102, 127  
 Kamerling, J. P., 173, 360  
 Kamitakahara, H., 228, 372  
 Kanai, M., 146, 163, 170, 358  
 Kaneda, K., 33, 85  
 Kaneta, N., 245–246, 375  
 Kanie, O., 228, 372  
 Kantchev, E. A. B., 314, 318, 387–388  
 Kantner, T., 105, 128  
 Kaper, T., 115, 135  
 Kappel, J. A., 33, 85  
 Karamanska, R., 173, 360  
 Kariuki, B., 271, 379  
 Kartha, K. P. R., 61, 93  
 Kasai, K., 143, 157, 162  
 Kasche, V., 122, 137  
 Kataoka, K., 173, 360  
 Katayama, H., 321, 388  
 Kato, H., 245–246, 248–249, 375–376  
 Katopodis, A. G., 282–284, 380  
 Katsuraya, K., 310, 385  
 Katzman, R. L., 8–9, 15, 18  
 Kaufman, R., 191–192, 364  
 Kauzlarich, S., 173, 360  
 Kawano, S.-i., 210, 368  
 Keading, W. W., 32, 84  
 Keim, W., 124, 137  
 Kemmink, J., 291, 382  
 Kemp, M. M., 190, 364  
 Kenny, T. W., 169, 357  
 Kensingler, R. D., 338–339, 391  
 Kessinger, R., 248, 375  
 Khan, A. S., 329–330, 390  
 Kicinska, A. M., 112, 133  
 Kieburg, C., 326, 389  
 Křen, V., 205, 367  
 Křenek, K., 205, 367  
 Kiessling, L. L., 140, 142, 146, 160–161, 163,  
 170, 233, 314, 357, 358, 372, 387  
 Kikkeri, R., 173, 277–281, 360, 379  
 Kikuchi, S., 256–257, 377  
 Kim, D. H., 125, 138  
 Kim, H.-R., 140, 159  
 Kim, J. M., 185, 201, 224, 235, 275–277, 363,  
 365, 371–372, 379  
 Kim, K. S., 37, 68, 87, 94, 235, 372  
 Kim, O.-K., 253, 377  
 Kim, T. H., 61, 93  
 Kim, Y. W., 105, 128, 235, 372  
 Kimizuka, N., 260, 378  
 Kimura, T., 256, 377  
 Kirchner, R., 236, 238, 373  
 Kirk, L., 115, 135  
 Kirsanovs, S., 108–109, 130  
 Kirumakki, S. R., 33, 84  
 Kishi, Y., 209, 368  
 Kishore Kumar, G. D., 34, 86  
 Kita, E., 349, 392  
 Kita, Y., 38, 88  
 Kitahata, S., 103, 128  
 Kitani, S., 44, 90  
 Kitov, P. I., 142, 161, 172, 219, 221–223,  
 358, 370  
 Kleban, M., 201, 366  
 Klette, I., 273–274, 379  
 Knauer, D. J., 240, 373

- Kneip, S., 119, *136*  
 Knol, J., 126, *138*  
 Ko, Y. H., 235, *372*  
 Kobayashi, K., 60, 93, 243, 245–246,  
     267–269, 374–375, *379*  
 Kochetkov, N. K., 230, *372*  
 Koepke, J. W., 34, *86*  
 Kohli, P., 252, *376*  
 Köhn, M., 218, *370*  
 Kojima, S., 268–269, *379*  
 Kolb, H. C., 77, *98*  
 Kolc, J., 310, *384*  
 Kolodny, E. H., 12, *19*  
 Kolomiets, E., 317, 387–388  
 Komba, S., 41, *89*  
 Komoto, M., 122–123, *137*  
 Konami, Y., 8, *18*  
 Kong, D.-L., 34, *86*  
 König, B., 236, 238, *373*  
 Koning, F., 312, 318, 387–388  
 Konitz, A., 73, *96*  
 Konstan, M., 312, *386*  
 Konstantinov, K. N., 140, *159*  
 Kooi, S., 253, *377*  
 Kopitz, J., 140, *160*, 208, *367*  
 Korakli, M., 115, *135*  
 Korneeva, O. S., 114–115, *134*  
 Koscielak, J., 7, *17*  
 Koshino, H., 350–351, *392*  
 Kostarelos, K., 252, *376*  
 Koth, D., 273–274, *379*  
 Kotsuki, H., 34, *86*  
 Kötter, S., 177–178, *361*  
 Kovensky, J., 78, 98, 189, 219–220, 363, *370*  
 Koya, M., 60, *93*  
 Koyama, T., 350–352, *392*  
 Kozak, K. R., 140, *160*  
 Kozianowski, G., 110, *132*  
 Koziel, H., 312, *386*  
 Kralj, S., 108–116, *130*,–*133*, *135*–*136*  
 Krallmann-Wenzel, U., 177–178, 182, 236,  
     238, 326, 361–362, 373, *389*  
 Kratz, F., 287, *380*  
 Krauss, I. J., 102, *127*, 230, *372*  
 Krausz, P., 209, 213–214, 367–368  
 Krebs, F. C., 339, *390*  
 Kreysa, G., 124, *137*  
 Krinichnaya, E., 253, *377*  
 Krishnamurthy, V. M., 310, *384*  
 Krishnudu, K., 79, *98*  
 Kroto, H. W., 241, *374*  
 Krufka, A., 159, *164*  
 Krummel, M. F., 159, *163*  
 Kuiper, J., 313, *387*  
 Kuldová, M., 205, *367*  
 Kulkarni, S. S., 79, *98*  
 Kulminskaya, A. A., 114, *134*  
 Kumar, R., 33, *85*  
 Kumar, V. S., 67, *94*  
 Kunwar, A. C., 79, *98*  
 Kunz, H., 173, 319–320, 359, *388*  
 Kunz, M., 120–121, 124, *136*  
 Kurose, M., 126, *138*  
 Kursa, M., 312, *386*  
 Kurszewska, M., 73, *96*  
 Kutner, W., 253, *377*  
 Kutterer, K. M. K., 185, *363*  
 Kuwahara, S., 256–257, *377*  
 Kuzuhara, H., 349–350, *392*  
 Kwok, W. S., 82, *99*  
 Kwon, Y. U., 102, *127*
- L**
- La Ferla, B., 354, *393*  
 Le Borgne, S., 114, *133*  
 Lacaze, G., 109, *131*  
 Lacerda, L., 252, *376*  
 Laere, A. V., 114, *134*  
 Lagnoux, D., 344–346, *392*  
 Lainé, V., 224, *370*  
 Laird, D. A., 74, *96*  
 Laketic, D., 69, *95*  
 Lamar, J. J., 12, *19*  
 Lammens, W., 114, *135*  
 Lamothe, J. P., 125, *138*  
 Lamparthe, I., 247, *375*  
 Landers, J. J., 327, *389*  
 Langermann, S., 189, *363*

- Langer, P., 181, 362  
 Langridge-Smith, P. R. R., 244, 374  
 Lansbury, P. T., 230, 372  
 Larroche, C., 74, 96  
 Lasala, F., 342, 392  
 Laszlo, P., 33, 85  
 Lau, K. S., 144, 162  
 Lauer, G., 79, 98  
 Laurent, T. C., 13, 19  
 Laurino, P., 173, 360  
 Lavelle, I., 209–210, 212–213, 367, 369  
 Law, H., 224, 371  
 Laya, M. S., 34, 86  
 Lazar, A. N., 201, 365  
 Le Roy, C., 140, 160  
 Le Roy, K., 114, 135  
 Le Strat, V., 70, 95  
 Leary, J. A., 178–179, 362  
 Leblanc, R. M., 247, 375  
 Lecomte, J., 33, 85  
 Ledvina, M., 310, 385  
 Lee, B. H., 68, 94  
 Lee, C., 144, 157–158, 163  
 Lee, D. Y. W., 45, 91  
 Lee, G. S., 253–255, 377  
 Lee, I., 327, 389  
 Lee, J.-C., 79, 98  
 Lee, M.-R., 171, 358  
 Lee, N. Y., 354, 393  
 Leer, R. J., 111, 132  
 Lee, R. T., 141, 160–161, 170, 310, 358, 384  
 Lee, Y. C., 34, 37, 87, 141, 160–161, 170, 177, 240, 310, 358, 361, 373, 384, 393  
 Lehmann, J., 195, 364  
 Lehn, J.-M., 265, 378  
 Lehrmann, H., 312, 386  
 Lensch, M., 142, 146, 150, 152–153, 155–156, 158, 161, 294–295, 382  
 Lepenies, B., 173, 360  
 Levy, H., 4, 16–17  
 Lewandowski, B., 69, 95  
 Lewis, L. A., 140, 160  
 Ley, S. V., 181, 362  
 Lhoták, P., 205, 367  
 Li, C., 78, 98  
 Li, H., 232, 253, 260, 312, 372, 377–378, 385  
 Li, N., 120–121, 136  
 Li, W., 264, 378  
 Li, X., 120–121, 137  
 Li, Y., 180, 287, 362, 381  
 Liang, P. H., 303–305, 383  
 Liang, W. W., 312, 386  
 Liang, Y. A., 169, 357  
 Lichtenthaler, F. W., 108, 130  
 Likhoshesterov, L. M., 230, 372  
 Likura, H., 250, 376  
 Lima, S., 72, 96  
 Lin, C.-C., 173, 360  
 Lin, Y., 253, 260–263, 376–377  
 Lina, B. A., 110, 132  
 Lindhorst, T. B., 177–178, 361  
 Lindhorst, T. K., 177–178, 182, 218, 228, 236, 238, 287, 299, 301–302, 326, 361–362, 370, 372–373, 380, 383, 389  
 Ling, H., 142, 161, 172, 219, 358  
 Linhardt, R. J., 45, 51, 91–92, 190, 364  
 Linsley, K. B., 12, 19  
 Liskamp, R. M. J., 173, 290–295, 307–308, 329–330, 361, 382–383, 390  
 Lisowska, E., 9, 18  
 Little, R. G., 214–215, 369  
 Liu, B., 180, 193–194, 197, 362, 364–365  
 Liu, F.-T., 140, 159  
 Liu, G.-y., 173, 360  
 Liu, I. Y., 11, 18  
 Liu, J.-H., 149, 156, 163, 228, 230, 260, 372, 378  
 Liu, X., 102, 127  
 Llinares, M., 332, 391  
 Loach, P. A., 214–215, 369  
 Lock, M. V., 4, 16  
 Lodish, S., 312, 386  
 Loganathan, D., 33, 37–38, 56, 58, 61, 84, 88, 92–93  
 Loing, E., 313, 387  
 Lok, S. M., 120–121, 136  
 Looock, B., 209–210, 213, 216, 367, 369  
 Lopes, R. G., 45, 91

López-Castro, A., 82, 99  
 Lopez-Munguia, A., 106, 108, 114, 125,  
*129–130, 133, 134, 138*  
 López-Nieto, M., 32, 84  
 Lord-Dufour, S., 188, 363  
 Loris, R., 140, 159  
 Lortie, R., 103, 128  
 Lotan, R., 146, 163  
 Lou, B., 180–181, 362  
 Lourvanij, K., 72, 74, 96  
 Loussouarn, A., 227, 371  
 Lovell, T., 183, 363  
 Lovering, A. L., 105, 128  
 Lu, A., 260, 377  
 Lu, F., 261–263, 377  
 Lu, J.-M., 33, 86  
 Lucas, S. D., 36, 87  
 Lukasavage, W. J., 310, 384  
 Lundquist, J. L., 170, 358  
 Luo, P. G., 261–263, 378  
 Lutov, D. N., 77, 97  
 Ly, H. D., 104, 128  
 Lyuksyutov, S., 260, 377

## M

Ma, X. F., 56, 92  
 MacGregor, E. A., 109, 131  
 Mackenzie, L. F., 104, 128  
 Madaj, J., 73, 96  
 Madhusudan, S. K., 63, 93  
 Madsen, R., 74, 96  
 Maggi, R., 32, 84  
 Magnusson, G. J., 40–41, 89, 180,  
*182, 362*  
 Magnusson, H., 340, 391  
 Mahender, G., 67, 94  
 Mahmood, A., 271, 379  
 Mahon, E., 312, 386  
 Maillard, P., 209–210, 212–213, 216,  
*367–369*  
 Majerski, P., 77, 97  
 Majoral, J.-P., 356, 393  
 Mäki-Arvela, P., 69, 74, 95  
 Makimura, Y., 268–269, 379

Makky, A., 216, 369  
 Malanga, C. J., 312, 386  
 Malkoch, M., 258, 289, 342, 344, 377, 381  
 Malmström, E., 340, 391  
 Maly, D. J., 170, 358  
 Mammen, M., 168, 172, 357–358  
 Mandaland, S., 53–54, 92  
 Mandal, D. K., 146, 163  
 Mangold, S. L., 328, 389  
 Mann, D. A., 170, 314, 358, 387  
 Mann, K., 149, 163  
 Mäntsälä, P., 119, 136  
 Manzoni, L., 271–274, 379  
 Marcato, P., 222–223, 370  
 Marchenay, Y., 125, 138  
 Marchesan, S., 242, 374  
 Marino, C., 38, 43, 88, 90  
 Marles, J., 105, 128–129  
 Marotte, K., 217, 369  
 Marques, J. P., 36, 39, 87  
 Marra, A., 76, 97, 196, 201, 203, 243,  
*365–366, 374*  
 Marshall, C. W., 4, 17  
 Marth, J. D., 140, 159–160, 170, 357  
 Martin, C. R., 252, 376  
 Martinez-Fleites, C., 115–116, 134  
 Martinluengo, M. A., 30–31, 83  
 Martin, N., 242, 374  
 Martin, S., 286, 325, 380  
 Martins, A., 45, 91  
 Martins, M. B., 173, 360  
 Masar, M. S., 265, 378  
 Mashima, H., 250, 376  
 Masson, C., 282–284, 380  
 Matalla, K., 117, 136  
 Mathiselvam, M., 58, 93  
 Matrai, J., 114, 135  
 Matricardi, P., 109, 131  
 Matsubara, Y., 61, 93  
 Matsui, T., 38, 46, 88  
 Matsumodo, T., 256, 377  
 Matsumotu, T., 40, 89  
 Matsumura, S., 40, 43–45, 89–91, 245, 375  
 Matsuo, G., 44–45, 90–91



- Matsuo, J.-I., 40, 89  
 Matsuo, T., 210, 369  
 Matsuoaka, K., 349–352, 392  
 Matsushita, Y.-I., 38, 45, 88  
 Matsuura, K., 260, 267, 378–379  
 Mattes, R., 120–122, 137  
 Matthews, M. M., 106, 111, 129  
 Maurer, S. V., 49–50, 91  
 Mauri, L., 203–204, 222, 292, 310, 351, 367  
 Mayer, R. M., 106, 111, 129, 310, 385  
 McBurney, W. T., 310, 314, 385  
 McCarthy, D., 252, 376  
 McGannon, C. M., 296–297, 382  
 McIntosh, L. P., 105, 128  
 McKean, D., 143, 157, 162  
 McKenzie, I. F., 312, 387  
 McKillop, A., 33, 86  
 McPherson, J. M. A., 312, 386  
 Mecca, T., 203, 366  
 Meedijk, J. D., 173, 360  
 Meier, L., 59, 93  
 Meijer, D. K., 312, 386  
 Meijer, E. W., 336–339, 391  
 Melai, B., 201, 365  
 Melchioni, C., 63, 94  
 Meldal, M., 173, 360  
 Mellet, C. O., 218, 370  
 Melnyk, O., 310, 313, 385, 387  
 Mendonça, A. F., 209, 368  
 Menendez, C., 115, 135  
 Meng, G., 114–115, 134  
 Meraj, S., 79, 98  
 Meritt, E. A., 239, 373  
 Merritt, E. A., 220, 239–240, 290, 370, 373, 382  
 Meunier, S. J., 201, 287, 306, 309–310, 365, 380, 383–384  
 Meyer, A. S., 4, 17, 240, 373  
 Meyer, K.-H., 3, 16  
 Meziani, M. J., 261–263, 378  
 Miceli, M. C., 140, 144, 160  
 Michel, J.-P., 216, 369  
 Mikata, Y., 209, 245–246, 368, 375  
 Millar, J. R. A., 244, 374  
 Milton, R. M., 30–31, 83  
 Minari, P., 201, 365  
 Minde, W. E., 290, 381  
 Minehan, T. G., 209, 368  
 Miniello, V., 126, 138  
 Minke, W. E., 238–239, 373  
 Minowa, M. T., 140, 160  
 Miquel, S., 35–36, 87  
 Mirkin, C. A., 265, 378  
 Mironov, A. F., 209, 211, 368  
 Mirza, O., 121, 137  
 Misra, A. K., 49, 51, 63, 91–93  
 Miyamoto, N., 43, 45, 90–91  
 Miyamoto, Y., 245–246, 375  
 Miyazawa, S., 349, 392  
 Mizubuchi, H., 110, 133  
 Mizugaki, T., 33, 85  
 Mizugushi, M., 349, 392  
 Mizuno, A., 245–246, 375  
 Mizuno, M., 60, 76, 93, 97  
 Mizuochi, T., 312, 387  
 Momenteau, M., 208–209, 367  
 Mommaas, A. M., 312, 318, 387–388  
 Monchois, V., 108, 111, 131–132  
 Monde, K., 224, 371  
 Monneret, C., 42, 90  
 Monnier, N., 42, 90  
 Monsan, P., 106, 108–109, 111, 121, 123–125, 129–131, 137–138  
 Monsigny, M., 310, 385  
 Montib, D., 205, 367  
 Moorefield, C. N., 249, 285, 376, 380  
 Moore, R. E., 209, 368  
 Moorhouse, A. D., 77, 98  
 Morales-Arrieta, S., 114, 134  
 Morales-Sanfrutos, J., 177, 219–220, 361, 370  
 Moran, M., 140, 160  
 Moraru, R., 103, 115–119, 127, 133, 136  
 Moreau, C., 33, 35, 69–72, 74, 85, 87, 95–96  
 Morgan, J. R., 328, 389  
 Moro, G. E., 126, 138  
 Morris, G. M., 319, 388

- Mortell, K. H., 146, *163*  
 Morvan, F., 240, *373*  
 Mosbach, K., 121, 124, *137*  
 Moses, J. E., 77, *98*  
 Mota, C. J. A., 56, *92*  
 Motokura, K., 33, *85*  
 Moulis, C., 110, *132*  
 Moumé-Pymbock, M., 217, *369*  
 Moura, T. R., 142–143, 145–149, 154–155,  
     *161*  
 Mravec, D., 30–31, *84*  
 Mseddi, S., 33, *85*  
 Mugishima, A., 126, *138*  
 Mukhopadhyay, B., 49–50, 52–55, 61, 63–64,  
     66, 68, 70, 91–95, 173, *360*  
 Mularo, F., 312, *386*  
 Mulder, A. A., 318, *388*  
 Mullegger, J., 105, *129*  
 Müllen, K., 354–355, *393*  
 Müller, A. H. E., 264, *378*  
 Müller, D., 273–274, *379*  
 Muller, S., 143, *162*  
 Mulvey, G. L., 142, *161*, 172, 222–223,  
     *358*, *370*  
 Mundwiler, S., 270, *379*  
 Murata, T., 173, *389*  
 Mutharasan, R., 69, *95*  
 Muthukrishnan, S., 264, *378*  
 Muzart, J., 352, 356, 392–393  
 Myc, A., 310, 327, *384*, *389*  
 Myc, P. P., 327, *389*
- N**
- Na'amnieh, S., 103, 115–119, *127*, *133*  
 Nabeshima, K., 321, *388*  
 Nabi, I. R., 140, *160*  
 Nadimpalli, S. K., 330–331, *390*  
 Nagahori, N., 310, *384*  
 Nagai, H., 40, 44, 89–90, 210, *369*  
 Nagail, T., 126, *138*  
 Nagaraju, N., 33, *84*  
 Nagasaki, Y., 173, *360*  
 Nagem, R. A., 114–115, *134*  
 Nagendrappa, G., 33, *85*  
 Nahas, D. D., 102, *127*  
 Nakabayashi, S., 11, *18*  
 Nakagiri, N., 33, *85*  
 Nakahara, Y., 321, *388*  
 Nakajima, H., 60, *93*  
 Nakakuki, T., 110, 123, 126, *132*, *137*  
 Nakamura, E., 250–251, *376*  
 Nakata, M., 44–45, 90–91, 312, *387*  
 Nam, J., 172, *359*  
 Nangia-Makker, P., 140, *159*  
 Narayanan, S., 33, *84*  
 Narsimulu, K., 79, *98*  
 Nascimento, K. S., 142–143, 145–149,  
     154–155, *161*  
 Nasir-ud-Din, 5, *17*  
 Natori, Y., 350–351, *392*  
 Naves, R. G., 5, *17*  
 Naylor, A. M., 286, *380*  
 Nelson, A., 300, 330, *383*, *390*  
 Nepogodiev, S. A., 173, 247, 287, 336–339,  
     347, *361*, *375*, *381*, *391*  
 Neri, P., 203, *366*  
 Neustroev, K. N., 114–115, *134*  
 Neves, A., 76, *97*  
 Neves, M. G. P. M. S., 209, 217, *368*, *370*  
 Newkome, G. R., 249, 285–286, 303, *376*,  
     *380*, *383*  
 Nguyen, H., 190, *364*  
 Nguyen, J. T., 140, *159–160*  
 Nicotra, F., 45, *91*, 204, 354, *367*, *393*  
 Niederhafner, P., 310, *384–385*  
 Nierengarten, J.-F., 248, *375*  
 Nieto, P. M., 341, *392*  
 Nifantiev, N. E., 330, *390*  
 Nii, S., 245–246, *375*  
 Niikura, K., 224, *371*  
 Nimtnz, M., 149, *163*  
 Nimtz, M., 103, 115, 118–119, *127*  
 Nishida, Y., 243, 245–246, *374–375*  
 Nishigori, N., 228, *372*  
 Nishijima, M., 349, *392*  
 Nishikawa, K., 349–351, *392*  
 Nishikawa, M., 312, *386*  
 Nishikawa, T., 45, *91*

Nishimura, S.-I., 224, 310, 371, 384  
 Nishino, R., 44, 90  
 Nishisaka, T., 245–246, 375  
 Niu, Y., 67, 94  
 Niyogi, S., 258, 377  
 Nogueras, M., 243, 374  
 Nolibe, D., 312, 386  
 Noll, S., 236, 238, 373  
 Noll-Borchers, M., 106, 108, 110, 130, 132  
 Nolting, B., 173, 360  
 Noodleman, L., 183, 363  
 Noorman, F., 313, 387  
 Nováková, J., 33, 85  
 Novikova, O. S., 230, 372  
 Nowogródski, M., 38–39, 88  
 Nugent, A. K., 183, 363  
 Numata, M., 78, 98, 256, 377  
 Nussbaum, G., 159, 164  
 Nyström, D., 289, 381

### O

Obata, M., 245–246, 375  
 Oberdorfer, F., 79, 98  
 Oberholz, A., 124, 137  
 O'Brien, S. C., 241, 374  
 Ochi, T., 70, 95  
 Ogawa, Y., 43, 90  
 Ogura, S.-i., 209, 368  
 Oh, D. H., 235, 372  
 Ohno, M., 243, 374  
 Ohshima, R., 34, 86  
 Ohtake, T., 245–246, 375  
 Ohtsubo, K., 140, 160  
 Ohtsuki, C., 245–246, 375  
 Ohya, Y., 173, 359  
 Okabe, N., 349, 392  
 Okada, M., 325, 328, 388, 390  
 Oka, H., 351–352, 392  
 Oku, K., 126, 138  
 Okumura, S., 256, 377  
 Okura, I., 209, 368  
 Okuyama, K., 310, 385  
 Olivares-Illana, V., 114, 133  
 Olvera-Carranza, C., 114, 134

Omura, S., 40, 89  
 Onaga, T., 351–352, 392  
 Onaka, M., 33, 85  
 Onchi, Y., 209, 368  
 Onda, A., 70, 95  
 Onderwater, M., 318, 388  
 Ono, H., 209, 368  
 Ookoshi, T., 33, 85  
 Oomen, L. C. J. M., 318, 388  
 Ooshima, T., 111, 132  
 Opalka, D. W., 102, 127  
 Oriol, E., 106, 130  
 Orlandi, S., 271–274, 379  
 Ortega, P. J. C., 326, 389  
 Ortega-Munñoz, M., 177, 219–220, 361, 370  
 Ortiz-Lombardia, M., 114, 116, 134  
 Ortiz Mellet, C., 219–220, 224, 227–228, 370–371  
 Orzel, L., 210, 369  
 Osawa, T., 8, 12, 18–19  
 Osborne, S. D., 178–179, 362  
 Osborn, H. M. I., 178–179, 362  
 Oscarson, S., 142, 146, 161, 189, 364  
 Ossendorp, F., 312, 387  
 O'Sullivan, M. L., 224, 370  
 O'Sullivan, P., 33, 85  
 Otero, J. R., 342, 392  
 Otsuka, H., 173, 359  
 Ottenhoff, T. H. M., 318, 388  
 Otter, M., 312, 385  
 Ouarne, F., 114, 123, 134  
 Ouchi, T., 173, 359  
 Oulmi, D., 209, 368  
 Owens, C. L., 143, 162  
 Ozawa, C., 321, 388  
 Ozimek, L. K., 108, 112, 114–115, 131, 134–135

### P

Pace, K. E., 140, 144, 157–158, 159, 163  
 Pagé, D., 142, 147, 150, 152–153, 155–156, 158, 161, 163, 170, 195, 310, 326, 357, 364, 384, 389  
 Painter, G. F., 310, 314, 385

- Pais, M. S., 76, 97  
 Palcic, M. M., 312, 385  
 Pale, P., 78, 98  
 Pancré, V., 313, 386  
 Pandey, A., 74, 96  
 Pandit, C. R., 217, 369  
 Pang, W., 30–31, 33, 83  
 Pannu, N. S., 142, 161, 172, 219, 358  
 Pantarotto, D., 252, 376  
 Pantophlet, R., 319, 388  
 Papadopoulos, A., 184–186, 363  
 Papot, S., 40, 89  
 Pappalardo, M., 206–207, 367  
 Papraeger, A. C., 159, 164  
 Park, K. M., 235, 372  
 Park, S., 171, 358  
 Park, W. K. C., 305–306, 383  
 Parnaik, V. K., 105, 110, 129  
 Parren, P. W., 319, 388  
 Partidos, C. D., 252, 376  
 Partridge, E. A., 140, 144, 160, 162  
 Pasetto, P., 209, 368  
 Pastorin, G., 252, 376  
 Pasumarthy, M., 143, 162  
 Patat, F., 106, 111, 129  
 Patch, R. J., 217, 369  
 Patel, A., 177–178, 361  
 Patel, R., 80, 99  
 Patman, R., 217, 369  
 Paul, F., 105–106, 108, 124–125, 129–130,  
     137  
 Paulson, J. C., 330, 390  
 Pavlovic, M., 115, 135  
 Pawling, J., 140, 160  
 Pawlowski, A., 102, 114–116, 118–119,  
     127, 133  
 Pazylnina, G. V., 330, 390  
 Pecka, J., 310, 385  
 Pedersen, S. F., 178–179, 362  
 Peerlings, H. W. I., 336–339, 391  
 Pegado, I. N., 209, 368  
 Pehrsson, P. E., 253, 377  
 Pelantová, H., 205, 367  
 Pelenc, V., 106, 108, 124–125, 129–130, 138  
 Penadés, S., 173, 359–360  
 Perales, J. C., 312, 386  
 Pereira, H., 76, 97  
 Perez, M. A., 326, 389  
 Perez, O., 105, 129  
 Perez, S. F., 142, 161  
 Perez, X., 105, 129  
 Perez-Balderas, F., 177, 201, 219–220, 361,  
     366, 370  
 Pérez-Garrido, S., 82, 99  
 Peri, F., 354, 393  
 Perillo, N. L., 140, 159  
 Perlot, P., 119–120, 136  
 Perly, B., 224, 370  
 Petit-Glatron, M. F., 115, 135  
 Petit, J. F., 312, 386  
 Pétrier, C., 42, 90  
 Peyron, D., 72, 96  
 Pezzella, A., 41–42, 90  
 Piancatelli, G., 75, 97  
 Pickens, J. C., 239–240, 290, 372, 381  
 Piedade, F., 76, 81, 97, 99  
 Pihler, L. T., 310, 327, 384, 389  
 Pieters, R. J., 172–173, 290–295, 307–308,  
     329–330, 358, 360, 381–383, 389  
 Pietersz, G. A., 312, 387  
 Pietsch, M., 117, 136  
 Pigaglio, S., 209–210, 212, 367  
 Pijning, T., 109, 112, 131, 133  
 Pillinger, M., 72, 96  
 Pincus, G., 4, 16–17  
 Pinkner, J., 189, 363  
 Pinto, B. P., 56, 92  
 Pisacka, M., 310, 385  
 Piskorz, J., 77, 97  
 Placide, V., 198–199, 365  
 Planas, A., 105, 129  
 Pluschke, G., 102, 127  
 Podlipnik, C., 204, 367  
 Polikarpov, I., 114–115, 134  
 Politi, M., 204, 367  
 Pompeo, F., 260, 378  
 Pons, M., 310, 384  
 Pons, T., 114–116, 134

- Pontrello, J. K., 140, 142, 160  
 Poon, S., 34, 86  
 Posner, G., 40, 89  
 Potier, P., 227, 371  
 Potocki-Veronese, G., 110, 132  
 Pourceau, G., 240, 373  
 Pourcheron, C., 71, 95  
 Prabhanjan, H., 180–181, 362  
 Prado, M. A. F., 67, 94  
 Praly, J.-P., 240, 373  
 Pramanik, K., 52–53, 55, 92  
 Prathapan, S., 33, 86  
 Prato, M., 242, 252, 374, 376  
 Preiswerk, E., 3, 16  
 Preston, C., 312, 386  
 Prévaille, C., 217, 369  
 Priebe, W., 39, 88  
 Primo, J., 33, 35–36, 85, 87  
 Prins, D. A., 3–4, 16  
 Prinsep, M. R., 209, 368  
 Probert, M. A., 40, 89  
 Pukin, A. V., 292–293, 382  
 Puntala, M., 119, 136  
 Pyun, J., 183, 363
- Q**
- Qin, D., 310, 384  
 Qin, H., 185, 363  
 Qiu, D., 180–181, 362  
 Qu, L., 253, 260, 377–378  
 Quaggin, S., 140, 160  
 Queneau, Y., 42, 69, 90, 95  
 Quinn, R. A., 261–263, 378  
 Quirasco, M., 106, 129
- R**
- Rabijns, A., 114, 134–135  
 Rabuka, D., 255, 377  
 Radaelli, C., 356, 393  
 Rades, T., 310, 314, 385  
 Radhika, S., 330–331, 390  
 Radlein, D., 77, 97  
 Raghavan, S. S., 12, 19  
 Raghavendra, S., 68, 94  
 Rahaoui, H., 111, 114, 125, 132–133  
 Rai, A., 79, 98  
 Rai, V. K., 79–80, 99  
 Raimundo, J.-M., 198, 200, 365  
 Rajasingh, P., 33, 86  
 Rajewsky, M. F., 212, 369  
 Rajput, V. K., 54, 63, 66, 68, 92, 94  
 Ramachandran, S., 74, 96  
 Ramalho, R., 76, 97  
 Ramanaiyah, K. C. V., 79, 98  
 Ramôa-Ribeiro, F., 30–31, 33, 36, 39, 57, 83, 87, 93  
 Ramos, C. I. V., 243, 374  
 Rani, S., 47, 91  
 Rao, A. M., 260, 377  
 Rapin, A. M. C., 9, 18  
 Rapport, M. M., 191, 364  
 Raslan, D. S., 67, 94  
 Rastall, R. A., 125, 138, 178–179, 362  
 Ratner, D. M., 171, 358  
 Rau, S., 273–274, 379  
 Rauter, A. P., 39, 45, 57, 76, 81, 87, 91 93, 97, 99  
 Ravaud, S., 119, 121–122, 137  
 Ravidà, A., 41–42, 90  
 Raymo, F. M., 210, 369  
 Raz, A., 140, 159  
 Razigade, S., 71, 95–96  
 Read, R. J., 142, 161, 172, 219, 358  
 Reddy, B. V. S., 79, 98  
 Reddy, G. V., 180–181, 362  
 Reed, T. B., 30–31, 83  
 Reh, K. D., 106, 108, 130–131  
 Reichstein, T., 3, 16  
 Reinhold, V. N., 12, 19, 144, 162  
 Reiniš, M., 310, 385  
 Reipen, T., 173, 359  
 Reis, C. A., 143, 162  
 Reischwitz, A., 108, 131  
 Remaud, M., 125, 129, 138  
 Remaud, P., 227, 371  
 Remaud-Simeon, M., 108–109, 111, 121, 124, 130, 132, 137  
 Renaudet, O., 228, 317, 372, 388

- Rendle, P. M., 310, 314, 385  
 Resasco, D. E., 260, 378  
 Resende, R., 76, 97  
 Reuter, J. D., 310, 384  
 Reymond, J.-L., 317, 387–388  
 Rhee, S. K., 115, 135  
 Rhodes, J. M., 143, 157, 162  
 Rieben, R., 330, 390  
 Riguera, R., 308–309, 384  
 Rijken, D. C. J., 312–313, 385–386  
 Rijkers, D. T. S., 173, 307–308, 361, 383  
 Rini, J. M., 140, 159  
 Rinzler, A. G., 260, 378  
 Rittenhouse-Olson, K., 311, 329, 385, 390  
 Rivalier, P., 69, 71–72, 95–96  
 Roach, C., 239–240, 290, 373, 381  
 Robbins, B. A., 140, 159  
 Robert, X., 121–122, 137  
 Robins, M. J., 61, 93  
 Robinson, P. D., 39, 88  
 Roby, J., 185, 363  
 Robyt, J. F., 103, 105, 108–109, 128–131  
 Roche, A.-C., 310, 314, 385, 387  
 Rochow, E. G., 34, 86  
 Röckendorf, N., 287, 380  
 Rodinovskaya, L. A., 77, 97  
 Rodriguez, A., 173, 359  
 Rodriguez, M. C., 173, 359  
 Rodriguez, M. E., 114, 134  
 Rodriguez-Macias, F., 260, 378  
 Rodriguez-Meizoso, I., 308–309, 384  
 Roeck, J., 286, 325, 380  
 Roessner, F., 33, 85  
 Röhrich, A., 236, 238, 373  
 Rojanasakul, Y., 312, 386  
 Rojas, A. L., 114–115, 134  
 Rojas, T. C., 173, 359  
 Rojo, J., 173, 341–342, 359, 392  
 Romagnoli, B., 178–179, 362  
 Romagnoli, P., 63, 94  
 Romanowska, A., 287, 309–310, 380, 384  
 Rommens, C., 310, 313, 385  
 Rorrer, G. L., 72, 74, 96  
 Ros, P., 71, 96  
 Rose, T., 119, 121, 124, 136  
 Rosenau, F., 317, 387  
 Rosilio, V., 216, 369  
 Rossmann, A., 115, 135  
 Rostovtsev, V. V., 78, 98, 183, 363  
 Roy, B., 52, 55, 68, 70, 92, 94–95  
 Roy, K. L., 114, 134–135  
 Roy, R., 142, 146–147, 150, 152–153, 155–156, 158, 161, 169–171, 173, 177, 180, 184–186, 188, 193–195, 197–199, 201, 217, 224, 235, 275–277, 287, 296, 305–307, 309–312, 318–319, 321–322, 326–333, 344–346, 353, 357, 359, 361–365, 369, –371, 373, 380, 382–385, 387–392  
 Royo, M., 310, 384  
 Rubin, Y., 245, 375  
 Rudd, P. M., 319, 388  
 Rüdiger, H., 170, 358  
 Rudolph, N., 49–50, 91  
 Ruiz, J., 352, 392  
 Russell, D. A., 49–50, 63, 91, 94, 173, 360  
 Russell, R. R., 111, 132  
 Russo, P. S., 303, 383  
 Ryder, J., 286, 325, 380
- S**
- Sá, M. M., 59, 93  
 Sabesan, S., 146, 152–153, 163  
 Sabin, C., 217, 240, 369, 373  
 Sablina, M. A., 330, 390  
 Sacchettini, J. C., 140, 146, 152–153, 160, 163  
 Sadalapure, K., 299, 383  
 Sadamoto, R., 224, 371  
 Sadeh, S., 11, 19  
 Sadhukhan, S. K., 195–196, 365  
 Sadowska, J. M., 142, 161, 172, 219, 222–223, 358, 370  
 Saigo, K., 244, 374  
 Saitz-Barria, C., 203, 366  
 Sakairi, N., 224, 371  
 Sakai, S., 245, 266–267, 375, 378–379  
 Sakakibara, R., 312, 387  
 Sakakibara, T., 80, 99

- Sakamoto, J., 354–355, 393  
 Sakuraib, K., 78, 98  
 Sakurai, K., 256, 377  
 Sakurai, T., 126, 138  
 Salmi, T., 69, 74, 94  
 Salto-Gonzalez, R., 219–220, 370  
 Samadani, N., 71, 95  
 Samet, A. V., 77, 97  
 Sanclimens, G., 310, 384  
 Sandhoff, K., 194, 364  
 Sanford, B. H., 12, 19  
 Sankaranarayanan, V., 143, 162  
 Sansone, F., 201, 203–204, 208, 222, 292,  
     310, 351, 365–367  
 Santacroce, P. V., 328, 389  
 Santana-Marques, M. G., 243, 374  
 Santos, C. F., 149, 163  
 Santos, H., 81, 99  
 Santoyo-González, F., 173, 177, 193, 195,  
     201, 203, 219–220, 224, 361, 364–366,  
     370–371  
 Saphire, E. O., 319, 388  
 Sarcabal, P., 121, 137  
 Sartori, G., 32, 84  
 Sasaki, K., 34, 37, 87, 268–269, 379  
 Sasaki, T., 266, 378–379  
 Sashiwa, H., 306–307, 330–331, 383, 390  
 Sato, K., 228, 372  
 Sato, M., 44, 90  
 Sato, S., 217, 369  
 Satyanarayana, M., 68, 94  
 Saunders, M. J., 303, 383  
 Sawai, T., 103, 128  
 Sawamura, M., 250, 376  
 Scettri, A., 75, 97  
 Schädel, U., 203, 366  
 Schäfer, B., 273–274, 379  
 Scharff, M. D., 159, 164  
 Scheel, A., 183, 363  
 Scheidegger, D., 318, 388  
 Schembri, M., 189, 363  
 Schengrund, C.-L., 326, 338–339, 389, 391  
 Schenker, V., 4, 16–17  
 Schenk, G., 106, 111, 129  
 Schermann, M.-C., 201, 365  
 Scherrmann, M.-C., 203, 366  
 Schiattarella, M., 41–42, 59–60, 89–90, 93  
 Schmalbruch, B., 112, 133  
 Schmid, D. M., 8, 17  
 Schmit, A. S., 11, 19  
 Schröder, D., 210, 368  
 Schultz, M., 173, 359  
 Schuster, D. I., 242, 244, 374  
 Schuster, M. C., 140, 142, 160, 233, 314,  
     372, 387  
 Schwengers, D., 108, 111, 130, 132  
 Schwientek, T., 143, 162  
 Scigelova, M., 103, 128  
 Scott, D. S., 77, 97  
 Seah, N., 328, 389  
 Šebestík, J., 310, 384  
 Sebyakin, Y. L., 209, 211, 368  
 Seeberger, P. H., 102, 127, 171, 173, 251,  
     277–281, 358, 360, 376, 379  
 Seeberger, S., 228, 372  
 Segovia, L., 114, 134  
 Seibel, J., 103, 105, 109, 111–113, 115–119,  
     127, 129–133, 135–136  
 Seidel, J., 236, 238, 373  
 Seilhamer, J. J., 140, 159  
 Selman, G., 115, 135  
 Semenov, V. V., 77, 97  
 Semetey, V., 310, 384  
 Sen, R., 258, 377  
 Sen, S. E., 30–31, 84  
 Sengupta, S., 195–196, 365  
 Seo, J. W., 115, 135  
 Sevillano-Tripero, N., 219–220, 370  
 Sgarlata, V., 203, 366  
 Shaikh, H. A., 228, 372  
 Shanmugam, P., 33, 86  
 Shanmugasundaram, B., 44, 90  
 Shao, M. C., 141, 161  
 Sharma, G. V. M., 33, 79, 85, 98  
 Sharma, R., 223, 370  
 Sharon, N., 8–9, 18, 146, 163, 185, 363  
 Sharpless, K. B., 77–78, 98, 183, 258, 342,  
     344, 363, 377

- Shashkov, A. S., 330, 390  
 Sheldon, R. A., 30–31, 84  
 Shelimov, K., 260, 378  
 Shen, G.-L., 209, 368  
 Shen, N., 310, 384  
 Shestopalov, A. A., 77, 97  
 Shestopalov, A. M., 77, 97  
 Shi, M., 33, 86  
 Shi, X., 312, 386  
 Shiao, T. C., 184–187, 198–199, 363, 365  
 Shigemasa, Y., 266–267, 306–307, 330–331, 378–379, 383, 389–390  
 Shi Kam, N. W., 252, 376  
 Shikata, K., 312, 387  
 Shimanouchi, T., 34, 86  
 Shimitz-Hillebrecht, E., 37, 87  
 Shimizu, Y., 312, 387  
 Shin, I., 171, 358  
 Shing, T. K. M., 82, 99  
 Shinkai, S., 78, 98, 210, 256, 368, 377  
 Shinohara, H., 245–246, 256–257, 375, 377  
 Shirahata, T., 40, 89  
 Shiral Fernando, K. A., 253, 377  
 Shiver, J. W., 102, 127, 230, 372  
 Shon, Y.-S., 260, 378  
 Shugars, D. C., 318, 388  
 Shukla, R., 69, 95  
 Sidhu, R. S., 191–192, 364  
 Siebert, H. C., 170, 358  
 Sigman, D. S., 245, 375  
 Sihorkar, V., 173, 359  
 Silber, C., 12, 19  
 Silva, A. M. S., 243, 374  
 Silva, F. V. M., 76, 97  
 Silva, J. C., 56, 92  
 Silva, M., 81, 99  
 Silvescu, C. I., 144, 162  
 Sinäy, P., 8, 17–18, 76, 97  
 Singh, M., 223, 370  
 Singh, P. K., 105, 128, 143, 162  
 Singh, R., 252, 376  
 Singh, S., 103, 128  
 Singh, T., 149, 156, 163  
 Siopa, F., 36, 39, 87  
 Sirois, S., 169, 185, 357, 363  
 Sisu, C., 292–293, 381  
 Sjaastad, M. D., 159, 163  
 Skorupowa, E., 73, 96  
 Skov, L. K., 121, 137  
 Skutelsky, E., 146, 163  
 Slättegård, R., 189, 363  
 Sleiman, M., 198, 200, 365  
 Sliedregt, L. A. J. M., 310, 385  
 Smalley, R. E., 241, 260, 374, 377  
 Smith, K., 32–33, 84–85  
 Smith, P., 286, 325, 380  
 Smith, S. M., 30–31, 84  
 Soares, A. R. M., 217, 370  
 Sobue, S., 111, 132  
 So, K. H., 82, 99  
 Soilleux, E., 310, 385  
 Sol, V., 209, 213–214, 367–368  
 Solin, N., 251, 376  
 Sommer, J., 78, 98  
 Song, H. C., 102, 127, 230, 372  
 Song, K. B., 115, 135  
 Song, S. K., 125, 138  
 Song, Y. H., 68, 94  
 Sönnichsen, F. D., 228, 372  
 Sonnino, S., 205, 367  
 Sorensen, A. L., 143, 162  
 Souteyrand, E., 240, 373  
 Sowmya, S., 44, 90  
 Spadaro, A., 206–207, 367  
 Spain, S. G., 173, 359–360  
 Spalluto, G., 242, 374  
 Specker, D., 173, 359  
 Spiro, R. G., 10, 18  
 Springer, G. F., 157, 163  
 Srinivas, O., 330–331, 390  
 Srivastava, V. P., 80, 99  
 Stahl, B., 126, 138  
 Standen, S. P., 33, 86  
 Stanfield, R. L., 319, 388  
 Star, A., 253, 377  
 Stearns, D. K., 5, 17



- Steinbach, J., 236, 238, 373  
 Stephan, H., 236, 238, 373  
 Steuerman, D. W., 253, 377  
 Stewart, P. L., 144, 157–158, 163  
 Stibor, I., 205, 367  
 Stockenhuber, M., 32, 84  
 Stoddart, J. F., 201, 210, 224, 247, 253, 264,  
 287, 289, 300, 330, 336–338, 348, 365,  
 369–370, 375, 377, 381, 388, 391–392  
 Stoffyn, P. J., 5–6, 8, 17  
 Stoll, D., 105, 128  
 Stoppok, E., 117, 136  
 Stowell, C. P., 354, 393  
 St-Pierre, C., 217, 369  
 Streiff, M. B., 282–284, 380  
 Stricker, H., 106, 111, 129  
 Strohmeyer, G. C., 328, 389  
 Strominger, J. L., 11, 18  
 Strong, L. E., 142, 146, 161, 163  
 Strynadka, N. C., 105, 128  
 Suarez, V., 115, 135  
 Sudo, M., 244, 374  
 Sugai, T., 256–257, 377  
 Sugamoto, K., 38, 45, 88  
 Suganuma, T., 80, 99  
 Sugunan, S., 33, 86  
 Sullivan, K. A., 30–31, 84  
 Sulzenbacher, G., 114, 134  
 Sun, Y.-P., 253, 260, 262, 377–378  
 Susuki, Y., 268–269, 379  
 Suzuki, A., 34, 37, 87, 141, 161  
 Suzuki, K., 40, 89  
 Suzuki, T., 126, 138, 228, 268–269, 372, 379  
 Suzuki, Y., 228, 351–352, 372, 392  
 Svensson, B., 109, 131  
 Swaminathan, K., 120–121, 136  
 Swar, J. P., 312, 386  
 Szabo, L., 105, 128  
 Szylit, O., 125, 138
- T**
- Tabata, K., 209, 368  
 Tada, T., 244, 374  
 Tagmatarchis, N., 252, 376  
 Takagi, S., 245–246, 375  
 Takahashi, D., 245, 375  
 Takahashi, T., 268–269, 374, 379  
 Takahura, Y., 312, 386  
 Takaku, H., 126, 138  
 Takamatsu, S., 140, 160  
 Takamura, S., 312, 386  
 Takashima, S., 349, 392  
 Takeda, T., 228, 372  
 Takeuchi, M., 140, 160  
 Tamaru, S.-i., 210, 368  
 Tamborrini, M., 102, 127  
 Tam, U. C., 255, 257, 259, 377  
 Tan, M. C. A. A., 318, 388  
 Tanahashi, M., 245–246, 375  
 Tanaka, K. A., 30–31, 84  
 Taniguchi, N., 34, 37, 87, 141, 161  
 Tanimoto, S., 245, 375  
 Tanriseven, A., 108, 130  
 Tarasiejska-Glazer, Z., 9, 18  
 Tarasiejska, Z., 9, 18  
 Tarbouriech, N., 114, 116, 134  
 Tarp, M. A., 143, 162  
 Tasis, D., 252, 376  
 Tatsuta, K., 34, 37–39, 45, 56–58, 74, 87–88,  
 91–93, 96  
 Taylor, A. T., 244, 374  
 Taylor, E. J., 114, 116, 134  
 Taylor, M. E., 140, 159, 310, 385  
 Taylor, R. J. K., 33, 86  
 Taylor, S., 253, 377  
 Taylor-Papadimitriou, J., 143, 162  
 Tenu, J. P., 312, 386  
 Terabatake, M., 349, 392  
 Tercio, J., 34, 86  
 Terunuma, D., 349–352, 392  
 Tewari, J., 118, 136  
 Théoleyre, T., 69, 95  
 Thielgen, C., 243, 374  
 Thiem, J., 34, 37–39, 44–45, 56–58, 74,  
 87–88, 91–93, 96  
 Tholen, N. T. H., 307–308, 383

Thoma, G., 282–284, 380  
 Thomas, B., 33, 86  
 Thomas, M., 40, 89  
 Thomas, T. L., 30–31, 83  
 Thomas, W. D., 314, 387  
 Thompson, D., 168, 357  
 Thompson, F., 102, 127  
 Thompson, J. P., 326, 388  
 Thorson, J. S., 45, 91  
 Timme, V., 117, 136  
 Timpte, C. S., 143, 162  
 Tiwari, P., 49, 63, 91, 93  
 Toh, H., 115, 135  
 Tokunaga, S., 310, 385  
 Toledo, M. E., 173, 359  
 Tomalia, D. A., 285–286, 310, 325, 380, 384  
 Tomé, A. C., 209, 217, 243, 368, 370, 374  
 Tomé, J. P. C., 209, 217, 368, 370  
 Tomita, T., 110, 132  
 Tomøe, C. W., 173, 360  
 Tomono, K., 126, 138  
 Toone, E. J., 170, 358  
 Torok, B., 33, 85  
 Torres-Pinedo, A., 203, 366  
 Torres, T., 217, 370  
 Torri, C., 77, 97  
 Tushima, K., 34, 37–38, 40, 43–45, 87–91, 245, 375  
 Touaibia, M., 169, 177, 183–188, 235, 357, 361, 363, 373  
 Treboule, G., 114–115, 133  
 Trincone A., 105, 118, 129  
 Trnka, T., 310, 385  
 Tsutsumiuchi, K., 328, 390  
 Tsvetkov, D. E., 330, 390  
 Tungland, B. C., 125, 138  
 Turnbull, W. B., 287, 330, 381, 390  
 Tuzikov, A. B., 330, 390  
 Tzeng, T.-R. J., 260, 378

## U

Ueda, H., 253, 377  
 Uedal, H., 125, 138

Uehara, K., 44, 90  
 Ueno, Y., 44, 90  
 Uhlmann, P., 243, 374  
 Uittenbogaart, C. H., 140, 159  
 Umeda, M., 78, 98, 256, 377  
 Ungaro, R., 201, 203, 208, 365–367  
 Urabe, K., 68, 94  
 Urbanke, C., 149, 163  
 Uryu, T., 310, 315–316, 385, 387  
 Ushiki, Y., 45, 91  
 Usui, T., 173, 358

## V

Vaddi, K., 312, 386  
 Valadon, P., 159, 164  
 Valdeira, M. L., 209, 368  
 Valdés, Y., 173, 359  
 Valencia, S., 32, 35–36, 84, 87  
 Valent, B. S., 190, 364  
 Valente, A. A., 72, 96  
 Valentini, P., 291–292, 294–295, 382  
 Valentjin, A. R. P. M., 310, 385  
 Valette, P., 125, 138  
 van Bekkum, H., 30–31, 69, 84, 95  
 Van Bergen, J., 312, 387  
 Van Berkel, T. J. C., 310, 312–313, 385–387  
 van Boom, J. H., 310, 385  
 Van de Bilt, H., 312, 386  
 Van den Eijnden, D. H., 12, 19  
 Van den Ende, W., 114, 135  
 van der Heiden, A. N., 318, 388  
 van der Maarel, M. J., 108–109, 111, 114–115, 125, 130–133, 135  
 van der Marel, G. A., 310, 385  
 van der Veen, B., 127, 138  
 van der Waal, J. C., 30–31, 84  
 van Geel-Schutten, G. H., 108–109, 111, 114, 125, 130–133, 135  
 van Geel-Schutten, I. G., 108–109, 111–112, 114, 131–132  
 Van Gerven, N., 190, 364  
 van Klink, G. P. M., 265, 378  
 van Koningsveld, G. A., 115, 135

- van Kooyk, Y., 159, 163  
 van Koten, G., 265, 378  
 van Teijlingen, M. E., 313, 387  
 Van Weely, S., 312, 386  
 van Well, R. M., 49–50, 91  
 Vanden Broeck, D., 204, 367  
 vanHijum, S. A., 108, 112, 114, 131  
 Vankar, Y. D., 47, 68, 91, 94  
 Vanqueref, E., 219–220, 370  
 Vargas-Berenguel, A., 224, 371  
 Varki, A., 102, 127, 140, 142, 156, 159, 161, 170, 357  
 Varma, R. S., 33, 85  
 Varrot, A., 198, 200, 365  
 Vasella, A., 243, 374  
 Vasseur, J.-J., 240, 373  
 Vaucher, J., 184–186, 363  
 Vaughan, M. D., 105, 118, 128  
 Vauzeilles, B., 75, 97  
 Vazquez, R., 115, 135  
 Veca, L. M., 261–263, 378  
 Vecchi, A., 201, 366  
 Velek, J., 310, 385  
 Velkova, V., 310, 385  
 Velter, I. A., 204, 367  
 Velty, A., 69, 74, 94  
 Veprek, P., 310, 385  
 Vera, W. J., 34, 86  
 Verez-Bencomo, V., 173, 359  
 Verhaest, M., 114, 134  
 Verkleij, A. J., 173, 360  
 Verlinde, C. L. M. J., 228, 230, 238–240, 290, 371–373, 381  
 Verneuil, B., 209, 367  
 Veronese, T., 120, 136  
 Vert, M., 312, 386  
 Vervoerd, D., 318, 388  
 Verykios, X. E., 69, 95  
 Vespa, G. N. R., 140, 160  
 Vestberg, R., 258, 342, 344, 377  
 Veyrières, A., 8, 18  
 Vias, S. P., 173, 359  
 Vicente, A. I., 36, 39, 87  
 Vidal, S., 240, 330, 373, 390  
 Vieira, P. C., 34, 86  
 Vignon, M., 106, 130  
 Villar, A., 173, 359  
 Viot, B., 183, 363  
 Vishnumurthy, P., 79, 98  
 Visser, G. M., 292–294, 382  
 Vladars-Usas, A., 77, 97  
 Vliegenthart, J. F. G., 173, 360  
 Vlitos, M., 116, 136  
 Voelcker, N. H., 282–284, 380  
 Vogel, R. F., 115, 135  
 Vögtle, F., 285–286, 336, 380  
 von Reitzenstein, C., 140, 160  
 Vondrasek, J., 310, 385  
 Voragen, A. G. J., 34, 37, 87, 122–123, 127, 137–138, 142, 161  
 Vrasidas, I., 290–292, 294–295, 382  
 Vuijičić-Žagar, A., 112, 133
- W**
- Waßmann, A., 236, 238, 373  
 Wachter-Odarte, C., 114, 133  
 Wagner, E., 312, 386  
 Wakita, K., 245–246, 375  
 Waldraff, C. A. A., 243, 374  
 Walker, E., 8, 17  
 Walseth, T. F., 106, 109, 129, 131  
 Walter, W., 117, 136  
 Wang, H., 33, 85, 261–263, 378  
 Wang, J.-Q., 34, 86, 232, 372  
 Wang, L.-X., 232, 372  
 Wang, N., 67, 94  
 Wang, Q., 184–186, 306, 363, 383  
 Wang, S., 247, 375  
 Wang, S.-K., 303–305, 383  
 Wang, S.-N., 305–306, 383  
 Wang, W., 253, 261–263, 377–378  
 Wang, X., 261–263, 378  
 Wang, Y., 244, 374  
 Warren, C. D., 11–12, 18–19  
 Warren, J. D., 230, 372  
 Warren, R. A., 105, 128–129

- Watanabe, J., 126, 138  
 Watanabe, M., 350, 392  
 Watzlawick, H., 121, 137  
 Wedgewood, J. F., 11, 18  
 Wehner, W., 286, 336, 380  
 Weidmann, H., 75, 97  
 Wei, G., 51, 92  
 Weijers, C. A. G. M., 292–293, 382  
 Weinstein, B., 32, 84  
 Weiss, A. A., 296–298, 382–383  
 Weitzel, U. P., 195, 364  
 Weiwer, M., 190, 364  
 Wellens, A., 185, 187, 189–190, 363–364  
 Wellsc, R. P. K., 32, 84  
 Wender, P. A., 252, 376  
 Werz, D. B., 251, 376  
 Wessel, H. P., 41, 89  
 Westermann, B., 228, 371  
 Whitaker, J. R., 122–123, 127, 137–138  
 Whitesides, G. M., 168, 172, 310, 357–358, 384  
 Wick, M., 109, 131  
 Wiczorek, E., 39, 88  
 Wigdahl, B., 339, 391  
 Wiśniewski, A., 73, 96  
 Wild, C. T., 318, 388  
 Willemot, R. M., 106, 108, 111, 121, 130–132, 137  
 Williams, J. F., 143, 157, 162  
 Wilma van Esse, G., 307–308, 383  
 Wilson, I. A., 319, 388  
 Wilson, S. R., 242, 244, 374  
 Wilstermann, M., 40–41, 89  
 Wimmer, T., 123, 127, 137  
 Winchester, B. G., 11, 19  
 Witczak, Z. J., 77, 97  
 Withers, S. G., 104–105, 128–129  
 Wittmann, V., 173, 228, 359, 372  
 Wittrock, S., 109–111, 131  
 Wojnowski, W., 73, 96  
 Wolfenden, M. L., 334, 336, 391  
 Woller, E. K., 327, 389  
 Wong, C.-H., 102, 127, 171, 228, 303–305, 358, 372, 383  
 Wong, D. W. S., 122–123, 127, 137–138  
 Wong, W. F., 82, 99  
 Wooley, K. L., 289, 381  
 Wrana, J. L., 140, 160  
 Wu, A. M., 149, 156, 163  
 Wu, J. H., 149, 156, 163  
 Wu, L., 120, 137  
 Wu, P., 183, 257–259, 342, 344, 363, 377  
 Wu, Q., 305–306, 383  
 Wu, Y.-C., 56, 92, 173, 360  
 Wuhler, M., 189, 363  
 Wulfing, C., 159, 163  
 Wyndham, K. D., 240, 373  
 Wyns, L., 140, 159, 190, 364
- X**
- Xavier, N. M., 39, 87  
 Xu, R., 30–31, 33, 83  
 Xu, T., 287, 381  
 Xu, Y., 264, 378
- Y**
- Yadav, J. S., 68, 79, 94, 98  
 Yadav, L. D. S., 79–80, 98–99  
 Yajima, H., 330–331, 390  
 Yajima, T., 110, 133  
 Yamada, A., 350392  
 Yamakawa, Y., 349, 392  
 Yamamoto, A., 328, 390  
 Yamamoto, K., 268–269, 379  
 Yamamoto, N., 312, 387  
 Yamasaki, C., 349, 392  
 Yamashita, F., 312, 386  
 Yamauchi, T., 40, 89  
 Yanagisawa, K., 70, 95  
 Yan, C., 203, 366  
 Yang, C.-Y., 173, 360  
 Yano, S., 209, 273–274, 368, 379  
 Yao, Z.-q., 286, 303, 380, 383  
 Yapo, A., 312, 386  
 Yariv, J., 191, 364

Yashiro, A., 243, 245–246, 374–375  
 Yates, M., 30–31, 83  
 Ye, X., 67, 94  
 Yeh, Y.-C., 173, 360  
 Yin, R., 310, 384  
 Yonashiro, M., 34, 86  
 Yonemura, T., 267–269, 379  
 Yorimitsu, H., 250, 376  
 Yoshida, A., 140, 160  
 Yoshida, T., 315–316, 387  
 Yoshihara, M., 61, 93  
 Yoshikai, Y., 110, 133  
 Young, D. A., 34, 86  
 Young, L. B., 32, 84  
 Yowler, B. C., 338–339, 391  
 Yu, J., 30–31, 33, 83  
 Yu, J. G., 56, 92  
 Yu, J.-J., 173, 360  
 Yu, K., 180, 362  
 Yu, L.-G., 143, 157, 162  
 Yu, R.-Q., 209, 368  
 Yu, S. H., 354, 393  
 Yuan, J., 264, 378  
 Yu. Murzin, D., 69, 74, 95  
 Yun, J. W., 114, 125, 133, 138

**Z**

Zampolli, M. G., 196, 365  
 Zanini, D., 142, 161, 287, 309–310, 312, 327,  
 331–333, 352, 380, 384–385, 389–390,  
 392  
 Zavalov, A., 189, 363  
 Zehavi, U., 8, 18  
 Zeitsch, K. J., 71, 95  
 Zeng, F., 289, 381  
 Zenke, M., 312, 386  
 Zesch, W., 169, 357  
 Zettl, A., 253–255, 257, 259, 377  
 Zhang, D., 121, 136–137  
 Zhang, J. S., 40, 56, 89, 92  
 Zhang, L. H., 121, 136–137  
 Zhang, P., 261–263, 378  
 Zhang, X.-B., 209, 368  
 Zhang, Z., 228, 230, 238–240, 372–373  
 Zhao, B., 258, 377  
 Zhao, Q., 233, 235, 372  
 Zhao, Z., 143, 157, 162  
 Zhou, B., 253, 377  
 Ziady, A., 312, 386  
 Ziegler, T., 217, 370  
 Žilková, N., 32, 84

# SUBJECT INDEX

## A

- Amino sugars, 9, 13
- Anomeric configuration, 26
- Aromatic hydrocarbons transformation, 32
- Asparagine-linked compounds, 10
- Aluminum-pillared montmorillonite (APM), 72
- Azido-functionalized Boltom<sup>®</sup> dendrimer, 342

## B

- Bacterial cell-wall peptidoglycan, 7–8
- Binding entropy
  - biopolymers, 159
  - dynamic bind and jump mechanism, 158
- GalNAc residues, 155
- hypothetical plot, microscopic values, 157–158
- nonproportional behavior, TΔS, 155
- Tn-PSM, 154–155, 158
- Biotin, 297–298

## C

- Carbodiimide coupling reagent, 10
- Carbohydrate nomenclature, 13–14
- Chemoenzymatic approach, 112, 117
- Chitin structure, 5
- Chitosan, 306–307, 330
- Chlorophyll c<sub>2</sub>-monogalactosyldiacylglyceride, 209
- Chondroitin sulfate, 6–7
- Colon cancer mucins, 143
- Connective tissue glycosaminoglycan structure, 6–7

## D

- Dealuminated HY zeolites, 69–70
- Dendronized chitosan–sialic acid hybrids, 307, 330–331
- Dermatan sulfate, 6–7
- Dextranucrase, 105–106
- 2,3-Dichloro-5,6-dicyanobenzoquinone (DDQ), 209

## E

- Elucidation, capsular polysaccharides, 25
- Epiglycanin, 13
- Erythrocytes extraction, 7

## F

- Fructansucrase (FS) enzymes
  - kinetics, 114
  - structure–function relationship
    - amino acid–sequence alignments, LS and IS, 114–115
    - Bacillus subtilis*, 114–116
    - B. megaterium*, 115–116
    - fructosyl transfer, 115
    - polysaccharide vs. oligosaccharide synthesis, 115
    - transfructosylation, 116
- Fructosyl residue, 116
- Fructosyltransferases, 118, 125
- Furfural, 71

## G

- Galabiose, 181, 350–351
- Galactitol dehydration, 73

- Galactosamine, 5–6
- Gallic acid, 303, 305–307
- Glucansucrases
- donor and acceptor-substrate engineering
    - chemical synthesis, thio sugars, 112–113
    - chemoenzymatic approach, 112
    - dextransucrase acceptor reaction, 111–112
    - glucan synthesis, 111
    - GTFR and GTFA enzymes, 112–113
  - kinetics
    - acceptor concentration, 106–107
    - dextran, 106
    - inhibitor constant, sucrose, 106
    - Leuconostoc mesenteroides*, 106
    - leucrose synthesis, 108
    - reaction pathways, 106
  - structure and enzyme engineering
    - exergonic glycosylation, 108
    - fermentative production, polysaccharide dextran, 109
    - glucan binding domain, 109
    - glycoside hydrolase (GH) enzymes, 108
    - glycosyltransferase R (GTFR), 109
    - isomaltose, 110
    - polymer linkage-type and alignment, 109, 111
    - regiospecificity, 109
    - wild-type (WT) GTFR and mutant S628D enzymes, 109–110
- Glucosamine, 5, 8, 260, 354–355
- Glycoclusters
- $\alpha$ 1-acid glycoprotein (AGP), 240
  - anticarbohydrate antibodies,
    - immunoprecipitation, 191
  - azamacrocyclic cyclam, 236, 238
  - branched aliphatic scaffolds
    - 2-aminoethyl galabioside, 180, 182
    - antiadhesive properties, 183
    - aryl pharmacophore positioning, 186
    - bacterial adhesion inhibition, 181
    - carboxylic acid activation, 180–181
    - C<sup>3</sup> hydroxy linker, 183
    - C<sub>3</sub>-symmetrical glycoclusters, 178
  - Cu(I)-catalyzed azide–alkyne [1,3]-dipolar cycloaddition (CuAAC), 183
  - E. coli* FimH ligand heptyl  $\alpha$ -D-mannoside, 189
  - Escherichia coli*, FimH, 177, 188
  - (2-mannosyloxy)ethanal, 178
  - extended tetramannosylated clusters, 183–184
  - hexakis mannoypyranosides, 185, 187
  - hexakis tetramannosylated clusters, 184–185
  - inhibition of hemagglutination (HAI) and bladder-binding assay (BBA), 190
  - inhibition titer (IT), 188
  - Lewis acid assisted mannosylation reaction, 183
  - longer spacer-equipped tetraol, 183
  - membrane type-1-matrix metalloproteinase (MT1-MMP), 189
  - mesenchymal stromal cells (MSC), 189
  - neuraminidase inhibitors, 190
  - nonavalent dendrons, 177
  - pentaerythritol and derivatives, 180
  - pentaerythritol tetrabromide, 180, 183
  - phytohemagglutinin concanavalin A, 187
  - reductive amination, 178–179
  - relative binding affinity, 188
  - Sonogashira coupling, 186, 188
  - subsite-assisted aglycone binding, 185
  - tetrakis[(4-iodophenoxy)methyl]methane, 186
  - tetramannosylated pentaerythritol, 182
  - tetrameric galabioside, 180, 182
  - tris(2-aminoethyl)amine, 178
  - trivalent tumor markers, 180–181
  - Ugi four component reaction, 180
  - yeast mannan, 180
  - Zemplén deprotection, 186
- calixarene core
- 2-acetamido-2-deoxy- $\beta$ -D-glucopyranose (GlcNAc), 205
  - anion-recognition properties, 203
  - Boc-glycine spacers, 206

- cholera toxin (CT) glycoconjugate  
 ligand, 203  
 cluster effect, 208  
 deprotected cluster interaction, 205  
 disymmetrical 25,26,27-tripropoxy-  
 28-hydroxy-*p-tert*-butylcalix[4]-  
 arene, 206  
 elongated nanostructures, tailored  
 spacer arms, 203  
 galectin-4, 208  
 glycosylated calix[4]arene, 206–207  
 heat-labile enterotoxin, 204  
 ligation strategies, 201–202  
 lipophilic cavity, 201  
 natural GM1 oligosaccharide, 203–204  
 natural killer (NK) cells, 205  
 NKR-P1 and CD69 receptors, 205  
*O*-, *N*-, or *C*-glycosyl calix[n]arenes,  
 201–202  
 peripheral blood mononuclear cells  
 (PBMC), 206  
 rigid calix[4]arene scaffold, 208  
 second-generation conjugate, 205  
 site-specific molecular delivery  
 systems, 203  
 S-linked Tn antigen glycomimetics, 206  
 tetra-Tn construct, immunogenicity, 208  
 2-thio- $\alpha$ -sialosides, 201  
 turbidimetric analysis, 203  
*Viscum album* agglutinin lectin and  
 asialofetuin, 208
- carbohydrate scaffolds  
 allyl 2,3,4,6-tetra-*O*-allyl- $\alpha$ - and  
 $\beta$ -D-glucopyranosides, 218  
 $\beta$ -D-glucosides, 224  
 clustering effect, 224  
 cyclodextrin (CD), 223–225  
 cytotoxicity assays, 222  
 DAISY, 222–223  
*Erythrina corallodendron* lectin  
 (EcorL), 224  
 glycocyclodextrins and dendronized  
 cyclodextrin-bearing mannose  
 ligands, 224, 226
- hemolytic uremic syndrome (HUS), 219  
 heptavalent GlcNAc-CD, 227  
 higher-valent D-glucose-centered  
 glycocluster, 218  
 6<sup>1</sup>-amino-6<sup>1</sup>-deoxy- $\beta$ -cyclodextrin, 227  
 IC<sub>50</sub>, pentavalent clusters, 219  
 lectin binding, geometrical  
 requirements, 217  
 molar activity, inhibitor, 222  
*N*-acetyl-D-glucosamines, 224  
 oligovalency, 220  
 Shiga-like toxins (SLTs), 219–220, 222  
 Shiga toxin (Stx), 219–220  
 STARFISH dodecamer, 219–221  
 STL-I and II, 222–223  
 tetrameric plant lectin concanavalin A,  
 227  
 versatile reactivity, terminal  
 alkene, 218  
 wheat germ agglutinin (WGA), 224
- cross-coupling reactions  
 C-glycosyl compounds, 196  
 chimeric-type galectin-3, 198  
 conformational flexibility, 195  
 Glaser reaction, 195  
 hemagglutination, 198  
 lactoclusters, relative affinities, 197  
 lactoside-bearing glycotope  
 bioisosteres, 197  
 one-step Pd-catalyzed methodology,  
 195–196  
*O*-, *S*-, or *C*-glycosidic linkages, 195  
 cucurbit[n]uril cavitand, 233–235  
 cyclophosphazene derivatives, 235–236  
 decamannoside, 236  
*E. coli* heat-labile enterotoxin, 239  
 enzyme-linked lectin assay (ELLA), 240  
 fluorescein isothiocyanate  
 (FITC)-spermine derivative, 235  
 HepG2 hepatocellular carcinoma  
 cells, 235  
 hexa chlorocyclotriphosphazene  
 (P<sub>3</sub>N<sub>3</sub>Cl<sub>6</sub>), 235  
 intermolecular cyclotrimerization



Glycoclusters (*cont.*)

- benzenehexaylhexamethylene hexakis-  
( $\beta$ -D-glucopyranoside)  
tetraeicoacetate, 192–193
- cobalt-catalyzed cyclotrimerization,  
propargylated glycosides, 192
- dicobalt octacarbonylmediated  
benzannulation, 195
- glycoasterisk, 192–193
- hexavalent glycocluster, 192–193
- molecular-asterisk, C-galactosyl group,  
193–194
- 2-propynyl 2,3,4,6-tetra-O-acetyl-  
D-glycopyranosides, 191
- Sonogashira cross-reaction, 194
- Zemplén O-deacetylation conditions,  
193
- intracellular translocation, 235
- mannosylated cyclophosphazenes, 235, 237
- m*-nitrophenyl  $\alpha$ -D-galactoside (MNPG)  
derivatives, 239
- oligoantennary oligosaccharides, 174
- pentaerythrityl phosphodiester oligomers  
(PePOs), 240
- peptide scaffolds
  - anti-HIV-1 gp120 conjugate vaccine,  
230–231
  - azide-bearing aglycone, 232
  - cholera toxin B pentamer, 228, 230
  - cyclic scaffolds, 228–229, 232
  - glycans, 227–228
  - horse radish peroxidaseconjugated  
antihuman IgG (HRP-IgG), 232
  - Man<sub>9</sub>GlcNAc<sub>2</sub>, high-mannose  
oligosaccharide, 230
  - solid-phase synthesis (SPS), 228
  - submicromolar IC<sub>50</sub> values, 228
  - tetrameric gp120 glycan epitope, 232
- persulfurated glycoclusters
  - aggregating effect, Concanavalin A,  
200–201
  - 2-azidoethyl tetra-O-acetyl- $\alpha$ -  
D-mannopyranoside, 198
  - Boc N-protection, 198
  - 2-bromoacetamido-tris[(propargyloxy)-  
methyl]aminomethane, 198
  - Burkholderia cenocepacia*, 198
  - 18  $\alpha$ -D-mannopyranoside residues,  
198–199
  - $\alpha$ -D-mannoside, 200
  - 2-ethoxy-1-ethoxycarbonyl-1, 2-  
dihydroquinoline (EEDQ), 200
  - $\alpha$ -glucose asterisk, 200
  - molecular asterisks, 200
  - O-deacetylation, 200
  - Zemplén conditions, 198, 200
- phthalocyanine, 217
- polyhedral oligosilsesquioxanes  
(POSS), 240
- porphyrin cores
  - amphiphilic character, 215
  - amphiphilic/lipophilic character,  
clusters, 213
  - chlorophyll *c*<sub>2</sub>-  
monogalactosyldiacylglyceride, 209
  - dimyristoylphosphatidylcholine (DMPC)  
liposome membrane, 215–216
  - galacto- and mannosubstituted  
tetraphenyl porphyrins, 212
  - glucosylated porphyrins, cationic  
head-groups, 214–215
  - high photoactivity,  $\alpha$ -galacto-manno  
porphyrins, 213
  - mannosylated porphyrin clusters, 216
  - meso*-arylporphyrin scaffold, 210
  - 5,10,15-*m*-tri(*p*-phenol)–20-  
phenylporphyrin, 212
  - neutral bisporphyrins, 214
  - O-glycosylated porphyrin dimers, 209
  - O-, S-, and N-glycoporphyrins,  
210–211
  - partition coefficients, deprotected  
bisporphyrin conjugates, 215
  - p*-chloranil, 214
  - photodynamic therapy (PDT), 210–211
  - polydispersity, 216
  - sugar aldehyde condensation, 209–210
  - tolyporphin A, 209

- tri- and hexavalent glycosylated porphyrins, 214
- in vitro* photocytotoxicity, K562 leukemia cell line, 215
- Williamson etherification, 212
- Y79 retinoblastoma cells, 212–213
- potent antiadhesins, 238
- 1,4,8,11-tetraazacyclotetradecane, 236
- trivalent  $\beta$ -D-galactoside, 217
- Glycocodes, 170
- Glycodendrimer
  - AB<sub>3</sub> systems, 347–348
  - aromatic AB<sub>2</sub> systems, 344–347
  - carbosilane
    - D-xylose dendrimers, 352–353
    - pendant galabiose disaccharides, 350–351
  - Scatchard plot analysis, 350
  - sialyloligosaccharide-capped dendrimers, 351–352
  - SLT-I and -II, 349–350
  - SUPER TWIGs, 349–350
- glycopeptide dendrimers
  - antisense gene delivery, 323
  - asialoglycophorin, 322
  - capsular polysaccharides (CPS), 318–319
  - carbohydrate-based vaccine, schematic representation, 319
  - carbohydrate-recognition domain (CRD), 317
  - commercial Tentagel resin, 315
  - COS-1-cells, 313
  - dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-SIGN), 312–314
  - diethylene glycol (DEG) spacers, 321
  - emmprin 34–58, 321
  - fluorescently labeled
    - mannodendrimers, 314
  - 2G12, protective anti-HIV immune response, 319–320
  - 4-hydroxybutanoic acid linker, 315
  - Lewis<sup>X</sup> tetrasaccharide antigens, chemoenzymatic process, 312
  - mannose-binding protein (MBP), 312
  - multiple antigenic glycopeptides (MAGs), 319
  - N,N-diisopropylidiphosphoramidite, 321–322
  - novel hyperbranched glycomimetics, L-lysine scaffolds, 313
  - optimized C-fucosylated glycopeptides, 317
  - poliovirus T cell epitopes, 319–320
  - poly-L-lysine scaffold, mannosylated dendron, 310–311
  - sialic acid, 310
  - synthetic anti-HIV vaccine candidate, 318
  - Thomsen Friedenreich (TF) disaccharide antigen [ $\beta$ -D-Gal(1→3)- $\alpha$ -D-GalNAc], 310–311
  - tris(2-ethylamino)amine, 315–316
- host–guest molecular recognition, 354
- hyperbranched Boltorn<sup>®</sup> dendrimers
  - bifunctional glycodendrons synthesis, 343–344
  - click methodology, 342
  - Ebola infection inhibitor, 342
  - Lens culinaris* lectin (LCA), 341
  - mannosylated dendrimers, 341
  - polyols, 340
  - propargyl  $\alpha$ -D-mannoside, 342
  - succinic anhydride, 341
- PAMAM dendrimers
  - amide linkages, 328–330
  - commercially available dendrimer scaffolds, 323–324
  - nucleophilic substitution, haloacetamido groups, 330–337
  - reductive amination, 330
  - thiourea linkages, 325–328
- peripheral D-xylose residues, 354, 356
- polyphenylenes building blocks,
  - glucosamine dendrimers, 354–355
- poly(propyleneimine) [PPI] dendrimers
  - cell infectivity inhibitors, 338–339
  - convergent synthesis, 338–339
  - galactosyl ceramide, 338

- Glycodendrimer (*cont.*)  
 MPPI, 339–340  
 poly(sulfogalactosylated)  
 dendrimers, 338  
 thioglycosides coating, 337–338  
*scyllo*-inositol, 352, 354  
 syntheses, 288–289
- Glycodendrons  
 AB<sub>2</sub> systems  
 AB<sub>2</sub>-sugar scaffold, glycodendrimer  
 synthesis, 299  
 2- and 4-aminothiazole lactosides,  
 dendrons, 295  
 analytical ultracentrifugation and  
 dynamic light scattering (DLS), 294  
 9-BBN transformations, 303  
 binding affinities, CT subunit, 291  
 biotin end group, mannosylated  
 dendrons, 298  
 biotinylated dendritic T-antigen, 296  
 3,6-diallylated precursor, 301  
 3,5-diaminobenzoic acid  
 scaffolds, 294–295  
 glycomagnetic beads, 298  
 GM<sub>1</sub> and agalacto-GM<sub>1</sub> ligands, 292  
 GM<sub>1</sub> oligosaccharide ligand, lactoside  
 analogues, 290  
 head-to-head dimerization, protein  
 toxin, 294  
 mannosylated dendrons, AB<sub>2</sub>-mannoside  
 scaffold, 301  
*m*-nitrophenyl  $\alpha$ -D-galactopyranoside  
 (MNPG), 290  
 multivalency effects and selectivity,  
 tetravalent lactoside, 295–296  
 mutant lacking pilus expression, 298  
 octameric glycodendrons, GM<sub>1</sub>  
 analogues, 293  
 ORN178 and ORN208, 298  
 pentameric bacterial toxin, 290  
 peripheral lactoside residues, dendritic  
 scaffold, 291  
 photochemical construction, lactosylated  
 dendrons, 300  
 polyether glycodendrons, methallyl  
 dichloride, 302  
 streptavidin, 297  
 Stx2c, 297  
 terminal galactose residue, anchoring  
 fragment, 290  
 toxin B pentamer, 291
- AB<sub>3</sub> systems  
 arborols, 303  
 azides and propargylated dendrons,  
 glycodendrimers, 308  
 azido-terminated gallic acid-triethylene  
 glycol dendrons, 308–309  
 catalyzed alkyne–azide 1,3-dipolar  
 cycloaddition reaction, 304  
 copper-catalyzed [3+2]  
 cycloaddition, 307  
 gallic acid-based glycodendrons,  
 305–306  
 Man<sub>4</sub> and Man<sub>9</sub>, 304  
 oligomannoside-ending azides,  
 HIV-1 gp120 mimetics, 303–304  
 polysialic acid dendronized chitosan,  
 306–307  
 propargylated dendrons, modified TRIS  
 scaffold, 304–305  
 sialic acid *p*-phenylisothiocyanate  
 derivative, 307  
 sialodendrons, 307  
 tris(hydroxymethyl)aminomethane  
 (TRIS), 303, 305
- self-assembly  
 dendritic scaffolds, outside-in  
 approach, 282  
 Galili antigen and Lac-SH, 283  
 $\alpha$ Gal-mediated lysis, pig erythrocytes,  
 284  
 G(1) and G(2) dendrimer generation, 282  
 glycodendrimers scaffold, hydrophobic  
 repeating-units, 283  
 optimal core–core interaction, 284
- Glycofullerenes  
 Buckminsterfullerene, 242  
 carbon, allotropic form, 241

- monovalent structures
  - C<sub>60</sub> preactivation, 244
  - Diels–Alder reaction, 245
  - DNA and protein-degradation properties, 245
  - [60]fullerenoacetyl chloride, 244
  - glycofulleropyrrolidine
    - monocycloadducts, 1,3-dipolar cycloaddition, 243
  - glycosylation, 245
  - selective degradation, HIV-protease, 245
  - spiro C-linked glycosyl-C<sub>60</sub> derivatives, 243
- multivalent structures
  - amphiphilic fullerenes, 247–248
  - azide-bearing mannosylated dendrons, 249
  - azido oligo(ethylene glycol)-terminated glycodendron, 249
  - bis( $\alpha$ -D-mannopyranosyl)fullerene, 248
  - bismannoside-C<sub>60</sub> adduct,
    - Bingel–Hirsch procedure, 248
  - C<sub>60</sub> malonates, Bingel's procedure, 247
  - [3+2]-cycloaddition reaction,
    - glycosyl azide, 245
  - degree of functionalization, 247
  - fulleropentathiol, alkylation, 251
  - HeLa cells, 246
  - mono- and bismannosyl fullereneols,
    - activity, 246
  - nucleophilic cyclopropanation, 246
  - pentavalent fulleroglycoconjugates, 250
  - peptide-coupling reaction, 248
  - peripherally protected glucopyranoside residues, 248
  - phototoxicity, 246
  - stable self-assembling structures, 246
  - thiolate–alkyl halide coupling reaction, 250
  - twofold cluster-opened
    - diazabishomofullerene adduct, 249
  - water-soluble fullerene sugar, 250
  - X-type Langmuir–Blodgett films, 248
- natural repulsion, water, 242
- spherical topology, 242
- Glycogen and deoxy sugars, complex carbohydrates
  - chemical synthesis, 4
  - elucidation, glycosaminoglycan structures, 4
  - enzymatic degradation of starch, 3
- Glycomimetics, 172–173, 177–178, 206, 313–314, 357
- Glyconanotubes
  - covalent interactions
    - amine-derivatized glyco wedges, SWNT acids, 261–262
    - amine-ending glycodendrons, 262–263
    - 2-aminoethyl glycopyranosides, 262
    - $\beta$ -D-galactoside-modified SWNT, 260
    - $\beta$ -D-galactosides, 264
    - carbohydrate-functionalized SWNTs, 263
    - carboxylic acid-functionalized SWNTs, 260–261
    - grafting from strategy, 264
    - morphology and arrangement,
      - glycodendrons, 263
    - MWNT, 264
    - MWNT-CO<sub>2</sub>H precursor, 264
    - surface defect oxidation, 260
  - noncovalent interactions
    - C<sub>18</sub>- $\alpha$ -MM-SWNTs, 255
    - confocal laser-scanning microscopic (CSLM) observations, 257
    - Cu(I)-catalyzed azide–alkyne [1,3]-dipolar cycloaddition (CuAAC) methodology, 258
    - fluorescent dye Texas Red, 255
    - $\alpha$ -GalNAc-HPA–CNT–cell surfaces complex, 255
    - glycodendrons, syntheses, 257
    - Helix pomatia* agglutinin (HPA), 255
    - Man-SWNTs, 258
    - mucin mimic (MM), 254
    - N-acetyl- $\alpha$ -D-galactosamine ( $\alpha$ -GalNAc), 254
    - O-linked glycans, dense clusters, 254
    - photoluminescence signal, 257

Glyconanotubes (*cont.*)

- poly(*p*-*N*-acryloylamidophenyl)- $\alpha$ -D-glucopyranoside, 257
- pyrene-based glycodendrons, 258–259
- schizophyllan, 256
- surface heterogeneity, 255–256
- SWNT, noncovalent functionalization, 253–254
- uniformity and purity, amphiphilic glycodendrimers, 258
- water-soluble SPG-Lac-SWNTs nanocomposites, 256
- spaghetti network, 252

Glycosaminoglycans, 4–8, 13, 159

Glycosyltransferases (GTFs), 102, 105, 118, 121–122, 127

GM1 [ $\beta$ Gal1 $\rightarrow$ 3 $\beta$ GalNAc1 $\rightarrow$ 4( $\alpha$ Neu5Ac-2 $\rightarrow$ 3) $\beta$ Gal(1 $\rightarrow$ 4) $\beta$ Glc1 $\rightarrow$ 1Cer], 204

**H**

H-mordenites, 72

Hyaluronic acid structure, 5

Hydrolysis of methylated polysaccharides, 24

5-Hydroxymethylfurfural (HMF), 69, 71, 74

**I**

Inulosucrases (ISs) enzyme, 114–115

Invertebrate matrix glycoconjugates, 8–9

Isomaltulose (IM), 119–120

**J**

Jeanloz, R., 3–15

**L**

Lactosucrose, 126

Levansucrases (LSs) enzyme, 114–115

Lindberg, B., 23–27

Lipid intermediates, glycoprotein biosynthesis, 10–11

Lipid-linked di-*N*-acetylchitobiose structure, 11

Lysosomal glycosidase deficiencies, 11–12

Lysosomal mannosidases, 11

**M**

Maltose hydrolysis, 69–70

Mammalian membrane glycolipids, 7

Mannosylated PPI dendrimers (MPPI), 339–340

Medium and large-pore zeolites

dehydration, 71–72

glycosylation

adsorption properties, 35

1,2-anhydro sugars, 38

aryl glycosides synthesis, 37–38

Fischer glycosidation, *N*-acetylgalactosamine, 36–37

Fischer glycosylation, D-glucose, 35

glycals, Ferrier rearrangement, 38–39

$\beta$ -glycoside and diol formation, 38–39

H-beta zeolite, 35

long-chain alcohols, 38

long-chain glucosides, 35–36

1-*O*-acetyl sugars, 37

2,3-unsaturated  $\alpha$ -glycosyl derivatives, 39–40

oxidation, 74–75

sugar protection and deprotection

acetylation procedure, 56–57

1,2:5,6-Di-*O*-isopropylidene- $\alpha$ -D-glucofuranose, 58–59

isopropylidene acetals, 57

monoacetals, 58

pyranoid diacetals, 57–58

pyranose, 56–57

Methylated heteropolysaccharide, 5

Methylation analysis, 5, 24–25

Michaelis–Menten kinetics, 106

3-, 4-, and 6-Monomethyl ethers, 5

Montmorillonite clays

dehydration, 74

glycosylation

*C*-glycosyl aromatic compounds, 45

*C*-glycosylation methods, 44–45

Fischer glycosylation, butanol, 42–43

1-*O*-acetyl-2,3,6-trideoxyhexoses, 42

*O*-glycosidation of glycals, 44

- olivoses (2,6-dideoxy-D- and -L-arabino-hexoses), 43
    - stereoselective synthesis, of 2-deoxy-2-iodo- $\beta$ -olivosides, 44
  - sugar protection and deprotection, 61–62
  - synthetic applications, 79–80
  - Mucins**
    - affinities, SBA and VML, 145–146
    - binding and cross-link, cell-surface mucins, 144
    - diagnosis, cancer, 143
    - gene products, 143
    - O-glycosylated linear glycoproteins, 142
    - oligosaccharide chains, 142
    - porcine submaxillary mucin (PSM), 143–144
  - Multivalency**
    - definition and role
      - arterial and central nervous system networks, 169
      - divalent entity, 168
      - fractal/dendritic architectures, 168
      - gecko's foot, 169
      - particle, 168
      - polyvalent interactions, 168
    - protein–carbohydrate interactions
      - cross-linking glycocluster effects, 170
      - glycocluster/dendritic effect, 170
      - premature degradation protection, 169
      - weak association constants, 170
  - Multivalent glycoconjugates**
    - artificial glycoforms, 172
    - binding affinities, 172
    - conjugation reactions, 173
    - glycomimetics, 172
    - ligand-binding specificity, lectins, 171
    - optimized multivalent glycodendrimers, steps, 172
  - Multivalent lectin–mucin interactions**
    - cross-linking interactions
      - bind and jump model, 156–157
      - entropy, 154–159
      - hill plot, negative cooperativity, 153–154
      - stoichiometric analysis, 153
    - face-to-face binding, 141–142
    - linear and nonavalent glycoprotein, binding, 141–142
    - thermodynamics, soybean agglutinin binding
      - Fd-PSM, 148–149
      - 38/40-mer Tn-PSM, 148
      - 81-mer Tn-PSM, 147–148
      - Tn-PSM, 146–147
    - thermodynamics, *Vatairea macrocarpa* lectin (VML)binding
      - Fd-PSM, 150
      - 81-mer Tn-PSM and 38/40-mer Tn-PSM, 149
      - Tn-PSM, 149
  - Multiwalled carbon nanotube (MWNT)**, 252, 264
  - Muramic acid**, 7
- N**
- Neoglycoconjugates, multivalent**
    - accelerated convergent strategies, 356
    - arborols, 286
    - coordinating metals, self-assembly
      - 2-aminoethyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy- $\alpha$ -D-glucopyranoside, 275
    - asialoglycophorin A, 266
    - chelating metal cations and divalent bipyridine scaffold, glycodendrimers, 267
    - cluster effect, 276
    - concanavalin A (Con A) and galanthus nivalis agglutinin (GNA), 282
    - $\beta$ -D-galactopyranoside precursors, 272
    - $\alpha$ -D-GalNAc 2,2'-bipyridine oligomers, copper(II) salt, 276–277
    - divalent  $\beta$ -D-galactopyranosides, oligopyridine metal ligand scaffolds, 272–273
    - dynamic molecular recognition, 266
    - egg-yolk decasaccharide, 269

- Neoglycoconjugates, multivalent (*cont.*)
- Fe(II)-bipyridyl complex, self-assembled glycodendrimers, 266
  - ferrous O- and N-glycoclusters, 268
  - flexibility, 268
  - galactose-oligopyridine conjugates, 271
  - Glycine max*, 267
  - glycosylated bi- or terpyridine ligands, 272, 274
  - hemagglutinin, amino acid residues, 269
  - lectin affinity, spacers, 268
  - $\Lambda$ -mer isomer, 266
  - mannosylated dendrons, 8-
    - hydroxyquinoline ligand, 277–278
  - mannosylated glycodendrimers,
    - bipyridine core, 279–280
  - metal-to-ligand charge transfer (MLCT) band, water, 268
  - monosubstituted terpyridine ligand,
    - glycoclusters, 270
  - $[\text{NH}_4]\text{Fe}(\text{SO}_4)_2 \cdot 6\text{H}_2\text{O}$ , 270
  - Pd(0)-catalyzed Sonogashira coupling, 272
  - pentafluorophenyl group, 4'-position, 271
  - photoinducible electron-transfer Ru(II)-complexes, 280–281
  - Re and  $^{99\text{m}}\text{Tc}$  glycoclusters, 273–274
  - self-assembled mannodendrons, 278–279
  - 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO), 281
  - Tn-antigen ( $\alpha$ -D-GalNAc) clusters, 275–276
  - Tn-dimers, 2,2'-bipyridine core, 275
  - tris-bipyridine ruthenium complex  $\Delta[\text{Pu}(\alpha\text{-Glc-3-bpy})_3]\text{Cl}_2$ , 268–269
  - unsymmetrical Bipy-GalNAc,
    - trimerization, 266
  - dendrimer, definition, 285–286
  - enhanced permeation retention (EPR) effect, 287
  - glyco carriers, 287
  - glycoclusters
    - $\alpha$ 1-acid glycoprotein (AGP), 240
    - azamacrocyclic cyclam, 236, 238
    - branched aliphatic scaffolds, 177–190
    - calixarene core, 201–208
    - carbohydrate scaffolds, 217–227
    - cross-coupling reactions, 195–198
    - cucurbit[n]uril cavitand, 233–235
    - cyclophosphazene derivatives, 235–236
    - decamannoside, 236
    - E. coli* heat-labile enterotoxin, 239
    - enzyme-linked lectin assay (ELLA), 240
    - fluorescein isothiocyanate (FITC)-spermine derivative, 235
    - HepG2 hepatocellular carcinoma cells, 235
    - hexa chlorocyclotriphosphazene ( $\text{P}_3\text{N}_3\text{Cl}_6$ ), 235
    - intermolecular cyclotrimerization, 191–195
    - intracellular translocation, 235
    - mannosylated cyclophosphazenes, 235, 237
    - m*-nitrophenyl  $\alpha$ -D-galactoside derivatives, 239
    - oligoantennary oligosaccharides, 174
    - pentaerythritol phosphodiester oligomers (PePOs), 240
    - peptide scaffolds, 227–233
    - persulfurated glycoclusters, 198–201
    - phthalocyanine, 217
    - polyhedral oligosilsesquioxanes (POSS), 240
    - porphyrin cores, 208–217
    - potent antiadhesins, 238
    - 1,4,8,11-tetraazacyclotetradecane, 236
    - trivalent  $\beta$ -D-galactoside, 217
  - glycodendrimer
    - AB<sub>3</sub> systems, 347–348
    - aromatic AB<sub>2</sub> systems, 344–347
    - carbosilane, 348–353
    - glycopeptide dendrimers, 309–323
    - host-guest molecular recognition, 354
    - hyperbranched Boltorn<sup>®</sup> dendrimers, 340–344
    - PAMAM dendrimers, 323–336

- peripheral D-xylose residues, 354  
 polyphenylenes building blocks,  
   glucosamine dendrimers, 352,  
   354–355  
 PPI dendrimers, 336–340  
*scyllo*-inositol, 352  
 syntheses, 288–289  
 glycodendrons  
   AB<sub>2</sub> systems, 290–303  
   AB<sub>3</sub> systems, 303–309  
   dendritic scaffolds, outside-in  
     approach, 282  
   Galili antigen and Lac-SH, 283  
    $\alpha$ Gal-mediated lysis, pig erythrocytes,  
     284  
   G(1) and G(2) dendrimer generation, 282  
   glycodendrimers scaffold, hydrophobic  
     repeating-units, 283  
   optimal core–core interaction, 284  
   polyvalent receptor (lectin), 285  
 glycofullerenes  
   Buckminsterfullerene, 242  
   carbon, allotropic form, 241  
   monovalent structures, 242–245  
   multivalent structures, 245–252  
   natural repulsion, water, 242  
   spherical topology, 242  
 glyconanotubes  
   covalent interactions, 258, 260–265  
   noncovalent interactions, 253–258  
   spaghetti network, 252  
 low molecular weight cascade  
   polyamine, 286  
 PAMAM [poly(amidoamine)], 286  
 prodrugs, 287  
 repetitive and controlled synthetic growth  
   concept, 286
- O**
- Oligosaccharide synthesis  
   biological recognition processes, 102  
   commercial products  
     cyclodextrin (CD), 126–127  
     galacto-oligosaccharides, 125  
     gentio-oligosaccharides, 126  
      $\alpha$ -gluco-oligosaccharides, 125  
     GTF, 122  
     IM manufacture, 123–124  
     immobilized glycosyltransferases, 123  
     technical production, isomaltulose, 124  
     trehalose [ $\alpha$ -D-glucosyl-(1 $\rightarrow$ 1)-  
        $\alpha$ -D-glucose], 126  
   enzymatic reactions, 102  
   fructansucrase (FS) enzymes  
     kinetics, 114  
     structure–function relationship,  
       114–116  
   glucansucrases  
     donor and acceptor-substrate  
       engineering, 111–114  
     kinetics, 105–108  
     structure and enzyme engineering,  
       108–111  
   glycosidases, glycosynthases,  
     thioglycosidases  
     disaccharides, 105  
     hydrolytic reaction, 103  
     thioglycoligation, 105  
     transglycosidation, 104  
     transglycosylation, 103  
   sucrose analogues  
     chemoenzymatic approach, 117  
     different products, substrates, 119–120  
     different routes, 117  
     fructose/glucopyranoside transfer, 118  
     kinetic parameters, 119  
     L-glucopyranosides, acceptors, 116  
     monosaccharides, transfer, 118  
     sequence analysis, 118  
   sucrose isomerase (SI)  
     active-site architecture, 121  
     immobilization, entrapment, 120  
     isomaltulose (IM), 119–120  
     *Klebsiella* enzymes, 120–121  
     thermostability, 121  
 Olivoses (2,6-dideoxy-D-and-L-*arabino*-  
   hexoses), 43  
 1,3-Oxazin-2-ones(thiones), 79–80



**P**

- Photofrin<sup>®</sup>, 210–211, 215  
 Protein-bound oligosaccharides, structural analysis, 9–10  
 Pyran-1,3-oxazine-2-ones, 80  
 Pyran-1,3-oxazine-2-thiones, 80

**R**

- Ruff oxidative degradation, 74

**S**

- Silica gel  
 catalytic systems, 34  
 glycosylation  
 avermectin B1 analogue synthesis, 51  
 epoxide hydrolysis, 45  
 Ferrier reaction, Tri-*O*-acetyl-D-glucal, 47–48  
 glycone, anti-leishmanial triterpenoid saponin, 54  
 Le<sup>a</sup> and Le<sup>x</sup> derivative, 49–50  
 methyl glycoside analogue, trisaccharide fragment, 51  
 octyl polyglucoside, 55–56  
 on-column synthesis approach, 49–50  
 stereoselective synthesis, glucoside terpenoids, 46–47  
 synthesis, HClO<sub>4</sub>-SiO<sub>2</sub>, 49–50  
 tetrasaccharide synthesis, 55  
 3,4,6-tri-*O*-acetyl-D-glucal and-galactal, 49  
 trisaccharide synthesis, 52–55  
 hydrolysis/isomerization of saccharides and glycosides, 70–71  
 sugar protection and deprotection  
 acetonation, H<sub>2</sub>SO<sub>4</sub>-SiO<sub>2</sub>, 63, 66  
 acetylation, H<sub>2</sub>SO<sub>4</sub>-SiO<sub>2</sub>, 62–65  
 benzylidene acetal groups, 65, 67  
 terminal *O*-isopropylidene groups, 68  
 trityl ether groups, 67  
 synthetic applications  
 carbohydrate-derived oximes, 82  
 miharamycin analogues synthesis, 81  
 nitroaldol reaction, methyl nitroacetate, 82  
 Single-walled carbon nanotube (SWNT), 252, 257, 262, 264  
 carbohydrate-functionalized SWNTs, 263  
 carboxylic acid-functionalized SWNTs, 260–261  
 noncovalent functionalization, 253–254  
 oxidation of defect sites, 260  
 pyrene-based glycodendrons, 258–259  
 solubilization, 256  
 Small-pore zeolites  
 dehydration, 72–73  
 glycosylation, molecular sieves  
 acid/water scavengers, 41  
 activation procedure, 42  
 $\alpha$ -ribonucleosides synthesis, 42  
 $\alpha,\alpha$ - and  $\alpha/\beta$ -selectivity, 40  
 stereoselectivity, 40  
 oxidation, 75–76  
 sugar protection and deprotection  
 acetylation, 59  
 deacetylation and debenzoylation, 60–61  
 mild benzhydrylation, 59–60  
 nucleosides inosine and guanosine, 59–60  
 Soybean agglutinin (SBA) binding  
 porcine submaxillary mucin (PSM), bind and jump model  
 affinities, 150  
 diffusion-jump model, 150–152  
 $\alpha$ GalNAc residues, 152–153  
 Hill plots, 152  
 stoichiometric analysis, mucin, 153  
 thermodynamics  
 Fd-PSM, 148–149  
 38/40-mer Tn-PSM, 148  
 81-mer Tn-PSM, 147–148  
 Tn-PSM, 146–147  
 Sugar-derived  $\alpha$ -keto amide, 75

**T**

- Tetrasaccharide  $\beta$ -GlcNAc-(1 $\rightarrow$ 4)- $\beta$ -MurNAc-(1 $\rightarrow$ 4)-MurNAc structure, 8

Thioglycoside hydrolysis, 70–71

Tolyporphin A, 209

Transformation reaction, 24

1,3,5-Tris-(*p*-glycosyloxyphenylazo)-2,4,  
6-trihydroxybenzene, 191

Tumor-cell glycoproteins, 12–13

## V

*Vatairea macrocarpa* lectin (VML)binding

PSM, bind and jump model

dissociation constants, 145, 152

final saturation density, 152

Tn-PSM, 150–152

thermodynamics

Fd-PSM, 150

81-mer Tn-PSM and 38/40-mer

Tn-PSM, 149

Tn-PSM, 149

## X

Xylose dehydration, 72

## Z

Zemplén's glycosides synthesis, 23–24

Zeolites and other silicon-based promoters

anhydro sugars, 77

cellulose pyrolysis, 77

click chemistry, 76–78

green chemistry, 30

heterogeneous catalysts, organic synthesis

Brønsted and Lewis acidity, 32–34

chemical and thermal stability, 32

clay minerals, 33

Friedel–Crafts acylation and  
alkylation, 32

high adsorption capacity, 32

isomerizations, 33

microporous crystalline materials, 31

synthetic transformations, 31

5-hydroxymethylfurfural synthesis, 71

medium and large-pore zeolites

dehydration, 71–72

glycosylation, 35–40

oxidation, 74–75

sugar protection and deprotection, 56–58

montmorillonite

dehydration, 74

glycosylation, 42–45

other synthetic applications, 79–80

sugar protection and deprotection, 61–62

organic synthesis, 77–78

silica gel

glycosylation, 45–55

hydrolysis/isomerization of saccharides  
and glycosides, 70–71

other synthetic applications, 80–82

sugar protection and

deprotection, 62–68

small-pore zeolites

dehydration, 72–73

glycosylation, 40–42

oxidation, 75–76

sugar protection and deprotection, 58–61

triazole derivatives, 78

## SUBJECT INDEX

### A

- Acetylated rayon fiber-cellulose acetate composites, 97
- Acid/base and metal-promoted reactions, fructosamine
- affinity, redox-active metal ions, 329
- anomeric hydroxyl group, 329
- $\beta$ -pyranose tautomer, 327-328
- dehydration
- di- and oligosaccharide derivatives, mechanism, 334
  - mass spectra, 332
  - occurrence, 332
  - peeling off mechanism, 335
  - products, 332-333
  - Strecker degradation reaction, 334
  - structure, carbohydrate carbon skeleton, 333-334
  - unsubstituted *D*-fructosamine and *N*-substituted derivatives, 334
- D*-fructose-amino acids, copper(II) and nickel(II)
- anchoring absence, 330
  - chelate rings, 329-330
  - complex-formation constants, 330
  - deprotonation, pH 6-7, 329
  - 3-hydroxyl groups, 329-330
- D*-fructose-glycine and  $\beta$ -alanine
- carbonyl band, 330
- dissociation constants, 328-329
- enolization
- carbohydrate portion dehydration, 332
  - D*-glucose/*D*-mannose formation, 332
  - 2,3-enolization, 331-333
  - 1,2-enolization product, 317, 331
  - first-order rate constants, 331
  - iodine uptake, 331
  - reversible 1,2-enolization, 331
- Maillard reaction, food and *in vivo*, 327
- oxidation
- autoxidation, 335
  - enolization, 335
  - by metal ions, 335-337
  - by molecular oxygen, 335
  - oxidants, 338
  - physiological oxidants, 337
- palladium (II) and platinum(II)
- carbonyl band, 330
- proton- and metal-binding characteristics, 327
- p*-toluidine
- carbonyl band, 330
  - reduction agents, 338
  - thermodynamic stabilities, 329
  - transformation reactions, 327
- Acrylonitrile, cellulose grafting with, 73
- Acute lymphoblastic leukemia (ALL)
- human NEU3 role in, 439
- Acylation reactions, 131-132
- of cellulose
- acid anhydrides and carboxylic acids, 74
  - DCC with, 73-74
  - electron diffraction diagrams, 77
- N*-Acyl hydrazine, 165
- N*-Acylneuraminyl glycohydrolases, 405

- Advanced glycation end products (AGEs)  
 formation, 348  
 recognition, 348  
 structures, 348–349  
*in vivo* and in foods, 348
- 6-Aldehyde cellulose, 124
- Alkali cellulose  
 cellulose chains arrangement, 53  
 X-ray diffraction characterization, 54
- Alkanethiols, 214
- Alkylation, 127–129
- Alkylene oxides, cellulose ethers from, 73
- Alkyl halides  
 route for preparation of cellulose ethers  
 from, 72
- Allomorphs of cellulose  
 relationships among, 40–41
- 2-Allyl ethers, 155
- Amadoriases oxidoreductase  
 substrate specificities, 339  
 type I  
*Corynebacterium*, 339  
 electrostatic and hydrophobic  
 interactions, 340  
 FAD, 340  
 fungal fructose–amino acid oxidases,  
 339–340  
 kinetic and structural studies, 340  
 as protein-deglycating enzyme, 339  
 type II  
 D-fructose–proteins, 340  
 FruVal/eFruLys-specific and  
 proteases/peptidases, 340  
 glycated proteins, 340  
*Pseudomonas* sp., 340  
 washing and cleaning formulations, 340
- Amadori rearrangement  
 enzymatically catalyzed (*see* Enzymatic  
 formation method, fructosamine)  
 glucosylamines (*see* Glucosylamines,  
 Amadori rearrangement)
- American Association of Cereal Chemists  
 (AACC), 10
- Amino acid sequence variants in human  
 sialidases  
 non-synonymous SNPs, 448  
 by PolyPhen, bioinformatic  
 tool, 449  
 synonymous SNPs, 448
- Aminocellulose, 76
- 6-Amino-6-deoxy-celluloses, 124
- 1-Amino-1-deoxy-D-fructose. *see*  
 Fructosamine and derivatives
- 1-Amino-1-deoxy-D-glucitol, 308
- 1-Amino-1-deoxy-L-sorbose, 296
- Amylopectin, 125, 170–171
- Amylose, 170
- Analytical methods, fructosamine derivatives  
 assay, 322  
 capillary electrophoresis and  
 MS, 324  
 chromatography  
 boronate affinity, 324  
 D-fructose–amino acids in dehydrated  
 fruits, 323  
 gas, 323  
 HPLC, 323  
 TLC method, 323  
 D-fructose–protein conjugates enzymatic  
 detection, 327  
 fructosamine assay  
 anemia, 327  
 enamine one-electron autoxidation, 326  
 enzymatic determination, 326–327  
 fluorescein–boronic acid, 326  
 nitroblue tetrazolium dye  
 (NBT), 326  
 furosine method  
 analyte proteins acid hydrolysis, 325  
 N<sup>α</sup>-D-fructose-and-lactulose–amino  
 acids, 325  
 protein quality assessment, 325  
 pyridosine, 325  
 reaction yield, 325
- HbA<sub>1c</sub>  
 β-subunit, 326  
 diabetic patients, 325  
 enzymatic approach, 326  
 modification, D-fructosyl residues,  
 325–326

immunological, 327  
 ionization, 323  
 LC/MS, 324  
 mass spectrometry (MS), 323  
 SDS-PAGE, 324  
 tautomerization, 323  
 Aortic smooth muscle cells (ASMCs),  
 414, 417–418  
 Arabinogalactans (AGP), 32  
*N*-Aryl-fructosamine, 292  
 6-Azido-6-deoxy-cellulose, 124

## B

Biocompatibility, 242  
 Bionanomaterials, 270  
 Bone marrow  
 BM extracellular fluid (BMEF), 420  
 BM stromal cells (BMSC), 420  
 BM transplantation (BMT), 419  
 Boronate affinity chromatography  
 glyeated proteins separation, 324  
 phenylboronate, 324  
 Büchi cyclocondensation reaction, 351–352  
 Bulk material, heterogeneities in  
 analysis of fractions, 182  
 cellulose derivatives, fractionation of,  
 180–181  
 starch derivatives, topochemical  
 differentiation of, 182–183

## C

Carbohydrates  
 carbohydrate–carbohydrate interactions, 251  
 carbohydrate–protein interactions, 269  
 functionalized QDs, 264  
 uses of, 16  
*N,N*-Carbonyldiimidazole, 124  
 Carboxylic acid chlorides, cellulose  
 acylation, 75  
 Carboxymethylation  
 of cellulose, rate constants, 129  
 of starches, 126  
 Cathepsin G (CG), 420

Cell-surface elastin receptor (CSER),  
 413–415  
 Cellulose, 26  
 in cell wall environment  
 electron microscopy, 31  
 microfibrils, 30  
 occurrence in nature, 29  
 plant sources, 28  
 plasma membrane, formed in, 32  
 prokaryotic and eukaryotes  
 organisms, 28  
 conformations and crystalline structure, 33  
<sup>4</sup>C<sub>1</sub> chair conformation, 37  
 degree of polymerization (DP), 35  
 distances for cellobiose fragments, 39  
 fiber repeat, periodicity, 36  
*gauche* and *trans* conformation, 38–39  
 glycosidic torsion angles, 37, 39  
 helical parameters, 37  
 homopolymer of β-(1→4)-linked  
 D-glucopyranose residues, 34–35  
 molecular representation of chain, 35  
 structural descriptors for, 38  
 three-dimensional structure, 37  
 X-ray fiber diffraction diagram of, 35–36  
 crystallinity and polymorphism  
 crystal density, 40  
 crystalline dimorphism, 43  
 degree of crystallinity, 40  
 forms, 40  
 intra- and intermolecular hydrogen  
 bonds, 40  
 morphologies, 55  
 polarity of crystals, 56–57  
 reactions conditions  
 under heterogeneous conditions, 69  
 under homogeneous conditions, 66–69  
 reactions sites in, 69  
 factors influencing characteristics of, 70  
 Cellulose acetate (CTA)  
 crystal and molecular structure, 55  
 postchemical enzymatic deacetylation, 124  
 transmission electron microscopy of, 56  
 Cellulose derivatives, 118, 121  
 applications, 177

- Cellulose derivatives (*cont*)  
 fringed micelle model of, 162  
 reductive depolymerization of, 156
- Cellulose ethers, 118, 121
- Cellulose I $\alpha$  and I $\beta$   
<sup>13</sup>C CP-MAS spectra of, 46  
 crystalline arrangement representation, 58  
 crystal structure and hydrogen-bonding system, 45–46  
 molecular modeling methodology, 44  
 neutron diffraction pattern, 44  
 “parallel-up” chain-packing organization, 46  
 real and simulated AFM images, 64  
 relationships between unit cell of, 49  
 relative slippage of cellulose chains between, 48  
 solid-state NMR spectrum of, 43  
 structural details, 46–47  
*trans-gauche* orientation, 46
- Cellulose III  
 conformational changes, 53  
 electron diffraction study, 52  
 molecular and crystal structure, 53  
 reversible crystalline forms, 52  
 solid-state NMR study, 52
- Cellulose-selective endo-enzymes, 172
- Cellulose synthase complexes  
 cartoon representation of, 34  
 in plasma membrane, 33
- Cellulose 6-tosylates, 124
- Cellulose triacetates, <sup>1</sup>H NMR, 148
- Ceric ammonium nitrate (CAN)  
 reaction with cellulose  
 cellulose–polyacrylonitrile graft copolymers, 72
- CFU-E cells. *see* Colony-forming uniterythroid (CFU-E) cells
- Chemical modification of (1→4)-glucans, 123
- Chinese hamster ovary (CHO), 422–423
- Chiral (–)-menthylxyacetates esters, 124
- Chitosan nanoparticles, 266
- Chromatogeny principle and engineering, 87
- Citrate–ligand exchange, 214
- Cobalt superparamagnetic nanoparticles, 245
- Cobb test, 91
- Collision-induced dissociation (CID), 158
- Colloidal gold, 213
- Colon cancer, human NEU3 role in, 438
- Colony-forming uniterythroid (CFU-E) cells, 426–427
- Concanavalin A (ConA) lectin, 255
- Cross-linked iron oxide (CLIO), 240
- CSER. *see* Cell-surface elastin receptor (CSER)
- Cyanobacteria, cellulose biosynthesis in, 28
- Cyanoethylation, 132  
 cyanoethyl glucans, 146–147
- Cyclodextrins, 120, 131
- Cytosolic sialidase NEU2  
 CHO, 422–423  
 functional implication  
 biotechnological application, 428  
 and cancer cell differentiation, 426–427  
 developments in, 429  
 influenza virus sialidase, inhibitors, 427–428  
 and muscle differentiation, 425–426  
 RMS, study, 426  
 transfected myoblasts, 425–426  
 human sialidase NEU2, crystal structure  
 arginine triad, 423–424  
 Asp-box, 424–425  
 N-acetyl and glycerol portions, 424  
 Protein Data Bank with, 423  
 molecular-modeling techniques, *usc*, 423  
 pH optimum, 423  
 and site-directed mutagenesis, *use*, 423  
 structural features of, 424

## D

- DCC *see* *N,N*-Dicyclohexylcarbodiimide (DCC)
- Degree of polymerization (DP), 120
- 6-Deoxy-celluloses, 124
- 1-Deoxy-D-fructosylation reagent, 311
- N*-(1-Deoxy-2,3:4,5-di-*O*-isopropylidene- $\beta$ -D-fructopyranos-1-yl)-amino acids, 308
- Deoxygenation of cellulose, 74–75
- 6-Deoxy-6-halo-celluloses, 124

- Dependence model, 168
- Detergent-resistant microdomains (DRMs), 435
- Dextran, 121
- D-Fructose–amino acids, 308
- D-Fructose–hemoglobin (HbA<sub>1c</sub>), 357
- D-Fructose–Leu-enkephalin, 307
- Dialdehyde cellulose, 124
- 2,3-Dialdehyde cellulose  
cellulose oxidation by sodium periodate, 72
- Diaminals  
in acid-catalyzed Amadori rearrangement, 298  
formation, 298
- N,N*-Diethylcyclohexylcarbodiimide (DCC), 73
- Diethylenetriaminepentaacetate (DTPA)–Gd complex, 266
- N,N*-Dimethylacetamide (DMAC), 68
- 4-Dimethylaminopyridine (DMAP), 124
- DMAC–LiCl system, cellulose in, 68
- DNA-functionalized gold nanoparticles, 214
- DRMs. *see* Detergent-resistant microdomains (DRMs)
- E**
- Economy based on cellulose, 84  
cellulose–cellulose composites  
macromolecular interaction involved in, 98  
scanning electron micrograph of, 97  
uses, 90–92  
cellulose–synthetic polymer composites  
uses, 85–89  
protective films  
uses, 89–90
- Elastin-binding protein (EBP), 414
- Elastogenesis  
in fibroblasts from sialidosis and GS patients, 415
- NEU1 and elastin-binding protein, role  
ASMCs, 414  
CSER, 413–414  
EBP, 414  
VGVAPG hydrophobic domain, 414
- NEU1 deficient mice  
concomitantly, fibulin-5 (Fib-5), 416  
elastin concentration and lamellae, 416  
*Neu1*-null mice, 416  
tight-skin (Tsk) mice, 416
- Electron-capture dissociation (ECD)  
technique, 323
- Electrontransfer dissociation (ETD)  
technique, 323
- Electrospray ionization (ESI), 323
- EMH. *see* Extramedullary hematopoiesis (EMH)
- Endogenous fructosamines, plants and animals, 354–355
- Alzheimer's disease, 358
- D-fructose–phosphatidylethanolamine (Fru-PE), 358
- diabetes and related complications  
biological effects, 355  
cardiac myocytes, ROS production, 355  
D-fructose–albumin activities, 357  
glutathione glycation, 358  
HbA<sub>1c</sub>, 357  
human serum albumin modification, 356  
Maillard reaction, 358  
MAPK p44/42 (ERK1/2) and p38, 356–357  
NADPH oxidase and protein kinase C (PKC- $\alpha$ ), 355–356  
PAI-1 promoters, 357  
vascular remodeling, 356
- opines  
enzymatic systems, 355  
production, 355
- physiological significance  
binding proteins, 355–356  
plasma proteins, human, 355  
plasma, 358
- Enzymatic alterations and modifications of  
cellulose fibers  
cellulolytic enzymes, 82  
digestion, 82  
hydrolysis, 81

- Enzymatic alterations and modifications of  
 cellulose fibers (*cont*)  
 cellulosomes, 82–83  
 modification by  
 transglycosylating enzyme, 84  
 xyloglucan endotransglycosylase, 84
- Enzymatic formation method, fructosamine  
 1-amino-1-deoxy-D-fructosamine derivative  
 chrysopine family, 314  
 crown galls, 314  
 production, 312–313  
 transfer DNA (T-DNA), 313
- D-fructosamine 6-phosphate, 315–316  
 D-glucose 6-phosphate, 315  
 glycerol phosphate oxidase (GPO),  
 catalase and aldolase (RhuA)  
 combination, 316  
 guanidine triphosphate (GTP)  
 cyclohydrolase I, 315  
 histidine biosynthesis, 314–315  
 opines, 313–314  
 pteridine metabolism, 315  
 ribozyme-catalyzed reactions, 316  
 thiazole biosynthesis, 315  
 tryptophan biosynthesis, 315
- Enzymatic hydrolyzates, chemical analysis, 174
- Enzyme-aided structure analysis of starch/  
 cellulose, 172–175
- Enzyme-catalyzed reactions, fructosamine  
 derivatives  
 hydrolytic  
 amadoriases, 343  
 endopeptidases, 343  
 glycosidases, 343  
 isomerases and epimerases  
 FN6K, 342–343  
*fri* operon, *E. coli*, 343  
 kinases  
 FN3K (*see* Fructosamine-3-kinase  
 (FN3K))  
 FN6K (*see* Fructosamine-6-kinases  
 (FN6K))  
 mannopine cyclase, 343  
 nitric oxide, 343  
 oxidoreductases  
 amadoriase, 339–340  
 mannopine, 341  
 plasma protein modification, 338  
 phosphatases, 342
- Esterases, 32
- Ester hydrolysis, 124
- Etherification reactions, 131  
 of cellulose, 72
- Extensins, 32
- Extramedullary hematopoiesis (EMH), 419
- F**
- Fast-atom bombardment (FAB), 323
- Fischer glycosidation, 322
- Fischer's approach, 295
- Fringed micelle model of cellulose  
 derivatives, 162
- Fructosamine and derivatives  
 acid-labile glucosylamine, 292  
 biological functions and therapeutic  
 potential  
 endogenous, plants and animals, 354–358  
 as potential pharma- and nutraceuticals,  
 358–366  
 carbohydrate modifications, 294  
 dehydrated foods, 359  
 D-fructosamine  
 core structures, 293  
 in literature, 294  
 formation methods  
 Amadori rearrangement, 294–295  
 enzymatic (*see* Enzymatic formation  
 method, fructosamine)  
 non-enzymatic (*see* Non-enzymatic  
 formation method, fructosamine)  
 hemoglobin A1c (HbA1c), 293  
 as intermediates and scaffolds  
 Maillard reaction, foods and *in vivo*,  
 344–349  
 neoglycoconjugates, 349–350  
 synthons, 351–354  
 isoglucosamine, 292  
 N-aryl-glucosylamine rearrangement,  
 292–293



- stable isomer, 292  
 structure and reactivity  
   acid/base-and metal-promoted reactions, 327–338  
   analytical methods, 322–327  
   enzyme-catalyzed reactions, 338–343  
   tautomers, solid state and solutions, 316–322
- Fructosamine-3-kinase (FN3K)  
 ATP-dependent phosphorylation  
   catalyzes, 341  
 catalytic phosphate group proximity, 341  
 $\alpha$ -fructosamine epitope and aglycon  
   structures, 341  
 inhibitor structures, 341–342  
 isolation and activity, 341  
 mammalian genomes, 342
- Fructosamine-6-kinases (FN6K)  
 ATP-dependent 6-phosphorylation,  
   catalyze, 342  
 bacterial extracts, 342  
*E. coli*, 342
- Fructosazines, 334
- Fünfkugelapparat method, 118
- Furan-2-carboxylates esters, 124
- G**
- Galactosialidosis (GS), 407, 411  
 $\beta$ -Galactosidase ( $\beta$ -GAL), 406  
 Galacturonanases, 32
- Garegg, P. J.  
 $\beta$ -mannosides formation  
   indirect and direct methods, 23  
 Norblad-Ekstrand Medal, 22  
 oligosaccharide synthesis, 22  
 Ph.D. studies, 21–22  
 research environment in carbohydrate  
   chemistry, 22  
 schooling, 21  
 synthetic carbohydrate chemistry, 22
- Gas barrier test, 91
- Glaucocystis nostochinearum*  
 cellulose study, 43  
 synchrotron and neutron diffraction data, 47
- Globotriose*-GNPs, 255
- Glucanases, 32, 169, 171  
   active site, 169
- Glucan derivatives, structural  
   complexity, 132  
   bulk material, heterogeneities in, 142–144  
   glucan chains, substituent distribution,  
     139–142  
   glucose residues, distribution, 133  
 Spurlin and Reuben models, 133  
   broadened substituent distribution, 136  
   carboxymethylation, determination of  
     relative rate constants, 137  
   (1 $\rightarrow$ 4)-glucans, monomer patterns, 134  
   hydroxyethylation, 139  
   inter- and intramonomeric effects, 138  
   mol fractions of regioisomers, 135  
   MS/DS ratio, 139  
   topochemical effects, 142–144
- (1 $\rightarrow$ 4)-glucans chemical modification, 121
- cellulose  
   characterization of products, 123  
   cross-linked celluloses, 123  
   glucose residues, 122  
   hydrogen-bond patterns, 122  
   kinetically controlled reactions, 122  
   linear  $\beta$ -(1 $\rightarrow$ 4)-linked glucan structure, 121  
    $\alpha$ -(1 $\rightarrow$ 6)-linked glucan, 121  
   polymer-based reactions, 123
- kinetically controlled reactions, 127  
   alkylation, 127–129  
   esterification, 131  
   hydroxyalkylation, 129–130  
   sulfopropylation, 130  
   Williamson-type etherifications, 130
- starch  
   “cationic starch”, 126  
   derivatives, 126, 175  
   granule structure, 125–126  
   thermodynamically controlled reactions  
     acylations, 131–132  
     cyanoethylation, 132  
     sulfation, 132
- Glucitols, 152, 154
- Glucose, recovery in pre-Christian era, 16

- Glucosylamines, Amadori rearrangement  
   acid catalysis  
     aldose diaminal intermediate, 300  
     amino group protonation in  
       *N*-alkyl-D-glucosylamines, 300  
     carboxylic acids, 299  
     D-glucosylamines derivation, 300  
     enaminol and ketosamine, 298  
     glucopyranosyl ring, 298  
     hemoglobin glycation, 300–301  
     hydrochloric acid, 299  
     Lewis acids, 300  
     metal complexation, 300  
     *N*-aryl D-glycosylamines, 298–299  
     protein-derived D-glucosylamines, 300  
     water, in foods and *in vivo*, 299  
   base catalysis  
     alcohols, 302  
     amines, 301  
     2-amino-2-deoxy-D-glucosyl- and-  
       mannosylamines, 302  
     enolization and resonance  
       carbocation, 301  
     food proteins, 303  
     in hemoglobin, 301  
     Lobry de Bruyn–Alberda van Ekenstein  
       transformation, 301  
     nucleophilic enolization catalyst, 301  
     phosphate, pH-buffering species, 301–302  
     in proteins, 301  
     proton-abstracting, 301  
     solvent nature, 302  
     water and aqueous syrups, 303  
   cocurrent reactions  
      $\alpha$ -amino groups of peptides, 307  
     imidazolidinones, 307  
     L-glutathione, 306  
     m-tyrosine/DOPA, catecholamines, 306  
     oxazolidin-5-one intermediate  
       decarboxylation, 305–306  
     thiazolidines formation, 306  
     tryptophan, 306–307  
   condensation reaction, 296  
   diaminals and *N,N*-aminodiglucoosides, 298  
   D-mannose and amines condensation  
     reaction, 296–297  
   formation of  
     classie method, 298  
     crystalline hexose–amine adducts, 297  
     *N*-aryl and *N*-alkyl D-glucosylamines, 297  
     *N*-aryl D-glucosylamines preparation, 298  
   glycosylamine–ketosamine transformation  
     mechanism, 297  
   intramolecular  
     amino acid esters, 305  
     cyclization, amino acid/peptide  
       conjugates, 305  
     D-fructosamine structures, 305  
   oxazolidin-5-one intermediates  
     acrylamide formation, 303  
     intramolecular cyclization, Schiff  
       base, 303  
   protein glycation by glucose  
     amino group and catalyst in  
       microenvironment, 304  
     catalytic power, 304  
     D-glucosylamine and D-fructosamine  
       formation comparison, 304  
      $\epsilon$ FruLys, 304  
     hemoglobin  $\alpha\beta$  dimer, 304  
     milk, lactose, 304  
     peptides, 304–305  
   Glycation, 293  
   Glycine, 32  
   Glycoconjugates  
     used in  
       direct syntheses of gold GNPs, 221–223  
       thiolated ligand exchange on, 232–234  
   Glyconanoparticles (GNPs), 213–214, 217  
     applications of  
       as antiadhesion agents, 260–264  
       in carbohydrate–carbohydrate interaction  
         studies, 251–254  
       in carbohydrate–protein interactions,  
         254–258, 269  
       in cellular and molecular  
         imaging, 264–269  
       interaction studies, 258–260

- in MALDI-MS-based structural characterization, 269
  - Au/Fe-containing GNPs, 240–241
  - Au<sub>102</sub>(*p*-MBA)<sub>44</sub> nanoparticle, X-ray crystal structure, 216
  - O*-carboxymethyl dextran-coated SPIO nanoparticles, 240
  - CdSe–ZnS-labeled carboxymethylchitosan, 266
    - characterization, 218
    - concept, 218
    - methods for preparation, 219
    - synthesis, 218
  - Glyconanotechnology, 217–218
  - Glyco-quantum dots, 245–250
  - Glycosidases, 32
  - Glycoside-cluster effect, 251
  - Glycosphingolipid (GSL), 229
  - Gold–biomolecule nanoparticles, 213
  - Gold GNPs
    - AFM images, 259
    - application, 267
    - characterization, 237–238
    - glycoconjugates used in direct synthesis of, 221–223
    - hybrid, 228–229, 236–237
    - iron-free, 241
    - as probes for analytical techniques, 269
    - of saccharide, 235
    - by *in situ* protection with, 229
    - strategies for converting, 241
    - synthesis of, 219, 226
  - Gold lactose–GNPs, antimetastatic effect of, 261
  - Gold nanoparticles, 213, 216
  - Grafting cell fibers, 88
  - Grease barrier test, 91
  - Gum arabic, 237
- H**
- Halodeoxycelluloses by halogenation, 74–75
  - Hemagglutinin–neuraminidase (HN), 434
  - Hematopoietic progenitor cells (HPCs), 419
    - Hemicelluloses, 121
      - polysaccharide molecules, 31
    - Hemoglobin A1c (HbA1c)
      - nonenzymatic glycosylation, 293
    - Heparin, 124
    - Heterogeneities, in bulk material analysis of fractions, 182
      - eellulose derivatives, fractionation of, 180–181
      - starch derivatives, topochemical differentiation of, 182–183
    - Heyns rearrangement reaction, 302
    - High-performance liquid chromatography (HPLC)
      - D*-fructose–peptides and–amino acid separation, 323
      - hydrolyzates treatment, 323
    - HLA. *see* Human leukocyte antigen (HLA)
    - HPCs. *see* Hematopoietic progenitor cells (HPCs)
    - Human leukocyte antigen (HLA), 407
    - Hyaluronic acid–immobilized gold nanoprobe, 267
    - Hyaluronidase (HAase), 267
    - Hybrid glyeoclusters, 235
    - Hybrid gold GNPs, 227
      - by direct *in situ* formation, 224–225
      - incorporating ligands in variable ratio, 228
      - by ligand place exchange, 236
    - 2-*O*-Hydroxyalkyl ethers, 155
    - Hydroxyalkylation, 129–130
      - of ethers, quantitative mass spectrometry, 165
      - of starches, 126
    - Hydroxypropyl starches, 126
- I**
- Insulin-like growth factor-1 (IGF1)
    - signaling pathways, 425
  - Insulin-like growth factor-2 (IGF-2), 417
  - International Carbohydrate Symposia, 9
  - Iron oxide-based GNPs, 243–245
  - Isoglucosamine
    - relation with fructose, 292

**K**

- K562 erythroleukemic cells, 426–427  
 Keto tautomer  
   acyclic  
     arboxyl hydration and the equilibrium  
       molar fraction N, 319  
     proportion, 319  
   isolation and structure, 319  
 Kinetically controlled reactions, 127  
   alkylation  
     kinetic data, 128  
     kinetics of, 129  
     laboratory scale, 127  
     nucleophilic substitution, 127  
     rate constants, 127  
     rate of reaction, 128  
     support for 2-OH deprotonation, 128  
   esterification, 131  
   hydroxyalkylation  
     carboxymethylation of cellulose, 129  
     sodium hydroxide concentrations, 130  
   sulfopropylation, 130  
   Williamson-type etherifications, 130

**L**

- Lactose-GNPs, 252, 254, 260–261  
 Lignins, 30  
 Liquid chromatography–mass spectrometry (LC/MS), 324  
 Lobry de Bruyn–Alberda van Ekenstein transformation, 301  
 Lysosomal-associated membrane proteins (LAMPs), 409, 421–422  
 Lysosomal integral membrane proteins (LIMPs), 409  
 Lysosomal sialidase (NEU1)  
    $\beta$ -GAL and PPCA, 406  
   cDNAs and genes, cloning, 407  
   galactosialidosis (GS), 407  
   histochemical staining, 417  
   human NEU1 deficiency  
     lysosomal storage, 412  
     NEU1 mutations, 412–413  
   sialidosis and galactosialidosis, 411–412  
   mouse model and disease pathogenesis,  
     study, 418  
   extramedullary hematopoiesis, 419–421  
   homozygous null mice, 419  
   and impaired bone marrow retention,  
     419–421  
   lysosomal exocytosis, negative regulator,  
     421–422  
   shock-like twitch, 419  
   and multi-enzyme complex  
     crystal formation, 411  
     NEU1 and  $\beta$ -GAL, 410  
     PPCA zymogen, 410  
     *in vitro* experiments, 410  
   primary structure of  
     Asp-box, 407–408  
     ganglioside nomenclature, 407  
     gene and protein symbols, 407  
     glycosylation sites, 407  
     HLA, 407  
   routing and formation  
     acid phosphatase, 409  
     adaptor protein complex-3 (AP-3), 409  
      $\beta$ -GAL precursor, 410  
     C-terminal tetrapeptide, 409  
     expression and, 409–410  
     intracellular routing of, 409–410  
     LAMPs and LIMPs, 409  
     PPCA functions, 410  
   structural model of  
     Asp-boxes, 408  
      $\beta$ -propeller fold, 408  
     Neu5Ac2en-binding, 408  
     sialic acid, 408  
   in tissue remodeling and homeostasis,  
     functions  
       deficient mice, elastogenesis in, 416  
       EBP/PPCA and signal transduction, 415  
       elastin-binding protein in elastogenesis,  
         role, 413–414  
       elastogenesis in fibroblasts from  
         sialidosis and GS patients, 415  
       in proliferation and cancer, role, 416–418

## M

- Magnetic Fe–Pt nanoparticles, 244
- Magnetic glyconanoparticles (MGNPs)  
based systems, 244  
iron oxide-based GNPs, 243–245  
superparamagnetic/paramagnetic, 240, 243  
iron oxide-based magnetic  
glyconanoparticles, 244  
maltose-coated Au and Au/Fe GNPs, 242  
paramagnetic Gd-based gold  
glyconanoparticles, 243  
strategies for converting gold GNPs  
into, 241
- Magnetic nanoparticles (MNPs), 239
- Maillard reaction  
aromas formation, in food  
aglycon, 346  
amino acid Strecker degradation  
products, 345  
carbohydrate intermediates, 344  
from D-fructosamine derivatives, 347  
L-proline, 346  
pyrolysis, 346  
sugar dehydration–fragmentation  
products, 344  
volatiles, 345  
definition, 344  
di- and oligosaccharide derivatives, 347  
end product classes, 344  
glycation end products  
AGEs (*see* Advanced glycation end  
products (AGEs))  
lysine and arginine, 347–348  
N<sup>ε</sup>-D-fructose–L-lysine, 347  
melanoidins  
characteristic feature, 346–347  
formation rate, 347  
molecular weight, 347  
structure, 347  
stages, 344
- Major histocompatibility complex (MHC), 433
- Mammalian sialidases  
cytosolic (NEU2), 406  
lysosomal (NEU1), 406  
mitochondrial/lysosomal/intracellular  
membranes (NEU4), 406  
pivotal and diverse functions, 406  
plasma-membrane (NEU3), 406  
*in silico* analysis, 406
- Mammalian target of rapamycin (mTOR)  
pathway, 425
- Manno-GNPs, 226–227  
as inhibitors of HIV transinfection, 263
- Mannopine (MOP) oxidoreductase, 341
- MAPK. *see* Mitogen-activated protein kinase  
(MAPK)
- Mariotte flask technique, 91
- Matrix-assisted laser desorption/ionization  
(MALDI), 323
- Mercerization process, 40
- Metal nanoparticles functionalization, 230
- 2,3,6-*O*-Methylated maltooligosaccharides, 158
- Methylation methods, 17
- N*-Methylmorpholine *N*-oxide (NMNO), 68,  
226  
and cellulose, interaction between, 69  
*O*-Methyl/*O*-methyl-*d*<sub>3</sub> derivatives, 164–165
- Methyl starches, 126
- MHC. *see* Major histocompatibility complex  
(MHC)
- Michael addition synthesis of cellulose  
ethers, 72
- Microfibril of cellulose, 58  
computer representation, 62  
molecular model of, 59  
size ranges, 59  
structural organization in plants, 66  
ultrastructural organization  
asymmetry in, 65  
distribution map of orientation of axes, 65
- Mitogen-activated protein kinase (MAPK),  
434
- Monocotyledons, 32
- Monomer composition  
glucose residue, substituent distribution in,  
150–151  
collision-induced dissociation of dimers,  
157–159

- Monomer composition (*cont*)  
 electrospray ionization-mass spectrometry, 157–159  
 sample preparation, 154–157  
 separation after depolymerization, 151–154
- Monomer residues along polymer chain  
 distribution, 159  
 enzymes selective tools, 169  
 cellulose derivatives, 177–179  
 enzyme-aided structure analysis, 172–175  
 starch derivatives, 175–177
- oligomer analysis after random degradation, 160  
 mass-spectrometric analysis, 163–166  
 quantitative evaluation, 167–168  
 sample preparation, 161–163
- Monomers  
 analysis  
 of methylated glucans by ESI-MS/CID, 158–159  
 patterns of (1→4)-glucans, 134
- Multifunctional envelope-type nanodevices (MEND), 259
- Multifunctional GNPs, tools for glycobiology, 270
- N**
- Nanobiomaterials, 212  
 Nanobiotechnology, 212  
 Nanotechnology, 264, 269  
 National Center for Biotechnology Information (NCBI), 427
- Native cellulose  
 crystalline morphology of, 57–58  
 crystalline structures of, 41  
 chain orientation, 42  
 dimorphism in, 43–44  
 I $\alpha$  and I $\beta$ , crystalline phases, 42–43  
 synchrotron and neutron techniques, 44  
 two-fold helicoidal symmetry, 42
- X-ray and neutron fiber diffraction patterns, 45  
 liquid ammonia, treatment with, 40  
 regeneration and mercerization  
 transition to crystalline form cellulose II, 40
- NCBI. *see* National Center for Biotechnology Information (NCBI)
- NDV. *see* Newcastle Disease Virus (NDV)
- Neoglycoconjugates  
 breast cancer cells, 350  
 casein, 350  
 cytotoxic nitroso compounds, 349  
 fructose-1-SNAP, 350  
 melanoma tumors, 350  
 N-nitroso derivatives, 349  
 properties, 349  
 radioiodinated octreotide, 350  
 radiolabeled bombesin analogues, 350
- Neuraminidase (NA), 427
- NEU4 sialidase  
 experiments on, 435  
 expression, 436  
 feature of, 435  
 functional implication  
 and cancer, 437  
 and lysosomes, 436–437  
 neuronal cell differentiation, 437–438  
 ganglioside GD3 and apoptosis, 436  
 mammalian sialidases and teleosts, 435  
 mitochondrial localization of, 435–436  
 NCAM activity and, 438
- Neutron diffraction pattern of cellulose I $\beta$ , 44
- Neutrophil elastase (NE), 420
- Newcastle Disease Virus (NDV), 434–435
- NMNO. *see* N-Methylmorpholine N-oxide (NMNO)
- Noble metal glyconanoparticles  
 characterization, 237–238  
 direct *in situ* formation, 219–220, 226, 228  
 two-step formation, 228–229, 231  
 chemical modification, 228–229, 231  
 non-covalent approaches, 237  
 thiolated ligand exchange, 231, 235, 237

- Non-enzymatic formation method,  
fructosamine  
catalytic hydrogenation, 311–312  
D-glucose phenyllosazone reduction  
1-deoxy- $\beta$ -D-fructopyranos-1-ylamine,  
295  
Fischer's approach, 295  
ketosamines preparation, 296  
N-substituted D-fructosamines, 295–296  
Pd-catalyzed hydrogenation, 295  
D-glucosone reductive amination  
advantages, 309  
free amino acid, NaCNBH<sub>3</sub> in water, 308  
ketosamine derivative, 309  
reaction with  $\alpha$ -amino acids, Strecker  
degradation pathway, 309–310  
secondary amines, 309  
glucosylamines, Amadori rearrangement  
(*see* Glucosylamines, Amadori  
rearrangement)  
Mitsunobu condensation, 312–313  
nucleophilic substitution reactions  
antitumor agents, 310  
D-fructose–amino acid preparation, 310  
2,3:4,5-di-O-isopropylidene- $\beta$ -D-  
fructopyranose activation, 310–311  
hydroxyl groups, 309–310  
tosylate treated with hydrazine hydrate,  
310  
triflate by azide, 311  
regioselective epoxide opening, 311  
Non-synonymous single nucleotide  
polymorphism (nsSNP), 427

## O

- Oil drilling, 120  
Oligosaccharides  
MALDI-TOF-MS, in quantitative analysis,  
165–166  
mediated nuclear transport of glyco-QDs,  
265  
Osazones, Fischer's discovery, 17  
Oseltamivir-phosphate, 427–428

- Oxidation, D-fructosamine  
metal ions  
copper and iron, 335  
copper-promoted autoxidation, 336  
glycated polylysine, iron(III), 336  
organic molecules, 335  
redox-active catalytic, 337  
superoxide ion-radical formation,  
335–336  
molecular oxygen  
catalyst-free, 335  
superoxide release rate, 335  
oxidants, 338  
benzoquinones, 338  
eFruLys formation, 338  
redox dye NBT, 338  
Strecker aldehydes, 338  
physiological oxidants  
flavin adenine dinucleotide  
(FAD)/copper, 337  
peroxynitrite, 337  
*Phanerochaete chrysosporum*, 337

## P

- "Parallel-up" chain-packing organization,  
44–45  
Particulate sialidase NEU4  
experiments on, 435  
expression, 436  
feature of, 435  
functional implication  
and cancer, 437  
and lysosomes, 436–437  
neuronal cell differentiation, 437–438  
ganglioside GD3 and apoptosis, 436  
mammalian sialidases and teleosts, 435  
mitochondrial localization of, 435–436  
NCAM activity and, 438  
Pathogens, real-time detection, 270  
PDGF. *see* Platelet-derived growth factor  
(PDGF)  
PDGFR. *see* Platelet-derived growth-factor  
receptor (PDGFR)

- Pectins  
 (1→4)- $\alpha$ -D-galacturonan, 32  
 (1→2)- $\alpha$ -L-rhamnan, 32  
 arabinan–arabinogalactan type, 32  
 of dicotyledonous higher plants, 32
- Peeling off mechanism, 335
- Periodate oxidation, 118
- Peroxidases, 32
- Phase-transfer catalyst, 215
- Phenylhydrazones  
 Fischer's discovery of, 17
- Phorbol 12-tetradecanoate 13-acetate (PMA), 434
- Phosphatidylinositol-3-kinase (PI3), 425
- Pictet–Spengler phenolic condensation, 306–307
- Plant  
 cell walls  
 contents, 28  
 enzymes, function of, 32  
 hydrophobicity, 30  
 liquid-crystalline matrix, 31  
 location of polysaccharide components, 30  
 mechanical strength, 30–31  
 microfibril, 30  
 pectins and ion-exchange capacity, 32  
 primary, 28  
 proteins in, 32  
 representation of, 30  
 rigidity, 30  
 secondary, 29  
 turgor pressure on plasmalemma, 30
- Plasminogen activator inhibitor-1 (PAI-1)  
 promoter, 357
- Platelet-derived growth factor (PDGF), 417
- Platelet-derived growth-factor receptor (PDGFR), 432
- PMA. *see* Phorbol 12-tetradecanoate 13-acetate (PMA)
- Polymeric glucan derivatives, 120
- Polysaccharide Chemistry*, 11
- Polysaccharide derivatives  
 as renewable resources, 119  
 applications, 120  
 enzymatic degradability, 121  
 modified glucans, 120  
 research, 118
- Polysaccharides: starch, 118
- Polyvinyl alcohol (PVA)  
 cellulose layer modification, 89  
 representation of, 91  
 waterproofing effect, 90  
 chromatogeny process, 90  
 molecular structure, 90
- Potential pharma-and nutraceuticals,  
 fructosamines  
 antibacterial/antifungal  
 D-fructosamine–and–lactulosamine  
 product derivatives, 364–365  
*Mycobacterium leprae*, D-fructose–  
 serotonin, 364  
*Staphylococcus aureus*, 364  
*Trypanosoma brucei*, 364
- antioxidant  
 D-fructose–L-tryptophan, 362  
 Fenton reaction, 362  
 fruits and plant tissues, dehydration, 362
- antitumor  
 lactulosamine derivatives, 363–364  
 LctLeu, 363  
 tomato thermal processing and  
 dehydration, 362–363  
 urological cancers, 362
- bioavailability  
 amino acids, 360  
 D-fructose–L-methionine, 360–361  
 eFruLys, urine and kidneys, 361  
 LctLys, feces, 361  
 LctLys/FruLys, blood, 361  
 N $\epsilon$ -D-fructose-L-lysine, 361
- in food  
 dehydrated, 358–360  
 dried carrots, 358  
 fumonisin B1, 360  
 ingested, 358  
 milk, 358  
 N-nitroso compounds (NOC), 360  
 olfactory properties, 360



- immunostimulatory  
 analgesia-enhancing effect, 365  
 D-fructose-L-lysine epitopes, 365  
 D-fructose-L-proline, 365  
 D-fructose-peptides, 366  
 lactulosamine structure, 365  
 lactulose conjugate, 365-366  
 thioureido derivatives, 366
- PPCA. *see* Serine carboxypeptidase protective protein/cathepsin A (PPCA)
- Proline, 32
- Pro-matrix metalloproteinase-1 (pro-MMP1), 415

## Q

- Quantum dots (QDs), 245
- Quartz crystal microbalance (QCM)  
 based biosensors, 256
- Quaternary aminopropylloxirane (QUAB), 126

## R

- Rayon fiber-cellulose acetate composites, 97  
 optical microscopy, 94  
 scanning electron micrograph of, 95  
 transmission infrared spectra, 94
- Rayon manufacture, 97
- Reactive oxygen species (ROS), 267
- Regenerated cellulose (Cellulose II), 48  
 cellulosic oligomers in, 50  
 hydroxymethyl group amount, 52  
 liquid ammonia, treatment with, 40  
 monoclinic cell, 51  
 packing energies of cellulose chains in unit cell, 50  
 resolution of, 50  
 structural details of, 51  
 synchrotron X-ray data, 51  
*trans-gauche* and *gauche-trans* positions, 51  
 two-fold symmetry, 50  
 X-ray diffraction studies, 49
- Regeneration process, 40
- Relenza. *see* Zanamivir

- Respiratory syncytial virus (RSV), 428
- Rhabdomyosarcoma (RMS)  
 study, 426
- Rosette particles in plasma membrane, 32-33
- RSV. *see* Respiratory syncytial virus (RSV)

## S

- Serine carboxypeptidase protective protein/cathepsin A (PPCA), 406
- Serine-threonine protein kinase AKT1, 425
- SFK. *see* Src family protein tyrosine kinases (SFK)
- Short hairpin RNA (shRNA), 433
- Sialidase NEU3, plasma membrane-associated  
 A431 squamous carcinoma cells, 430  
 $\beta$ -barrel structure, 429  
*cis*- and *trans*-activity of, 430  
 functional implication of  
 and cell differentiation, 432-434  
 and membrane microdomains, 431-432  
 and virus infection, 434-435  
 localization of, 431  
 metabolic labeling, 430
- Sialidases, 405  
 cancer and human NEU3  
 in acute lymphoblastic leukemia (ALL), 439  
 apoptosis, 438  
 in colon cancer, 438  
 EGF receptor, 438  
 LacCer and, 438  
 overexpression, 439  
 Ras/ERK pathway, 438  
 functional implications of  
 abnormal growth of VSMC, 443  
 axon outgrowth, 442  
 extracellular matrix proteins and, 443  
 ganglioside substrates, 444  
 myelin associated glycoprotein (MAG), 443  
 N-acetylneuraminyl-laetitol, 444

Sialidases (*cont*)

- NCX/GM1 complex, 444
- normal and atherosclerotic human aortic intima, 443
- TNF- $\alpha$  induction of matrix metalloproteinase-9 (MMP9), 443
- TrkA tyrosine protein kinase receptor activation, 442

## and immunity

- Clostridium perfringens* sialidase, 439
- in human myeloid cell differentiation, 441
- inhibition of adhesion, 440
- Lewis X expression, 441
- monocyte differentiation, 441
- neutrophil adhesion, 441
- overexpression of, 441
- regulator of toll-like receptors (TLRs) activation, 441–442
- role in, 440

*in silico* analysis, gene expression patterns

- expression profile, 446–447
- GeneAtlas data, 447
- GeneAtlas Gene Expression Database, 445–446
- tissue-specific RNA expression pattern, 445–446
- UniGene cluster, 445
- UniGene's EST Expression Profile Viewer, 444

## in teleosts

- cell-fractionation experiments, 450–451
- data from, 452
- expression of, 451
- GM3 synthase overexpression, 451
- organization of genes in man and, 450
- in zebrafish *Danio rerio*, 449

## Sialidosis

- type I (normomorphic) sialidosis
  - cherry-red spot-myoclonus syndrome, 411
  - clinical phenotypes of, 411
  - symptoms, 411–412
- type II (dysmorphic) sialidosis
  - clinical phenotypes of, 412

## Sialyl Lewis X (sLeX), 243

*sLe<sup>x</sup>*-GNPs, 268

- SILICA 2010 Yellow, 88
- Silicone oligomers polymerizing, 86
- Smith degradation, 118
- Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), 324
- Spirobicyclic tautomer, 321
- Src family protein tyrosine kinases (SFK), 432
- Starch, 125
  - chemical modification of, 126
  - derivatives, applications, 175
  - elemental analysis for, 145–146
  - granule structure, 125–126
  - starch derivatives, 126
- Strecker degradation reaction, 334
- Structure analysis of (1 $\rightarrow$ 4)-glucans
  - derivatives
    - average degree of substitution, 144
    - elemental analysis, 145–146
    - NMR spectroscopy, 146–150
    - Zeisel method, 145
  - monomer composition (*see* Monomer composition)
  - monomer residues along polymer chain (*see* Monomer residues along polymer chain distribution)
- Sulfation, 132
- Sulfopropylation, 130
- Surface features of cellulose
  - AFM images, 63
  - conformations, 64–65
  - hydroxyl group in, 63
  - interreticular distance, 63
  - intra- and intermolecular hydrogen bonds, 62
  - organization of, 63
  - periodicities, 63
- Synthons
  - Büchi cyclocondensation reaction, 351–352
  - 1-deoxy-D-erythro-hexos-2,3-diulose, 351
  - D-fructose-N-hydroxyurea, 352
  - glycosidase inhibitors, 351–352
  - isothio-isoseleno-cyanates, 353

*N*-protected *D*-fructosamine, 352–353  
 oxazolidinone and morpholinone,  
 353–354  
 phosphoramidites, 353–354

## T

Tamiflu. *see* Oseltamivir-phosphate

Tautomerization scheme, 317

Tautomers, 316

*D*-fructosamine and *N*-alkyl-/-carboxyalkyl  
 derivatives

amino acids and proteins, 317

anomeric/carbonyl (carbon-2) signals,  
 317

*D*-fructose–amino acids crystal structure  
 feature, 319

enamine, NMR technique, 317

hydrochloride and hydroacetate salt  
 molecular and crystal structure, 318  
 ring conformations, 318

disaccharides, 320

1-amino-1-deoxy-4-*O*-glycopyranosyl-  
*D*-fructose analogues, 320  
 glyeosyl substituent at *O*-6, 320

form proportions, 317–318

fructosamine, fixed structure

anomeric hydroxyl group, glycosidation/  
 carbamoylation, 321–322

*N*-alkenyl derivatives, 322

treatment, triphosgene transformed, 322  
 X-ray diffraction, 322

*N*-aryl derivatives

acyclic keto proportion, 318–319

*D*-fructose–aniline equilibria, 319

fructosamine carbonyl group hydration  
 rates, 319

keto isolation and structure, 319

*N*-allyl-*N*-(1-deoxy- $\beta$ -*D*-fructopyranosyl-  
 1-yl) aniline, 320

*N,N*-di-*D*-fructosamines

1,2-enolization, 321

monofructose–amines tautomerization  
 pattern, 317, 320

spirobicyclic structure, 321

X-ray diffraction, 320–321

tautomerization scheme, 317

T-Cell helper peptide, 226

Tetrakis (hydroxymethyl)phosphonium  
 chloride (THPC), 235

2,2,6,6-Tetramethylpiperidine-1-oxy radical  
 (TEMPO)

mediated oxidation of cellulose, 71

Tetraspanin-enriched microdomains  
 (TERMs), 432

Thermodynamically controlled reactions

acylations, 131–132

cynoethylation, 132

sulfation, 132

Thermoplastic composites of cellulose–  
 cellulose acetate, 93–95

“grafting” of cellulose acetate chains, 95

macromolecular interaction

involved in, 96

mechanical performance, 95–96

optical microscopy, 94

production of, 95–96

T Lymphocytes, 262

Topochemistry of cellulose, 75

acetylation of cellulose, 76

conversion of cellulose I into cellulose II  
 model of, 79

morphological modifications, 80

“shish-kebab” morphology, 80–81

nanocrystals of, 80

“cellulose whiskers,” 81

chemical modifications by  
 cross-linking, 81

solid-state conversion of cellulose I into  
 cellulose III<sub>1</sub>, 76–77

morphological changes, 78

Transesterification reaction, 75

Transforming growth factor  
 (TGF)- $\beta$ 1, 357

Transglycosylases, 32

Trans-sialidases (TS)

apoptosis, 453

in biotechnology use, 454

Trans-sialidases (TS) (*cont*)

- conformational switch in active center of, 457
- detection of activity, 453
- endothelial cell signaling, 453
- in *Endotrypanum* species, 452
- inhibitor of, 454
- lactose-binding site, 455
- in microorganisms, 452
- polyclonal B cells activity, 453
- reaction of, 452
- sialyltransferase activities with CMP-Neu5Ac, 453
- sleeping sickness and Chagas disease, 453

*T. brucei* TS

- protein sequence, 458
- trans-sialylation activity, 458

*T. cruzi* trans-sialidase

- amino acid sequence with, 455
- analysis, 458
- binding studies with, 456
- hydrolysis and transfer reactions catalyzed by, 456
- protein conformation involved in, 457

## Shed Acute Phase Antigens (SAPA) repeats, 455

- STD NMR experiments, 457
- types of enzyme reaction, 456

*T. rangeli* sialidase

- crystal structure of, 455

## Trifluoromethylsulfonylation, 310

*O*-(3-Trimethylammonium-2-hydroxy)propyl starch, 126Tri-*n*-butylphosphine (TBP), 247Tri-*n*-octylphosphine oxide (TOPO), 247Tri-*n*-octylphosphine (TOP), 247Tri-*O*-methylated disaccharides, 159

## Tunicin microcrystals

- diffraction patterns, 60
- surface chains in, 61
- transmission electron micrographs, 61

## V

*Valonia* cellulose

- diffraction-contrast transmission electron microscopy, 80
- electron diffraction studies, 42
- microcrystals, action of cellulases on, 83
- triellinic organization, 63
- X-ray patterns of, 44

## Vascular cell adhesion molecule (VCAM)-1, 420

## Vascular endothelial growth factor (VEGF), 357

## Vascular smooth muscle cells (VSMC), 443

## W

## Water barrier test, 91

## Water-soluble metallic nanoparticles, 215

## Whiskers, 58

- acetylation of, 92
- of celluloses, 60
- mechanical modulus of, 59
- production and application, 93

## Whistler, R. L.

- American Association of Cereal Chemists, 11
- American Chemical Society
  - Division of Carbohydrate Chemistry Executive Committee, 10-11
  - Claude S. Hudson Award of Division of Carbohydrate Chemistry, 13
  - Fred W. Tanner Lectureship of Chicago Section, 13

*Carbohydrate Chemistry for Food Scientists*, 12

## in carbohydrate nomenclature committee, 6

- consultant to
  - companies producing industrial gums, 11
  - corn wet-milling company, 11
  - guar gum structural analysis, 7
- Industrial Gums*, 12

- Methods in Carbohydrate Chemistry*  
series, 12
- National Representative of United States, 11
- Polysaccharide Chemistry*, 6, 11
- polysaccharides  
calorie intake, 8-9  
concept of sweetness, 8  
derivatives of, 8  
industrial utilization, 3  
infrared (IR) spectrophotometry for  
analysis of, 9  
structure and function, 3
- satellite conferences on carbohydrates, 10
- Starch, Chemistry and  
Technology*, 12
- Starch/Stärke*, 12
- Steering Committee for International  
Carbohydrate Symposia, 9-10
- U.S. Carbohydrate Nomenclature Committee  
glycan rule, 12
- Williamson ether synthesis, 72
- Williamson-type etherifications, 130
- Wood  
cells crosssection, 67  
cellulose in  
electron microscopy, 31  
helical orientation, 67  
fiber structure  
representation, 67
- X**
- Xanthate system, 68
- Xyloglucans, 32
- Z**
- Zanamivir, 427-428
- Zeisel method, 118  
for DS/MS of alkyl/hydroxyalkyl  
starches, 145

## SUBJECT INDEX

### A

- ABCh. *see* *N*-(2-aminobenzoyl)cysteine hydrazide
- Agar group, polysaccharides
  - agaran–agarose hybrid, 163
  - algal species, 164
  - calcareous algae, 164
  - galactan structures, 162
  - gelling properties, 163
  - Gracilaria* species, 162–163
  - neutral regular agarose, 162
  - porphyrans, 162
  - sulfated polysaccharides, 165
- Aldol–Wittig type of reaction, 74
- Automated glycan analysis
  - development, 264–265
  - glycobiology and glycotecology
    - biosynthetic pathway, glycoproteins, 221–222
    - synthesis and purification, 222
  - glycoblotting technology and SweetBlot machine, 262
  - glycomics technologies
    - glycoblotting method, 234–261
    - mass spectrometry, 223–234
    - tryptic digests, 234
  - glycoproteins and GSLs, 220
  - GlycoWorkbench and SysBioWare, 261
  - N*-glycan profiling and ratios, 263–264
  - proteomics and glycomics
    - glycosylation, 220–221
    - ORFs and PCR amplification, 221

### C

- Carrageenan, polysaccharides
  - Callophyllis hombroniana*, 166–167
  - Gigartina lanceata*, 167
  - KCl-soluble fraction, 166
  - partial reductive hydrolysis, 167
  - samples, 166
  - types, 165

### D

- DL-hybrids
  - agarans and carrageenans, 168
  - carrageenan-type structure, 169
  - polymeric molecules, 168
  - polysaccharides, 168

### E

- ECD. *see* Electron-capture dissociation
- Electron-capture dissociation (ECD)
  - O-glycosylation site identification, 230–231, 234
  - spectra, 231, 233

### F

- Ferrier reaction, 58, 59
- Fischer's phenylhydrazone reaction, 234–236
- Floridean starch, storage carbohydrates
  - amylolytic enzymes, 118, 119
  - elimination reaction, 119
  - enzymatic formation, 118
  - low-molecular glycosides, 117
  - structure and chirality, 117–118

## G

- Glycoblotting method  
 ABCh and BlotGlycoABC™, 236–239  
 analysis, O-glycans, 242–244  
 BlotGlyco H beads  
 preparation and SEM view, 239, 240  
 protocol, 239, 241  
 Fischer's phenylhydrazine reaction,  
 234–236  
 human IgG N-glycans, 236, 237  
 human-milk osteopontin  
 BOA-labeled O-glycans, 243, 245  
 O-glycomics, 243, 244  
 mouse P19C6 cells vs. neural cells,  
 239–240, 243  
 N-glycans expression levels, 240–241  
 plant glycoproteins, 241–242  
 reverse  
 AFP, fibrinogen and recombinant human  
 EPO, 247–248  
 chromatography-based enrichment  
 processes, 246  
 fragment-ion counts, 259, 260  
 glycan heterogeneity and glycosylation  
 sites, 246, 247  
 GSL-aldehydes, 261  
 human cerebrospinal fluid, 248  
 mouse-serum PA-labeled sialyl  
 glycopeptides, 252–258  
 MRM, 258–260  
 MS/MS spectrum, PA-labeled sialyl  
 glycopeptide, 252, 259, 260  
 nonsialylated glycopeptides, 259, 261  
 sialic acid-focused glycoproteomics,  
 250–252  
 sialylated glycopeptides, 246–247  
 terminal sialic acids, 246, 248  
 trans-iminization reactions, 239, 242  
 Glycofragment mass fingerprinting (GMF),  
 225, 226  
 Glycosphingolipids (GSLs)  
 aldehydes, 261  
 biological roles, 220  
 GlycoWorkbench, 261

## Glycuronans

- galactose and glucuronic acid, 173  
 sulfated galactans, 173–174

GMF. *see* Glycofragment mass fingerprinting

GSLs. *see* Glycosphingolipids

## H

Hall, L. D.

- Cambridge period, 1984–2005  
 biofilm reactors, 37  
 calcium alginate, 38  
 Experimental NMR Conference (ENC),  
 38–39  
 food materials, 36–37  
 human diseases, 36  
*in vivo* and *ex vivo* imaging, 36  
 MRI, 35–36  
 zero-quantum NMR methods, 34–35  
 graduate students, UBC, 34  
 NMR spectroscopy, carbohydrate  
 analysis, 12–13  
 sugars, pyranose ring, 12  
 angular dependence, coupling  
 constants, 18  
 Carr–Purcell–Meiboom–Gill spin-lock  
 sequence, 25–26  
 2-C-diacetoxythalliation, D-galactal  
 triacetate, 22  
 chemical microscopy, 30  
 chemical shift-resolved tomography, 33  
 chitosan, 31–32  
<sup>13</sup>C NMR spectra, 23  
<sup>13</sup>C T<sub>1</sub> values, sugars, 27–28  
 cyclic phosphates, 20  
 decoupling, 24  
 1,2:3,4-di-O-isopropylidene- $\alpha$ -D  
 -galactopyranose, 19–20  
 2D NMR methods, 31  
 electrophilic addition, fluorinated  
 species, 16–18  
 europium, thulium and praseodymium,  
 25  
<sup>19</sup>F–<sup>19</sup>F couplings, 19  
 fluoro sugar period, 17

- <sup>19</sup>F NMR, fluorinated carbohydrates, 15  
glycopyranosyl fluorides, 16  
glycosyl fluorides, 15  
<sup>1</sup>H-<sup>1</sup>H dipole-dipole relaxation  
  mechanism, 26  
<sup>1</sup>H spin-lattice relaxation times, 26  
internuclear double resonance  
  (INDOR), 24  
interproton distances, 29  
<sup>4</sup>J couplings, 18–19  
J-multiplets, 30  
Karplus dependence, 14  
methoxymercuration, acetylated glycols,  
  21–22  
nitroxide adducts, ESR spectroscopy, 33  
noise decoupling technique, 23  
nuclear magnetic double-resonance  
  methods, 19  
paramagnetic ions, 32  
pentopyranosyl fluorides, 16  
radiofrequency (RF) carrier, 23  
scientific literature, 14–15  
shift reagents, 25  
stereospecific effects, anomeric  
  protons, 27  
syn-diaxial and vicinal gauche effect, 27  
tin coupling constants, 21  
T<sub>1</sub>-null method, 28–29  
zeugmatography technique, 30  
HILIC. *see* Hydrophilic-interaction  
  chromatography  
huEPO. *see* Human erythropoietin  
Human erythropoietin (huEPO)  
  glycan heterogeneity, 222, 227  
  glycoproteomics technique, 247–249  
Hydrophilic-interaction chromatography  
  (HILIC)  
  glycopeptide separation, 228, 234  
  reverse glycoblotting method, 246
- M**
- MALDI. *see* Matrix-assisted laser-desorption  
  ionization  
Mass spectrometry (MS)  
  description, 223  
  disaccharides characterization, 147  
  glycomics  
    cross-ring fragments and  
    permethylation, 225, 227  
  elucidation, glycan compositions, 225  
  GlycosidIQ platform, 225  
  GMF procedure, 225–226  
  MALDI-based ionization, 223, 225  
  N- and O-glycans, 223  
  protocol, 223, 224  
  glycoproteomics  
    ECD-MS/MS spectrum and analysis,  
    230–232  
    electron-induced dissociations, 230  
    HILIC and lectin-affinity  
    chromatography, 228  
    huEPO, 222, 227  
    O- and N-glycosylation sites, 231,  
    233–234  
    periodinate-based nonspecific oxidation,  
    227–228  
    purified human plasma serotransferrin,  
    228, 229  
    methyl groups, 146  
  post-source decay (PSD) mode, 148  
  prompt fragmentation, 149  
  red algal galactans, 147  
  soft-ionization methods, 148  
  sulfated oligosaccharides, 147–148  
Matrix-assisted laser-desorption ionization  
  (MALDI)  
  mass mapping, 223  
  plate, 262  
  TOF and TOFMS analysis  
    asialo-glycopeptides, 247  
    crude tryptic digests, human IgG,  
    236, 237  
    N-glycan profiling, 263  
    O-glycans, 243, 244  
Methylation analysis  
  alkoxide, 142–143  
  D-galactose residues, 142  
  polysaccharide, 143  
  red algal galactans, 143



Montreuil, J.

- glycomics, 5
- human milk glycoproteins, 5
- lactotransferrin discovery, 5
- pentose-containing nucleic acids, 4

MRM. *see* Multiple-reaction monitoring

MS. *see* Mass spectrometry

Multiple-reaction monitoring (MRM)

- channels, 259
- experiments, 252, 259
- glycoblotting-assisted assays, 250, 252
- reverse glycoblotting-assisted assays, 259–261
- technology, 248, 250

## N

*N*-(2-aminobenzoyl)cysteine hydrazide (ABCh), 237, 238

Noise decoupling technique, 23

Nuclear Overhauser enhancement spectroscopy (NOESY), 30, 31

## O

Open reading frames (ORFs), 221

ORFs. *see* Open reading frames

## P

Partial acid hydrolysis

- agarose and 3,6-anhydrogalactose, 133–134
- borane-4-methylmorpholine, 133
- carrageenans autohydrolysis, 132
- galactans, 132
- glycosidic bonds, 138
- oligosaccharides, 135–137
- partial depolymerization, 135
- pyruvic acid residues, 135
- structural analysis, agar, 133

PCR. *see* Polymerase chain reaction

Polymerase chain reaction (PCR)

- amplification, 221
- glycanspecific enrichment, 234

## R

Red algae polysaccharides

- agars and carrageenans, 116
- algal systematics and polysaccharide composition
  - acid hydrolysis, 179
  - advantages, 178
  - chemical structures, 177
  - molecular genetics, 179
  - NMR spectroscopy, 178–179
  - reductive hydrolysis procedure, 178
- cellulose, mannans and xylans
  - acid hydrolysis, 120
  - biosynthesis, 120
  - cellulose preparations, 120
  - chemical structure, 121
  - conchocelis and generic phases, 120
  - matrix-assisted ultraviolet laser, 121
  - relative insolubility, 119–120
  - water-insoluble, 122
- chemical investigation, 116
- galactans structural analysis, 116–117
- gelling galactans, 117
- glycuronans, 173–174
- storage carbohydrates, floridean starch, 117–119
- sulfated galactans
  - agar group, 162–165
  - biological activity, 169–171
  - carrageenan group, 165–167
  - chemical methods, 129–145
  - DL-hybrids, 168–169
  - enzymatic and immunological methods, 155–161
  - information and nomenclature, 122–127
  - isolation, 127–128
  - physicochemical methods, 145–155
- sulfated mannans
  - anticoagulant action, 173
  - aqueous sodium chloride, 172
  - mannose and xylose, 171–172
- unicellular and freshwater
  - heteropolysaccharides, 174–177

- Freezing–thawing procedure, 127
- Retrosynthetic analysis, trehalozin
  - functionalized cyclopentitol, 49, 50
  - thiourea derivative, 49

## S

- Spin-echo correlated spectroscopy (SECSY), 30, 35
- Sulfated galactans
  - biological activity
    - anticoagulant activity, 169
    - bacterial lipopolysaccharides, 171
    - carragenans, 169
    - exhibit antioxidant activity, 171
    - inhibitory effect, 170
    - matrix-degrading enzymes, 170–171
    - potent antiviral activity, 170
  - chemical methods
    - composition analysis, 129–132
    - desulfation, 138–142
    - methylation analysis, 142–144
    - partial acid hydrolysis, 132–138
    - periodate oxidation, 144
  - DL-hybrids, 168–169
  - enzymatic and immunological methods
    - agarolytic enzymes, 155–159
    - carrageenans, 159–160
    - enzymes releasing sulfate, 160–161
    - immunological methods, 161
  - information and nomenclature
    - biological source, 124
    - carrageenans, 124–125
    - desulfation procedures, 127
    - “deviating” structures, 123
    - disaccharide repeating units, 122
    - physicochemical properties, 122
    - red algal galactans, 123–124
    - shorthand terminology system, 126
    - structural analysis, 126–127
  - isolation
    - algal biomass treatment, 127
    - analytical procedures, 128
    - carrageenans fractionation
      - procedure, 128

- gel-forming ability, 127
- Freezing–thawing procedure, 127
- size-exclusion chromatography, 128
- physicochemical methods
  - mass spectrometry, 146–149
  - nuclear magnetic resonance spectroscopy, 149–155
  - vibrational spectroscopy, 145–146
- polysaccharides
  - agar group, 162–165
  - carrageenan group, 165–167
- Sulfated mannans
  - anticoagulant action, 173
  - aqueous sodium chloride, 172
  - mannose and xylose, 171–172
- Swern oxidation, 54–55
- SysBioWare, 261

## T

- Trehalase inhibitors
  - enzymes, 46
  - glycoconjugates, 46
  - sugar isothiocyanate fragment, synthesis
    - azido derivative, 51
    - $\beta$ -elimination, unstable dithiocarbamide triethylamine salt, 51, 52
    - benzylation and mesylation, 51–52
    - D-galactose pentaacetate, 51, 53
    - metal isothiocyanate, 50
    - S<sub>N</sub>2-type azidation, 51, 53
    - Wittig–Horner–Emmons type of reaction, 51, 52
- trehalozamine fragment synthesis
  - acylated oxazolidinones, 81–82
  - analogues, 53, 54
  - cis*-2-butene-1,4-diol, 82–85
  - cyclopentadiene, 77–81
  - D-arabinose, 65–66
  - D-glucose, 54–60
  - D-mannitol, 66
  - D-mannose, 60–63
  - D-ribonolactone, 73–77
  - D-ribose, 63–65
  - 3-hydroxymethylpyridine, 85–87

- Trehalase inhibitors (*cont.*)  
  *myo*-inositol, 68–73  
  norbornyl derivatives, 85  
  sugar 1,5-lactones, 66–68
- trehazolin  
  biosynthesis, 48–49  
  description, 47  
  natural occurrence and characterization,  
    47–48  
  retrosynthetic analysis, 49–50  
  synthesis (*see* Trehazolin synthesis)
- Trehazolamine fragment synthesis  
  acylated oxazolidinones, 81–82  
  analogues, 53, 54  
  *cis*-2-butene-1,4-diol, 82–85  
  cyclopentadiene, 77–81
- D-arabinose  
  *p*-methoxybenzyl (PMB) group, 65–66  
  2,3,5-tri-*O*-benzyl D-arabinose, 65
- D-glucose  
  5-*epi*-trehazolin, 57, 59  
  epoxidation, 55  
  Ferrier reaction, 59  
  hydrogenation, azido group, 57  
  open-chain *O*-methyloxime derivative,  
    54, 55  
  reductive carbocyclization, 55, 57  
  regiospecificity, 60  
  silylation and benzylation, 57, 58  
  Swern oxidation, 54–55  
  ZnCl<sub>2</sub> treatment, 57
- D-mannitol, 66
- D-mannose  
  deacetylation and monoacetonation, 60  
  free-radical cycloisomerization, 61, 62  
  *O*-benzylhydroxylamine, 61  
  regio-selective benzylation, 60–61  
  trehazolamine diastereoisomeric  
    analogue, 61, 62  
  triethylborane plus triphenyltin  
    hydride-mediated carbocyclization,  
      63
- D-ribonolactone, 73–77
- D-ribose  
  anhydrous ethanol treatment, 63–64  
  free-radical cyclization, 63  
  *N,N*-dimethylformamide (DMF), 65  
  3-hydroxymethylpyridine, 85–87  
  *myo*-inositol  
    acid hydrolysis, 72–73  
    *cis*-hydroxylation, 72  
    deacylation, 69  
    exo-alkene, spiroepoxide, 69, 70  
    free hydroxyl group oxidation, 71  
    osmium tetroxide treatment, 70  
    penta-*N,O*-acetyl derivatives, 70, 71  
    periodate oxidation, 68–69  
    peroxyacid oxidation, exo-methylene  
      group, 73  
  norbornyl derivatives, 85  
  sugar 1,5-lactones  
    glycosidases inhibition, 68  
    hydrogenation, 67–68  
    2-iodo-5-formyl-1,5-lactone and  
      precursor synthesis, 66, 68
- Trehazolin synthesis  
  anomeric center, trehazolamines  
    amino alcohols, 93, 95  
    aminocyclitol condensation, 90  
    benzyl groups removal, 96, 98  
    bromodeoxy and epoxy analogues, 99  
    coupling, 92, 93  
    cyclization, 99, 100  
    cyclohexyl analogue, 99–101  
    diastereoisomer, 92, 94  
    5-*epi*-trehazolin, 90, 92  
    HCl, MeOH, 96, 97  
    hydrogenolysis, 89  
    intramolecular cyclization, 87  
    *N*-alkyl and *N*-aryl ureas, 89, 91  
    oxazoline formation, 96, 98  
    replacement, aminocyclitol, 93, 95  
    2,3,4,6-tetra-*O*-benzyl-1-deoxy- $\alpha$ -  
      D-glucopyranosyl isothiocyanate,  
      89, 90  
  trehalostatin diepimer, 96  
  trehazolin tribenzyl ether, deprotection,  
    89, 91

- biosynthesis, 48–49  
deoxynojirimycin analogues  
  1-deoxynojirimycin-trehalamine fused  
    compounds, 106, 107  
  desilylation, tetrasilylated compound, 107  
  disubstituted thiourea, 108  
  *N*-(*tert*-butoxycarbonyl)glycine, 106, 107  
1-thiatrehazolin  
  acetal hydrolysis, 104  
  intramolecular nucleophilic  
    displacement reaction, 104, 105  
trehazolamines  
   $\alpha$  and  $\beta$  anomers, 103, 105  
  6-isothiocyanoglucose derivative,  
    coupling, 100, 102  
  maltose-type trehazolin derivatives,  
    101, 103  
  oxazolidinone hydrolysis, 101, 104  
  pseudodisaccharides, inhibitory  
    activities, 100  
  2,3,4-tri-*O*-benzyl-6-deoxy-  
    6-fluoro- $\alpha$ -D-glucopyranosyl  
    isothiocyanate, 102, 105

## U

- Unicellular and freshwater  
  heteropolysaccharides

- Apophloeae lyallii*, 177  
  medullary cells, 176  
  molecular structure, 174–175  
  NMR spectroscopy, 175  
  oligosaccharides, 175  
  osmotic and ionic conditions, 176  
  partial acid hydrolysis, 174  
  polyacrylamide gel electrophoresis, 177  
  viscosity, 176

## W

- Wittig–Horner–Emmons type of reaction,  
  51, 52

## X

- Xylans  
  acid hydrolysis, 120  
  biosynthesis, 120  
  cellulose preparations, 120  
  chemical structure, 121  
  conchocelis and generic phases, 120  
  matrix-assisted ultraviolet laser, 121  
  relative insolubility, 119–120  
  water-insoluble, 122

## SUBJECT INDEX

### A

- 2-Acetamido-1,2,5-trideoxy-1,5-imino-D-glucitol, 192–193
- 1-C- (5-Adamantanylmethoxy)pentyl-1-deoxynojirimycin, 252
- Alditols-oxo-Cr(V) complexes
- classification of, 80
  - difference, EPR parameters, 81
  - EPR spectra, 79–80
  - five-membered vs. six-membered chelates, 78
  - g and  $^{CrA}$  tensors, 78
  - hyperfine substructure, 79–81
  - isomers, 84
- Aldohexoses-oxo-Cr(V) complexes
- anomeric forms, 89
  - D-galactose and D-fructose ligands, 86–87
  - EPR signals, 88
  - furanose sugars, diol groups of, 92–93
  - ligand-exchange reactions, 89
  - NADH, 87
  - redox reaction pathways, 87–88
  - reduction mechanism, 93–94
  - room-temperature CW-EPR spectra, 90–92
  - six-coordinated complex formation, 88
- N-Alkyl-1-deoxy-D-galactonojirimycin, 210
- 2-O-Alkylated iminoxylitol, 252
- Allosteric glycosidase inhibitors. *See* Noncompetitive glycosidase inhibitors
- Ambroxol, 206
- Amine-based inhibitors, 208–211
- 6-Amino-6-deoxycastanospermine, 238
- 5-Amino-5-deoxy-D-glucose, 189, 212

- 2,3-anhydro-4,6-O-benzylidene- $\alpha$ -D-mannopyranosyl 4,6-O-benzylidene- $\alpha$ -D-glucopyranoside, 36
- 3,4-Anhydro-5-O-benzyl-1,2-O-isopropylidene- $\alpha$ -D-galactoseptanose, 132
- (-)-Anisomycin, 49
- Antisense oligonucleotides (AONs), 168
- Antisense therapy, 171
- Azepanes, 125

### B

- Beciparil, 176–177
- 5,7-O-Benzylidene-3-deoxy-3-nitro- $\alpha$ -D-glycero-D-*altro*-septanoside, 150
- 5-O-Benzyl-1,2-O-isopropylidene- $\alpha$ -D-galactoseptanose, 132
- 5-O-Benzyl-1,2-O-isopropylidene- $\alpha$ -D-glucoseptanose, 132
- 5-O-Benzyl-1,2-O-isopropylidene- $\alpha$ -D-glucoseptanose, 132
- 6-O-Benzyl-2,3-O-isopropylidene-D-ribose, 143–144
- 5-O-Benzyl-1,2-O-isopropylidene-4-O-methyl- $\alpha$ -D-galactoseptanose, 132
- 5-O-Benzyl-1,2-O-isopropylidene-3-O-methyl- $\alpha$ -D-guloseptanose, 132
- 5-O-Benzyl-1,2-O-isopropylidene-4-O-tosyl- $\alpha$ -D-galactoseptanose, 132
- Brevetoxin, 126
- Broussonetine E, 192
- N-Butyl-1-deoxynojirimycin vs. ceramide, 250
- 5-O-*tert*-Butyldiphenylsilyl-2,3-O-isopropylidene-D-ribonolactone, 146

## C

- Calystegine B2, 192
- Carbohydrate-related glycosidase inhibitors  
 competitive inhibitors, 208–211  
 substrate-related covalent inhibitors,  
 206–208
- Castanospermine, 218  
 superposition of, 229, 231
- Chloroethyl pyranoside, spiroacetal  
 derivatives of, 54
- 4-Chloro-galacto-sucrose, 21–23
- Chromium(V) complexes  
 applications, 71  
 carcinogenicity, 70–71  
 chromium(VI) oxidation reaction,  
 70–71  
 spectroscopic techniques, 72
- Ciguatoxin, 126
- Competitive glycosidase inhibitors, 208–211
- Conduritol B epoxide, 230
- Conformational analysis, septanose  
 monosaccharides  
 anomeric effect, 159  
<sup>13</sup>C NMR shifts, 161–162  
 conformational map of, 157  
 low-energy conformations, 156–160  
 methyl  $\alpha$ -D-glycero-D-ido-septanoside,  
 154–156  
 methyl  $\alpha$ -septanoside, crystal structure,  
 159–160  
 observations, 157–158  
 5-O-methyl septanosides, 161  
 pseudorotational wheel, 157  
 seven-membered rings, 154–156  
 six-membered ring systems, 154  
 T conformers, interconversion of, 156
- Covalent glycosidase inhibitors,  
 203–204
- [CrO(cis-O1,O2-cyclohexanediolate)<sub>2</sub>]<sup>-</sup>, 81
- [CrO(trans-O1,O2-cyclohexanediolate)<sub>2</sub>]<sup>-</sup>, 81
- C-6-substituted septanosides, conformational  
 analysis, 158

- C-6-unsubstituted septanosides,  
 conformational map of, 157
- Cyclophellitol, 207

## D

- DADMe-immucillin-H, 243–244
- Database CAZy (Carbohydrate-Active  
 EnZymes), 196
- 6-Deoxycastanospermine, 218
- 5-Deoxy-2,3:6,7-di-O-diethylidene-D-  
*allo*-heptitol., 165–167
- 3-Deoxy-3-fluoro-calystegin B2, 221
- 1-Deoxyfluorocastanospermine, 218
- 6-Deoxyfluorocastanospermine, 218
- 6-Deoxy-6-fluorocastanospermine, 223
- 1-Deoxy-L-fuconojirimycin, 239
- 1-Deoxynojirimycin. *See* 1,5-Dideoxy-1,5-  
 imino-D-glucitol
- Desosamine hydrochloride, Guthrie  
 phenylhydrazine cyclization, 18–20
- D-Galactose diethyl dithioacetal, 127–128
- 1,6-Dideoxy-6,6-difluoronojirimycin,  
 219–220
- 1,7-Dideoxy-7-fluorocastanospermine, 218
- 1,4-Dideoxy-4-fluoronojirimycin, 218
- 1,4-Dideoxy-1,4-imino-D-arabinitol,  
 191–193, 240
- 1,5-Dideoxy-1,5-imino-D-glucitol,  
 189–190, 212  
 superposition of, 229, 231
- 1,4-Dideoxy-1,4-imino-D-mannitol,  
 192–193
- 1,5-Dideoxy-1,5-imino-D-mannitol, 191
- 2,5-Dideoxy-2,5-imino-D-mannitol, 190, 212
- 2,5-Dideoxy-2,5-imino-D-mannitol, 192
- 1,5-Dideoxy-1,5-imino-L-fucitol, 192–193
- 4,4-Difluoro isofagomine, 221
- 3,21-Di-O-acetylcichoridiol, 204
- 2,7-Di-O-benzyl-4-deoxy-4-nitro- $\alpha$ -D-  
*glycero*-D-*talo*-septanoside, 150
- Dissociative ion-pair SN1-type mechanism,  
 12

**E**

- Electron paramagnetic resonance (EPR),  
72–73. *See also* Oxo-Cr(V)-sugar  
complexes, structural characterization
- Endoplasmic Reticulum  $\alpha$ -1,2-Mannosidase  
I, 233
- 4-*epi*-isofagomine, 210
- pKa value, 213–214
- Ethyl  $\beta$ -D-galactofuranoside, 133

**F**

- Fagomine. *See* 1,2,5-Trideoxy-1,5-imino-D-  
*arabino*-hexitol
- Fischer nitromethane cyclization, 15–18
- 4-Fluoro-galacto-sucrose, 45

**G**

- $\alpha$ -Galactosidases, 202
- Glucosylolactam, 229
- Glucotetrazole, 229
- Glycon structure
- $\alpha$ -galactosidases, 202
  - $\beta$ -galactosidases, 199
  - $\alpha$ -glucosidases, 200–202
  - $\beta$ -glucosidases, 197–199
  - $\alpha$ -mannosidases, 202–203
- Glycosidase inhibitors
- carbohydrate-related inhibitors
    - competitive inhibitors, 208–211
    - substrate-related covalent inhibitors,  
206–208
  - high-molecular-weight inhibitors, 203
  - nonsugar inhibitors, 204–206
  - small molecules, 203–204
- Glycosidases, structure determination  
of, 216
- Glycoside hydrolases
- general features of, 193–194
  - inverting and retaining enzymes, 195
- Golgi  $\alpha$ -mannosidase II, 233–235
- g* tensor, 72–73
- Guthrie phenylhydrazine cyclization,  
18–20

**H**

- Heptoses, 123
- 2,3,6,1',4',6'-Hexa-*O*-pivaloylsucrose, 24
- High-molecular-weight glycosidase  
inhibitors, 203
- Hydroxy acids-oxo-Cr(V) complexes
- aldonic acids, 102
  - D-gluconic acid, 103
  - D-gluconic acid, 105–107
  - l-hydroxy acids, 100–101
  - uronic acids, 104–105
- L-*glycero*-D-*manno*-Heptose, 127–128

**I**

- Imino sugars
- aza-sugars, 211
  - breakthrough of, 191
  - catalysis visualization
    - N*-acetylhexosaminidases, 236–239
    - fucosidases, 239–240
    - D-galactosidase, 236
    - D-glucosidase inhibitors, 224–233
    - D-mannosidase inhibitors, 233–236
    - nucleoside hydrolases, 242–246
    - pyrrolidine, 240–242
  - deoxyfluoro derivatives, 217–224
  - discovery of, 189–192
  - enzyme—inhibitor complexes, 259–274
  - functional groups, significance of, 216–217
  - increased hydrophobicity, 248–254
  - lipophilic inhibitors, 254–256
  - non-glycon binding sites, 246–256
  - PDB-entries, table of, 259–274
  - pKa value, 213
  - stereochemical considerations, catalytic  
protonation, 214–216
- Immucillin-GP, 243
- Immucillin-H, 243
- Inverting glycohydrolases, 195
- mechanism of, 195
- Irreversible glycosidase inhibitors. *See*  
Covalent glycosidase inhibitors
- Isofagomine, 209–210

## K

Kifunensine, 192–193

## M

Mannoimidazole, 234–236

$\alpha$ -Mannosidases, 202–203

Methyl 2-acetamido-3,4,5,7-tetra-*O*-acetyl-2-deoxy- $\alpha$ -D-glycero-D-ido-septanoside, 134–136

Methyl 2-acetamido-3,4,5,7-tetra-*O*-acetyl-2-deoxy- $\alpha$ -D-glycero-D-ido-septanoside, 134–135

Methyl  $\alpha$ -D-glycero-D-ido-septanoside, 163

Methyl  $\alpha$ -D-glycero-D-talo-septanoside, 141

Methyl  $\beta$ -lactoside, benzylation of, 30–31

Methyl 3-bromo-3-deoxy- $\beta$ -maltoside, 22

Methyl 2,5-di-*O*-benzoyl-3,4-*O*-isopropylidene- $\beta$ -L-ido-septanoside, 130–132

Methyl glycosides-oxo-Cr(V) complexes  
potential binding modes, 95  
room-temperature CW-EPR signal, 94–95  
synthesis models of, 97

Methyl 2,3-*N*-acetylepimino-4,6-*O*-benzylidene-2,3-dideoxy- $\alpha$ -D-allopyranoside, 20–21

Methyl 2,3,4,5-tetra-*O*-acetyl- $\beta$ -D-galactoseptanoside, 134–135

Methyl 2,3,4,5-tetra-*O*-benzyl- $\beta$ -D-glycero-D-gulo-septanoside, 148–149

Methyl 3,4,5,7-tetra-*O*-benzyl-2-benzylamino-2-deoxy- $\alpha$ -D-glycero-D-ido-septanoside, 134–135

Methyl 3,4,5,7-tetra-*O*-benzyl-2-benzylamino-2-deoxy- $\alpha$ -D-glycero-D-ido-septanoside, 134–135

Methyl 2,3,4,5-tetra-*O*-methyl- $\beta$ -D-glucoseptanoside, 128–129

5'-Methylthioadenosine nucleosidase (MTAN) inhibitors, 210–211

Methyl 3,4,6-trideoxy-3,4-epimino- $\alpha$ -L-galactopyranoside, 20–21

Monosaccharide septanoses, 127–133

Mycaminose, 17

## N

4-Nitrophenyl 6-deoxy- $\beta$ -D-galactopyranoside, 198

4-Nitrophenyl 6-deoxy- $\beta$ -D-glucopyranoside, 197

Nojirimycin, 125

Noncompetitive glycosidase inhibitors, 203–204

Nonsugar inhibitors, 204–206

## O

$\alpha$ -1-C-Octyl-1-deoxynojirimycin, 252

Oligonucleotides (ONs), 122–123

Oxacycloheptatriene, 138–139

Oxepines

aldoseptanoses synthesis, intermediates in, 141

cyclopropanation and ring expansion, 138–141

glycosylations, 147–149

isomers, 145

RCM strategy, 144–145

ring-closing metathesis, 143–147

types of, 145

Oxidative degradation, sugar diethylsulfonyl dithioacetals, 12

Oxo-Cr(V) complexes

ENDOR spectrum, 75–76

HYSORE spectrum, 75–76

temperature CW-EPR spectra, 74

advantage and drawback, 73

alditols, 77–86

aldohexoses, 86–94

aldopentoses, 86–94

hydroxy acids, 100–108

isotropic hyperfine coupling, 74–75

methyl glycosides, 94–97

parameters, 72–73

Oxo-Cr(V)—sugar complexes, structural characterization

2-acetamido-2-deoxy-D-glucose, 98

alditols

classification of, 80

difference, EPR parameters, 81



- EPR spectra, 79–80  
 five-membered *vs.* six-membered  
 chelates, 78  
 g and  $C^r$ A tensors, 78  
 hyperfine substructure, 79–81  
 isomers, 84
- aldohexoses  
 anomeric forms, 89  
 EPR signals, 88  
 furanose sugars, diol groups of, 92–93  
 D-galactose and D-fructose ligands,  
 86–87  
 ligand-exchange reactions, 89  
 NADH, 87  
 redox reaction pathways, 87–88  
 reduction mechanism, 93–94  
 room-temperature CW-EPR spectra,  
 90–92  
 six-coordinated complex formation, 88
- aldopentoses, 86–94  
 2-deoxy-D-*arabino*-hexose, 98  
 2-deoxy-D-*erythro*-pentose, 98  
 ENDOR spectrum, 75–76
- hydroxy acids  
 aldonic acids, 102  
 D-gluconic acid, 103  
 D-gluconic acid, 105–107  
 1-hydroxy acids, 100–101  
 uronic acids, 104–105
- methyl glycosides  
 potential binding modes, 95  
 room-temperature CW-EPR signal,  
 94–95  
 synthesis models of, 97
- oligosaccharides, 108–114  
 3-O-methyl-D-glucopyranose, 99–100  
 polysaccharides, 108–114
- P**
- Penarolide, 204  
 2,3,4,5,6-Penta-O-acetyl-1-chloro-1,1-  
 dideoxy-1-ethylthio-D-galactose  
 aldehydrol, 133  
 (-)-Pentenomycin I, 48, 50
- Phosphoramidites, synthesis of, 167  
 Protein–septanose interactions, lectin-binding  
 studies, 172–174  
 Purine nucleoside phosphorylase (PNP)  
 inhibitors, 210–211  
 Pyrimethamine, 206
- R**
- Raffinose, chlorination of, 41, 42  
 RCM strategy. *See* Ring-closing metathesis  
 (RCM) strategy  
 Retaining glycohydrolases  
 mechanism of, 196  
 pathway, 196  
 Reversible glycosidase inhibitors. *See*  
 Competitive glycosidase inhibitors  
 Richardson's rules, 57–58  
 pictorial summary of, 59  
 Ring-closing metathesis (RCM) strategy,  
 144–145  
 RNaseH, 171
- S**
- Septanose carbohydrates  
 fused polycyclic marine toxin ethers, 126  
 investigations, 163–177  
 oligonucleotides, 168–171  
 protein–septanose interactions, 172–176  
 polyhydroxylated azepanes, 125  
 research areas, 125  
 strategies, septanosides  
 cyclization via C—O bond formation,  
 127–138
- Septanose monosaccharides, conformational  
 analysis  
 anomeric effect, 159  
 $^{13}\text{C}$  NMR shifts, 161–162  
 conformational map of, 157  
 low-energy conformations, 156–160  
 methyl  $\alpha$ -D-*glycero*-D-*ido*-septanoside,  
 154–156  
 methyl  $\alpha$ -septanoside, crystal structure,  
 159–160  
 observations, 157–158

- Septanose monosaccharides, conformational analysis (cont.)  
   5-*O*-methyl septanosides, 161  
   pseudorotational wheel, 157  
   seven-membered rings, 154–156  
   six-membered ring systems, 154  
   T conformers, interconversion of, 156  
 Septanoses synthesis, ring expansion of cyclic ketones, 150–151  
 Septanose sugars  
   expanded monomer approach, 123  
   transannular reactions of  
     electrophilic intermediates, 153  
     precursors, 153  
     products of, 153  
 Septanosides, 123–125  
 Siastatin B, 192  
 Small molecules glycosidase inhibitors, 203–204  
 (S)-Spirobi-1,4-dioxane, 55  
 Substrate-related covalent glycosidase inhibitors, 206–208  
 Sucralose. *See* 4,1'6'-Trichloro-4,1'6'-trideoxy-galacto-sucrose (TGS)  
 Sucrose, hepta-pivaloylation of, 21–23  
 Sugar diethylsulfonyl dithioacetals, oxidative degradation of  
   Fischer nitromethane cyclization, 15–18  
   plausible mechanism, 13  
   Richardson and Hough's mechanistic proposal, 14  
   stereostructure of, mycaminose, 17  
 Swainsonine, 191, 212  
 (-)-Swainsonine, 48, 52
- T**
- 2,3,4,5- Tetra-*O*-acetyl-6-*O*-tosyl-D-galactose diethyl dithioacetal, 151–152  
 2,3,4,5-Tetra-*O*-methyl-D-glucose, 128–129  
 1,3,4,6-Tetra-*O*-pivaloyl- $\beta$ -D-fructofuranosyl 2,3,6-tri-*O*-pivaloyl- $\alpha$ -D-glucopyranoside, 21–23  
 5-Thio-D-5-thio-D-xylopyranose, 189–190  
 5-Thio-L-idopyranose, 189–190  
 6-Thioseptanosides, 151  
 Thymidine, 169  
 Trehalose, 3,30-dideoxy-analogues of, 35  
 4,1'6'-Trichloro-4,1'6'-trideoxy-galacto-sucrose (TGS), 10–11  
 1,2,5-Trideoxy-2-fluoro-1,5-imino-D-glucitol, 218  
 1,2,5-Trideoxy-1-fluoro-2,5-imino-D-mannitol, 223  
 1,4,6-Trideoxy-6-fluoro-1,4-imino-D-mannitol, 220  
 1,4,6- Trideoxy-6-fluoro-1,4-imino-D-mannitol, 222  
 1,2,5-Trideoxy-1,5-imino-D-*arabino*-hexitol, 125, 189  
 1,4,6-Trideoxy-1,4-imino-D-mannitol, 212  
 Triethylamine-mediated cycloisomerization, 146  
 2,3,5-Tri-*O*-benzyl-D-arabinofuranose, 143–144